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The pharmaceutical nexus is large, international and successful. It is also very 
complex. Heterogeneous in its components, stretching both upstream to research, 
clinical trials, product development and disease construction, and downstream 
through doctors and experts, it enables and enrols regulatory bodies, lawmakers, 
lobbyists, judicial systems, marketing professionals, producers, medical practi-
tioners and consumers. And it does this on a global scale, dominating the medical 
approach in advanced Western countries and spreading its territory to domains 
in the developing world. Pharmaceuticals are colonizing and creating new mar-
kets in geographically and socially diverse parts of the world and throughout all 
aspects of the industry. The pharmaceutical industry is trying, and succeeding, to 
work and profit in very different contexts, with very different regulatory frame-
works, marketing needs and consumer bases. And while the industry has had an 
international approach since before World War II, the global market for pharma-
ceuticals and the profit margins, which large, multinational companies are chas-
ing, have grown exponentially in recent decades.
These themes are prevalent in critical studies of global pharmaceuticals from 
within the social sciences (see Elliot 2003; Moynihan and Cassels 2005; Petryna 
and Kleinman 2006; Williams et al. 2011a). In this book, we present a close look 
at the glocal of global pharma in Sweden. By attending to the specificities of the 
local in Sweden within a conceptual framework of global pharmaceuticals, we 
will be showing global trends and local responses in a Western/Northern, highly 
developed and regulated state. To do so, we employ the term glocal to signify 
that the local specificities of a cultural context, including its regulatory bodies, do 
something to the global pharmaceuticals that are integrated into it, and, likewise, 
global pharmaceuticals impact the local context.
Critical studies of pharmaceuticals have developed out of academic work on 
medicalization, a concept often traced back to work inspired by Parsons’s analysis 
of the sick role in the 1950s. Medicalization became a sociological tool with which 
to think about the interplay between medicine, individuals and society. Parsons’s 
proposition, that the sick role allows the individual to avoid blame for his/her ill-
ness while simultaneously legitimating and excusing his/her shortcomings in the 
workplace or family as long as the individual seeks medical help (Parsons 1951), 
has resonated throughout medical sociology and influenced the development of 
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the field since. Within sociology, studies of medicalization initially focused on the 
hospital as a professional institution within which the patient figured, but where 
doctors (and to a lesser extent, nurses) were particularly interesting to study as 
they assumed professional roles, made decisions, directed practice and policy and 
(almost peripherally) attended the ill (see Eaton and Weil 1955; Balint 1957; Fox 
1959; Becker et al. 1961; Coser 1963; Freidson 1963). One finds echoes of the 
sick role in Illich (1976), Fox refers to it in her work on medicalization in America 
(Fox 1977, 15), and current interests in the process of pathologizing emotions 
(Healy 2004) and behaviour (Hart et al. 2006; Conrad 2007) touch on the inter-
play between illness and society.
How exactly medicalization occurs is, of course, up for debate, as is what 
should be included in the term. Illich famously called it ‘iatrogenesis’, combining 
the Greek iatros, ‘physician’, and genesis, ‘origin’ (Illich 1976, 3), yet it is used 
to convey a very broad set of processes, sites and actors beyond the physician and 
his/her workplace. The concept of medicalization has expanded beyond the idea 
of the sick role, to include ideas of how a patient’s complaint becomes a medi-
cal diagnosis (Balint 1957), and how social deviance becomes medicalized (cf. 
Fox 1977). It now applies to ‘a process by which nonmedical problems become 
defined and treated as medical problems, usually in terms of illness and disorders’ 
(Conrad 2007, 4), including, and worryingly, the transformation of difference 
into pathology (Conrad 2007, 148). Forty years ago, Illich pointed to the way ill 
health is created by what he termed the medical bureaucracy, which defined the 
need for medical care – defined non-normative ways of being as diseased and in 
need of medical treatment – and discursively limited the ability or opportunity 
for other forms of care, be that social, familial, spiritual or self-care (Illich 1976, 
40). Critical studies of medicalization in the social sciences today look beyond 
the immediate medical context to explore how commercial, state and media inter-
ests also produce illness. And while, within medical sociology, medicalization 
is still largely used to direct attention to issues of how illness is understood and 
used in social contexts, work by Mol (2002) and other science and technology 
studies (STS) researchers broaches and questions the illness/disease divide, and 
has begun to approach biomedical technologies with a critical lens (Berg and 
Mol 1998; Johnson and Berner 2010). These examine how illness and disease 
are enacted, but also how their particular formations shape medical practice and 
governance.
Medicalization conceptually sets the stage for the idea of pharmaceuticaliza-
tion, understood to mean the introduction and acceptance of drug-based responses 
to (and creation of) health issues, as illustrated in Dumit’s (2012) book Drugs for 
Life. Williams, Martin and Gabe use the term pharmaceuticalization to interrogate 
how many different aspects of life are becoming opportunities for pharmaceuti-
cal intervention. In their usage, pharmaceuticalization is a broad term, and can 
be applied to processes of ‘discovery, development, commercialization, use and 
governance of pharmaceutical products centred around chemistry-based technol-
ogy’ (Williams et al. 2011a, 711). This is opposed to Abraham’s more medically 
focused use of the term (Abraham 2010, 604). In its broader definition, which 
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we embrace in this book, pharmaceuticalization can also be applied to the use of 
pharmaceuticals to address issues currently outside of medical practice, like some 
lifestyle drugs or the use of nicotine replacement therapies in chewing gum or 
e-cigarettes (see Elam 2012). This broader stance is not as new or controversial 
as the Abraham (2011) versus Williams and colleagues (2011b) exchange would 
suggest. As Illich pointed out long before our current obsession with lifestyle 
drugs, pharmaceuticals do not need doctors and hospitals to pervade society, nor 
are most ‘poisons’, ‘remedies’ and ‘placebos’ necessarily destined for the sick 
(Illich 1976, 61).
Reminding us of pharma’s ambiguity, Illich noted: ‘The Greek’s only word 
for “drug” – pharmakon – did not distinguish between the power to cure and the 
power to kill’ (Illich 1976, 45). While not as radical in their take on pharmaceu-
ticals as Illich, Williams and colleagues point out that both medicalization and 
pharmaceuticalization are ostensibly value-neutral terms (Williams et al. 2011a, 
711), and medicalization and pharmaceuticalization both describe processes that 
may imply benefits or drawbacks to society and individuals. But, as has been 
the case with medicalization, in social science studies of pharmaceuticalization 
there seems to be a tendency to see these processes as negative, or at least suspi-
cious. Abraham echoes this reticence towards pharmaceuticals when he writes 
‘that increased pharmaceuticalization can sometimes be suboptimal for signifi-
cant therapeutic advances in the interests of public health’ (Abraham 2010, 603).
The relationship between pharmaceuticalization and medicalization is some-
times very intertwined, and many critical studies of pharmaceuticals have shown 
how drugs are being used to manufacture diseases which can then be treated with 
them. But the process of pharmaceuticalization can imply more than just increased 
medicalization. Many examples exist where pharmaceuticalization changes the 
method of treating an already existing medical condition. As Abraham notes, 
‘pharmaceuticalization can grow without expansion of medicalization, because 
some drugs are increasingly used to treat an established medical condition involv-
ing no transformation of a non-medical problem into a medical one’ (Abraham 
2010, 605; emphasis in the original). This volume discusses the influence of phar-
maceuticalization on the treatment of established medical conditions, as well as 
on marketing communication and the governance of access to such treatment, 
using the example of Viagra and the treatment of impotence.
What is the subject of the process of pharmaceuticalization? Williams and col-
leagues use the term pharmaceutical regime to cover the networks of institutions, 
organizations, actors, artefacts and cultural values one can identify in studies of 
pharmaceuticalization. Others have used the term pharmaceutical nexus (cf. Pet-
ryna and Kleinman 2006), and Abraham talks in terms of processes (Abraham 
2010). What we take from these discussions is the idea that pharmaceuticals are 
one actor within a complex and heterogeneous collectif (Callon and Law 1995) of 
actors, institutions and ideas, including clinicians, patients, consumers, regulators, 
sales reps and marketing departments. This collectif of actors notably includes the 
drugs themselves in very specific technological forms – pills, patches, sticks and 
shots. We treat these material artefacts as a useful prism to see through and with, 
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to bring into focus and refract various values, ideas and desires that are manifested 
in and through the drugs we are studying.
The theoretical framework of pharmaceuticalization employs analysis of hetero-
geneous aspects of pharmaceuticals in society, and can productively be approached 
from within different disciplines. Because of this, the work in this book is multi-
disciplinary. It is positioned in social science and cultural studies approaches to 
pharmaceuticals, and employs theories and terms that attend to the flexibility of 
pharmaceuticals as medical technologies, especially when they become mobile 
across countries, regulatory frameworks and value systems (cf. Dugdale 2000; 
Kruse 2016). Our book can be read as a study of pharmaceuticals at an intersection 
of political, economic and ethical dimensions (cf. Petryna and Kleinman 2006; 
Brody 2007). Approaching such a multi-scaled and complex nexus demands an 
analytical toolbox which is heterogeneous and broad, so we have mixed liber-
ally from our disciplinary backgrounds to create an approach drawing from post-
humanities studies, STS and medicine and management and organizational studies. 
This approach is influenced by the authors’ own boundary crossings into and within 
interdisciplinary fields: gender studies; STS and medicine; and social studies of 
accounting. We bring with us theoretical and methodological baggage from our 
respective fields, including a shared interest in the materialities of pharmaceuticali-
zation. Methodologically, our research, like much of that we draw inspiration from, 
is qualitative, and relies on close readings of visual and written discourses. These 
discourses are taken from regulatory contexts (legal and court documents), profes-
sional debates (medical journals and testimonials from medical experts, court wit-
nesses and committee members) and commercial material (advertisements for the 
drugs, often on ‘informational websites’ and other Internet forums, to circumvent 
the Swedish prohibition on direct-to-consumer (DTC) advertising of prescription 
pharmaceuticals). The different discourses are then analyzed to trace the glocal 
contours of Swedish Viagra and the Swedish Viagra man.
Despite our disciplinary promiscuity, or ‘theoretical eclecticism’ (cf. Williams 
et al. 2011a, 722), and the diversity of material we analyze, the overarching theo-
retical framework in all three sections of this book can be related to the concept 
of pharmaceuticalization (Abraham 2011; Williams et al. 2011a), from which we 
garner specific questions to query the shapes and forms that global pharmaceuti-
cals assume as they are integrated into local discourses, and how the discourses 
and the pharmaceuticals change in the process. Pharmaceuticalization has many 
aspects. Abraham, for example, argues that it involves dimensions from biomedi-
calism, medicalization, industry drug promotion, consumerism and the ideology 
or policy of the regulatory state (Abraham 2010, 606). Williams and colleagues 
(2011a) identify several more aspects, including the role of the media and the use 
of drugs outside of the medical domain. In this book, we specifically attend to 
three aspects of pharmaceuticalization that we think are particularly tangible and 
visible in the case of Swedish Viagra, yet also relevant to a discussion of glocal 
pharmaceuticalization. These are: the way pharmaceuticals change forms of gov-
ernance; the redefinition of health problems as issues with a pharmaceutical solu-
tion; and the creation of new techno-social identities around drugs and the way 
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pharmaceuticals become essential actors in relationships between subjects. Our 
analysis of these aspects in Sweden shows how the local context is an important 
influence on the process of pharmaceuticalization.
The first aspect of pharmaceuticalization, which we will discuss in this book, 
is the way pharmaceuticals reshape forms of governance. In the global debate, 
examples of pharma-governance are often related to questions about emerging 
markets, equitable access, cost and patent protection, with political decisions at 
the nation state level contravening international decisions and regulations – and 
sometimes even forcing these regulations to change (see Biehl 2006). However, 
the presence and influence of international pharmaceuticals is also very tangible 
in governance decisions and policy responses in established and well-regulated 
nation states, like Sweden, that have a reputation for being obedient to interna-
tional treaties and understandings. While our material does not provide examples 
of patent infringement and black or grey market infringement, it does show a 
nation state finding new ways of regulating and governing pharmaceutical access 
and subsidies, changing the role of medical doctors and regulatory decision mak-
ers at the point of clinical diagnosis.
Critical studies of pharmaceuticals also discuss the redefinition of health problems 
as issues with a pharmaceutical solution (see Healy 2004; Kassirer 2005; Moyni-
han and Cassels 2005; Law 2006; Moynihan and Mintzes 2010; Williams et al.  
2009, 712). As Moynihan notes, this process involves, among other things, exam-
ples of how pharmaceutical advertising and regulation turn ordinary ailments into 
medical problems, present mild symptoms as serious, and treat inter-personal 
problems as medical (Moynihan and Cassels 2005). Our study of the medical 
discourses around Viagra show this happening very clearly in the Swedish con-
text. Predictably, impotence became erectile dysfunction, and urology replaced 
relationship counselling and sex therapy as the site of treatment for erectile prob-
lems. Yet because of the ideological framework of the Swedish health care sys-
tem, Viagra was also discursively connected to diabetes, multiple sclerosis and 
spinal injuries, which tints the identity of the drug and the Swedish Viagra man in 
the medical discourse.
The creation of new techno-social identities around drugs
In our analysis of the Swedish patient information pages on pharmaceutical web-
pages, men, doctors and the partners of men with erectile dysfunction are enrolled 
into a Viagra discourse which presents them with specific tasks and functions in 
the recognition of, need for and enabling of Viagra. As Chapters 6 and 7 describe, 
these roles are similar to patient, doctor and partner identities in North American 
Viagra advertising yet also tweaked to fit perceived Swedish values and norms. As 
the concept of pharmaceuticalization would predict, Viagra is positioned as a nec-
essary component in these identities and, important, in the relationships between 
the subject positions that Viagra facilitates. But the shape and shades of these 
identities and relationships reflect very traditional understandings of the local cul-
ture, an interesting example of glocal identities.
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Much of the work on global pharmaceuticals explores encounters between 
developing, non-Western/Northern countries and a commercial pharmaceutical 
industry. We see the value of this work, and laud its approach to questions of 
social justice, equitable access to health care and global commercial forces as they 
discover and create new markets (see Lakoff 2005). We draw theoretical lessons 
from these studies. For our work, the most useful studies of this global process 
examine local manifestations of pharmaceuticals with close, qualitative and eth-
nographically inspired approaches (i.e. Petryna and Kleinman 2006; Wailoo et 
al. 2010) For example, analysis of knowledge about, access to and use of antiret-
roviral therapies in Uganda articulates how social relations and distinctions are 
embedded in the social meanings of medicines, as well as how the medicines 
enable and articulate the doing of family relationships (Whyte et al. 2006, 260), 
articulations we see resonances of in our material on Viagra. Just as Applbaum 
(2006) shows in his study of antidepressants in the Japanese market, and with 
Lakoff’s work on antidepressant use in Argentina (Lakoff 2006, 133), our work 
shows how the market, medical profession and regulatory actors all struggle to 
define disease and patient groups, and to influence each other in the process. As 
Lakoff writes, ‘the mutual imbrication of science, regulation and business in the 
circulation of pharmaceuticals is best seen not as a contamination of pure science 
but rather as part of a distinctive and emergent regime for authorizing knowledge 
claims and expert action’ (Lakoff 2006, 111–12). We draw inspiration from this 
approach in our analysis of relationships enabled by pharmaceuticals, as well, 
and with an eye to our own culture, but we challenge the tendency in this body 
of research to see global as a euphemism for West versus the Rest (Löwy 2010; 
Stockel 2010; and Lindén 2013 are exceptions to this). We assert that it is also 
interesting and valuable to explore relationships between the local and the global 
in a developed, Western/Northern, non-US context.
Pharmaceuticals in Sweden
Medical care available in Sweden can be characterized as technically advanced, 
‘scientifically grounded’, evidence-based medicine soundly positioned in the 
Western/Northern medical knowledge paradigm. This knowledge paradigm is 
based on the idea that universal medical facts about the body and health exist, 
and that these should not be dependent on cultural context. Medical facts should 
travel unhindered across geographical borders. It is this assumption that makes 
the global reach of pharmaceuticals (and other medical responses to health and 
illness) possible at the theoretical level. It is also this assumption that allows the 
global analysis of pharmaceuticals to assume that the West/North is one unit of 
analysis.
In our close reading of pharmaceuticals in Sweden, however, we problematize 
this assumption by showing the uniqueness of the Swedish case, and demonstrat-
ing that Western/Northern medicine is not a useful analytical category. Western/
Northern is actually a trope that hides a great deal of diversity, even beyond the 
obvious difficulties of placing countries like Japan and Australia in this nominally 
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geographical category (see Abraham 2011, 727). The nation states that would fit 
into it are a heterogeneous group which responds to global pharma in unique 
ways. This is an important point to remember in social science and cultural stud-
ies work on the pharmaceutical industry and the medical practices it engenders.
Living in an oft-cited example of socialist medicine, Swedish citizens have 
access to state-subsidized and state-delivered medical care at very little out-of-
pocket cost. Funded by the tax system, the Swedish health care structures are 
based on the idea that everyone should have equal access to the same high quality 
of care. This is a concept and a system which is firmly ideological and politically 
linked to the history of socialist rule in Sweden during most of the twentieth cen-
tury (Shenkin 1973). While the Swedish health care system has not been immune 
to privatization and neo-liberal impulses during the past decades (see Johans-
son Krafve 2015), it still remains a system which attempts to provide close-to-
free health care for close-to-everyone. This understanding of health care includes 
heavily subsidized pharmaceutical treatments.
Because the Swedish state subsidizes pharmaceutical costs for all drugs 
approved within the scheme with a very minimal individual co-pay, our study 
presents a context in which the individual’s theoretical ability to pay is of little 
interest. We argue that in Sweden, global pharma is confronted with a very regu-
lated market populated by hyper-individualized patients who are also comfortable 
with a paternalistic welfare state that has long been responsible for giving them 
their drugs for almost free, as opposed to the privatized and decentralized health 
care systems in which states are losing (or have never really had) control of phar-
maceutical use (see Petryna and Kleinman 2006). Individuals in Sweden are not 
familiar with the idea that they should pay for their pharmaceuticals at the point of 
purchase, but are concerned about the collective costs of pharmaceuticals to their 
tax bill, even as they demand access to treatment.
This setting problematizes discussions in the extant literature which centre on 
individuals’ willingness (and ability) to pay. The development of some pharma-
ceutical therapies (for erectile dysfunction, male pattern baldness or wrinkles, 
for example) and not others (malaria is a commonly cited one), and the growth 
of pharmaceutical treatments labelled lifestyle drugs, is testament to the underly-
ing market mechanisms which encourage drug companies to target markets (con-
ceived of as groups of individuals with similar medical and/or pharmaceutical 
needs) which are capable and willing to pay for their products. ‘As drug costs 
escalate and access becomes hyperindividualized, pharmaceuticals markets gen-
erate new social distinctions based on the individual’s ability to pay’ (Petryna and 
Kleinman 2006, 7). This common assertion is to some extent an oversimplifica-
tion. Our book shows with specific empirical studies how this is a more compli-
cated process of market subdivision and creation within well-regulated markets 
and distribution channels. Specifically, our work provides an example of what 
happens in pharmaceutical marketing and distribution practices when the tension 
between cost to the individual meets the Swedish solidarity principle and idea 
that health care is a general public good. We highlight the tensions in this con-
cept of ‘hyperindividualized’ pharmaceutical consumption, teasing out how state 
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structures and local and temporal medical consensus can influence access to and 
use of brand name pharmaceuticals.
Two aspects of the Swedish case are particularly relevant to the glocal relation-
ships of pharmaceuticals: 1) there is a ban on DTC advertising on prescription 
medicine (with the exception of vaccines), yet the industry seems to sidestep this 
ban with little reprimand; and 2) the state pays for the majority of the prescription 
costs for the population. The first has allowed us to analyze ‘Patient Information’ 
websites about erectile dysfunction and the localization elements they incorpo-
rate. The second has created a very interesting economic context within which 
doctors debate the use of pharmaceuticals in relation to other costs, the state takes 
interest in limiting pharmaceutical use, and the judicial system tests these deci-
sions, at the same time as the state has developed industry regulations in close 
collaboration with commercial interests.
Abraham has pointed out that pharmaceuticalization is occurring even in coun-
tries which have a DTC advertising ban on prescription pharmaceuticals, sug-
gesting that we need to look at shifts in regulatory ideology or policy to explain 
pharmaceuticalization, not just commercial forces (Abraham 2010, 606). While 
this is certainly true, we would assert that analysis of DTC advertising may also 
need to be expanded to the actual practices pharmaceutical companies employ, 
not only the legal frameworks they work within. Sweden has a ban on DTC 
advertising, like the rest of Europe, but there may be reason to suspect that this 
ban is only partially functional. The industry-supported information pages about 
diseases sometimes shamelessly propose the use of pharmaceutical solutions. At 
times, media reports about new drugs read like industry press releases. When 
Viagra arrived it was advertised on full-sized posters at bus stops in southern 
Sweden, despite the ban. And, as research has shown, in Sweden (as in the United 
Kingdom) there seems to be widespread disregard for the regulations restricting 
DTC advertisement, and little bite to the regulatory bodies which are supposed 
to police it (Zetterqvist and Mulinari 2013; Zetterqvist et al. 2015). Thus, in the 
European context, the legality of DTC advertising is not necessarily a sufficiently 
well-formulated research parameter.
Pharmaceuticalization and the interplay of pharmaceuticals and state regula-
tory bodies has a long tradition in Sweden, which began regulating approval and 
marketing of pharmaceuticals in 1934 (Abraham and Lewis 2000, 55), but its 
form, and that of regulatory systems in the West/North in general, has changed 
significantly over the past decades. The current state of today’s regulatory frame-
work for pharmaceuticals, developed under neo-liberalism, shows how regulatory 
bodies have been refashioned to facilitate drug development, rather than protect 
the public, and in particular how these regulatory bodies are co-opted to serve the 
industry’s will rather than the public’s need (Brody 2007; Abraham and Ballinger 
2012). In Sweden, this has seen the creation of the Medical Products Agency in 
1990, which was funded entirely by industry fees and was supposed to accelerate 
drug approval times (Abraham and Ballinger 2012, 448). As Abraham and Ball-
inger note, the pattern of establishing a regulatory body to improve approval pro-
cesses for industry also occurred in the United Kingdom and in Germany during 
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the 1980s and 1990s, which then influenced the EU supranational drug regulatory 
system with their neo-liberal approach (Abraham and Ballinger 2012, 449; Junker 
2014).
Much academic critique of the regulatory system looks at the regulatory bod-
ies that approve pharmaceuticals before they are made available to the public. 
The work we present in Part 1, however, particularly in Chapter 2, examines a 
less commonly discussed regulatory actor – the legal system and court decisions 
on the appropriate use and funding of drugs. Here the Swedish case is very dif-
ferent from that of the United States, as the state pays for prescription drugs and 
the use and cost of drugs are thereby regulated by a separate administrative body 
(the Dental and Pharmaceutical Benefits Agency, previously the Pharmaceutical 
Benefits Board), whose decisions can be appealed through the court system (see 
Sjögren 2006). This has traditionally not been a course of action (Abraham and 
Lewis 2000, 71), but the legal battles over subsidizing Viagra marked a change in 
the regulatory praxis.
Outline of this book
The Swedish case shows how a highly developed nation, which provides univer-
sal health care, including universal access to prescription medicine, responds to 
and shapes the pharmaceutical solutions that a global market presents through the 
health care system. The existence of a single, tax-based payer for pharmaceuticals 
can change the faces (in the STS spirit, we would argue this changes the very 
products themselves) of the pharmaceutical options available to the public. As 
the following chapters will show, a global blockbuster drug like Viagra becomes 
a different product in Sweden than Viagra in the United States, and the users of 
Viagra are glocalized, too.
This book is divided into three parts. In Part 1, we consider policy and bureau-
cratic responses to the introduction of new pharmaceuticals, in particular Viagra 
and the possibility of pharmacogenomics. The work here identifies certain argu-
ments which appear to direct the response: solidarity; provision to those in need; 
how need is determined; and how the pharmaceutical technologies can actually 
assist or even replace medical doctors in the determination of need. Close reading 
of the debates surrounding these products shows how a system founded on the 
principles of solidarity and equal access to health care, including pharmaceuticals, 
can respond to the profit-driven industry which is providing these products to the 
state. Part 1 begs questions about how solidarity, citizen rights and biological 
rights are related, and how they are created in relationship with each other and 
with pharmaceuticals.
In Part 2, we analyze the medical discourses that surround the introduction of 
new pharmaceuticals. The first chapter looks at Viagra and how it has influenced 
the medical understandings of impotence and erectile dysfunction in Sweden. It 
shows how the presence of an international drug can have implications for medi-
cal terminology and the colloquial use of words to describe a social and medical 
problem, even in a small, linguistically bounded community like Sweden (with 
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approximately nine million speakers). Chapter 5 traces debates around the intro-
duction of alpha-blockers for benign prostate hyperplasia to the Swedish health 
care market and the shift in treatment methods they implied for an already med-
icalized condition. Together, these chapters present local examples of how the 
pharmaceutical products redefine existing health problems as issues with phar-
maceutical solutions and how their presence frames the medical community’s 
responses. Impotence shifts from being a condition treated with sex and couple’s 
therapy to a condition for which one takes a pill. Lower urinary tract symptoms 
for older men move from being treated with surgery to being treated with a medi-
cation. Interestingly, this shift is nearly complete in the Viagra case, but is, fifteen 
years later, still being contested in the case of alpha-blockers.
Part 3 articulates subject positions for pharmaceutical consumers which are 
created in commercial discourses in Sweden. Specifically, we examine the adver-
tising, disguised as web-based disease informational pages, for Viagra. By think-
ing through our cases within a theoretical framework of pharmaceuticalization, 
we see that pharmaceuticals are creating new subject positions around the drugs. 
Chapter 6 examines the construction and enrolment of (consumer) subjects which 
are not directly consuming the pill. Here we see how the commercial Viagra dis-
course produces and enrols the man’s partner and his doctor in the production of 
the Swedish Viagra man. This discourse also directs the relationships the man 
develops and maintains with his partner and his doctor, and tries to approach 
the partner and doctor to help them maintain Viagra-mediated relationships with 
the consuming Swedish Viagra man. Chapter 7 then discusses the creation of the 
Swedish Viagra man and the particular characteristics assigned to him. It pre-
sents an analysis of the culturally specific aspects of Swedish masculinity which 
Pfizer (or at least its marketing departments and agencies) deemed strong and 
stable enough to be associated with a product which addresses an image of failed 
masculinity.
Chapter 8 concludes this volume by returning to the multiplicity of aspects that 
the term pharmaceuticalization contains. Using the literary trope of the Swed-
ish Viagra man, we discuss how the local and the global interact in the Swedish 
context.
Glocal pharma
The changes in governance practices to reflect pharmaceuticals’ presence, the 
redefinition of health problems as sites of pharmaceutical treatment and the crea-
tion of new techno-social identities around drugs are general aspects of pharma-
ceuticalization apparent in the Swedish case material we present in this book. 
However, they are also aspects of the local, specific to the Swedish context, which 
are important to analyze and integrate into a concept of pharmaceuticalization 
because they show nodes in the pharmaceutical network which are receptive to 
influence by local specificities. The results of these local influences are what we 
refer to as the ‘glocal of pharmaceuticalization’, the local specificities which 
appear in the discourses embedding global pharmaceutical products and practices 
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in local markets. When local responses to global pharma are enacted in Sweden, 
the local pushes back.
Persistent traces of the local can be interpreted in a couple of different ways. One 
could see the process of pharmaceuticalization as an irresistible, all-consuming 
process, and these local specificities can point to weaknesses in the process. Our 
observations could be interpreted as aspects of pharmaceuticals where they are not 
quite strong enough to resist and redirect the local context to their will. Or, these 
nodes of difference could be seen as examples of where the pharmaceutical dis-
course is flexible enough to consume and adapt to the local context, where it shows 
its strength through a colonizing, but not neutralizing practice of meeting local 
cultures. As Williams and colleagues note, ‘there are important sources of resist-
ance to the expansion of pharmaceutical markets from the media, government, 
medicine, patients and diverse publics thereby making de-pharmaceuticalization 
a possibility in principle, if infrequent in practice’ (Williams et al. 2011a, 722). 
Perhaps our examples of the glocal response to subsidizing Viagra in Sweden 
in Chapter 2 can indicate that this is more than mere optimism. Resistance is 
possible. But our analysis of the information sites for Viagra treatments and the 
medical discourse around Viagra and alpha-blockers in Sweden are harder to read 
as support for this optimism.
In drawing conclusions about the glocal of pharmaceuticalization, it is useful to 
ask how a drug’s presence has altered the concept of a disease and its treatment, 
who suffers from it, and how to cure it, in the local context and internationally. 
This book shows how drugs interact with stereotypical imaginaries of a patient, 
and include markers of class, race and sexuality. Drugs can influence laws and 
policies to regulate the practices of both doctors and patients. Yet it is not the 
chemical compound that prescribes behaviours or identities, it is the network of 
decision makers, commercial actors, medical experts and consumers who attach 
the drug to specific demands, images and expectations to influence the behaviours 
of groups they are trying to govern, cajole or cure. And because actors in different 
countries have different cultural starting points and are working within different 
institutional frameworks, how they use a pharmaceutical varies.
By looking at the pharmaceutical nexus and its actors, we can see that a global 
drug does more than fix the biomedical body’s problems. As the following chap-
ters will show, the mere existence of a pharmaceutical product impacts medi-
cal knowledge and discourses, reinforces and even constructs cultural ideas and 
identities, changes the practices of experts and laypeople, and changes policy. But 
local circumstances also influence how drugs are presented and prescribed and 
what they are allowed to be. Together, the global and local aspects of the pharma-
ceutical nexus create glocal pharma.

Part 1
Changes in forms of 
governance

2  Governing by drugs
Conniving patients, beguiled 
doctors and disciplining drugs1
Ebba Sjögren and Ericka Johnson
In April 2001, the Swedish government decided to immediately remove Viagra 
from the public pharmaceutical reimbursement system (Swedish Book of Statutes 
2001, 140). All patients who still wanted their use of these pharmaceuticals to be 
subsidized were henceforth required to submit individual applications for subsidy 
to the government itself.
This highly publicized and much-debated decision marked a clear break with 
the established practice whereby prescription drugs that were granted marketing 
approval were consistently included in the public pharmaceutical benefits scheme. 
Under this scheme, patients prescribed subsidized drugs paid only a portion of 
their direct cost. Following the government’s decision, Viagra was still available 
for purchase in pharmacies by those holding prescriptions, but the patients were 
now to assume the cost.
The decision to exclude Viagra from the benefits scheme was made in a setting 
of long debate concerning the rising costs for health care in general, the growing 
public expenditure on pharmaceuticals in particular, and a concern that a block-
buster drug like Viagra would put undue pressure on the public purse.2 Yet having 
the government decide on the subsidization of Viagra on a case-by-case basis was 
as extraordinary as it sounds. Prior to this, decisions were made on an aggregate 
level, and this change is an example of the first aspect of pharmaceuticalization 
we will be discussing, when drugs change the form of governance (Williams et al.  
2011a). Because of Viagra (and concerns about pharmaceutical costs in general 
at the time), case-by-case decision practice was first applied and then a new gov-
ernmental agency was instituted with the responsibility for deciding which phar-
maceuticals to subsidize: the Pharmaceutical Benefits Board (here called the TLV 
to reflect its current name, the Dental and Pharmaceutical Benefits Agency).3 This 
new government agency changed the configuration of commercial, regulatory and 
public interests at the pharmaceutical nexus in Sweden, and led to a series of court 
cases questioning the TLV’s decisions, which we will examine in this chapter. 
That the decision to deny Viagra from the public pharmaceutical benefits scheme 
was appealed through the courts is particularly interesting because, while this 
option had existed in Sweden for some time, it was rarely employed (Abraham 
and Lewis 2000, 71). The Viagra cases marked a new way of using the courts in 
the regulation of pharmaceutical policy, but did so within a changed bureaucratic 
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landscape that had a new regulatory body and was grappling with how to define 
disease, with questions of trust, and with the involvement of patient groups and 
commercial actors.
Many Western welfare states have, in recent decades, faced the question of how 
to set boundaries for public fiscal responsibility for health care services. One recurrent 
solution has been to create central health care assessment organizations tasked with 
evaluating the appropriateness of undertaking and publicly funding particular treat-
ment methods. The importance of using scientific facts as a decision-making tool in 
these organizations is typically emphasized (Jost 2005) and has been explored and 
criticized by social scientists (Pope 2003; Timmermans and Berg 2003, Gray and 
Harrison 2004; May et al. 2006). But whatever the shortcomings of, for example, 
evidence-based medicine and clinical trials, the organized collection, evaluation, 
codification and distribution of evidence about treatment effects is still conceived 
of as a means to achieve a more fair and effective prioritization of limited resources 
(cf. Cuyler and Newhouse 2000; Mitton and Donaldson 2004). In response to the 
conceptualization of an evidence-based prioritization imperative, state bodies have 
been constructed and tasked with the job of turning scientific facts into public policy. 
The TLV, which was formally launched in October 2002, is an example of such an 
organization.
By law, the decision-making board of the TLV is instructed to approve subsidy 
for a drug when: ‘the cost of using the pharmaceutical . . . is reasonable from med-
ical, humanitarian and socio-economic perspectives’ (Swedish Book of Statutes 
2002, 160, Section 15; authors’ emphasis added). The TLV is further instructed 
to take into consideration the three principles of priority-setting that Parliament 
approved in 1997, namely: equal human value, meaning all people have an equal 
right to life and health, need solidarity, that those with greatest need of treatment 
have priority over those with lesser need and cost-effectiveness, that the benefit of 
treatment must be reasonable in relation to its cost (Socialutskottet 1997).4
The subsidization status of Viagra was one of the first cases the TLV decided. 
After a period of deliberation, the TLV decided to exclude Viagra entirely from 
the Swedish pharmaceutical benefits scheme on 26 March 2003. The marketing 
company, Pfizer AB, soon appealed the TLV’s decision. A series of court battles 
ensued, ending with a decision by the Swedish Supreme Administrative Court on 
14 March 2008. In its ruling, the court upheld the TLV’s decision to exclude Via-
gra from the pharmaceutical benefits scheme in Sweden. Prior to this, two lower 
courts had overturned the TLV’s decision and approved restricted subsidy for 
Viagra when treating specific categories of patients, which were deemed to fulfil 
the legal criteria for subsidy. Still today, Viagra is not eligible for use with public 
subsidy. As the Swedish Supreme Administrative Court took this decision, there is 
no further legal recourse for appeal of the case. However, the option remains for 
the pharmaceutical marketing company to submit a new application for subsidy if 
and when substantively new developments open for the possibility of a different 
outcome.
In this chapter, we will place the argumentation in the TLV’s decision justifica-
tion documents and the various court rulings in a discussion of trust in regulatory 
bodies and expert practices by looking at how the TLV and the courts conceive 
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of patients, doctors and subsidized pharmaceuticals. In particular, we will focus 
on how patients, doctors and drugs are framed within the subsidy discourse sur-
rounding Viagra and how drugs themselves are used as diagnostic tools and to 
enforce subsidy decisions. We will argue that, notwithstanding the legal criteria 
for approving subsidy, the ultimate denial of subsidy in the Viagra case relied on 
a construction of imagined behaviours and roles for patients, doctors and drugs as 
recipients and enforcers of subsidy decisions. A comparison of the various deci-
sion justifications points to a concern for patient misuse of the subsidy, difficulties 
for doctors to deny subsidy and an organizational concern for bracket creep, all of 
which were thought to potentially lead to unreasonably high public spending on 
Viagra. In our discussion we problematize some of the assumptions on which the 
framing of actors is based.
While the particular circumstances of the Viagra case are specific to Sweden, we 
see the TLV and its work as an example of a strengthened emphasis on mechanical 
objectivity and bureaucratic compliance in the management and control of health 
care services, issues which are relevant in other contexts, as well. This develop-
ment – while by no means unidirectional – is nonetheless relevant to consider in 
light of the many rules, standards and decisions which target the contents of medi-
cal practice from a distance (Timmermans and Berg 2003; Lagrelius and Sjögren 
2004). We see that the example of Viagra raises a number of pertinent practical 
and theoretical concerns linked to the emergence of techno-social identities. We 
also want to emphasize the way the pharmaceuticals themselves, especially the 
materiality of their delivery technologies, were enrolled in the regulatory deci-
sions and that these actors shaped the local regulatory practices.
Empirical material
The following account focuses on how the TLV justified its decision to deny 
subsidy for Viagra use, and how these justifications were judged. Our material 
derives from: the TLV’s original decision justification document, 26 March 2003 
(Pharmaceutical Benefits Board 2003a); the argumentation set out in court rulings 
made by the Stockholm Lower Administrative Court in June 2004 (Länsrätten 
2004a); the argumentation set out in court rulings made by the Stockholm Admin-
istrative Appellant Court in April 2005 (Kammarrätten in Stockholm 2005a); the 
argumentation set out in court rulings made by the Supreme Administrative Court 
in March 2008 (Regeringsrätten 2008 a, b, c).
We will also consider the contents of the Pharmaceutical Benefit Board’s deci-
sion justification documents concerning two other pharmaceutical-based treat-
ments of erectile dysfunction for which the TLV approved subsidy: Caverject and 
Bondil. The TLV’s decisions in these two cases were referenced in several court 
proceedings, thereby making them empirically relevant for our analysis.
Of note is that the decisions these documents present were made by collec-
tives, and they were not unanimous decisions. Dissenting members of the TLV’s 
decision-making board and the Supreme Administrative Court have stated their 
grounds for disagreeing with the final outcome of particular decision-making pro-
cesses in writing.
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The Pharmaceutical Benefits Board, the law and Viagra
With the creation of the TLV, by law, the decision about whether to subsidize a 
pharmaceutical was to be determined by characteristics of its use.5 Regardless of 
which conclusion the TLV reaches as regards a pharmaceutical’s subsidization 
status, it must publicly justify this outcome in a so-called decision justification 
document. This document has an important legal status. It is the basis for any 
appeal of the TLV’s decision (Swedish Book of Statutes 2002, Section 26, 160). 
Various procedural requirements are set out for the appeals process. Notably, the 
law restricts the right of appealing the decision concerning a particular drug to the 
company marketing that pharmaceutical. The appeal must be submitted within 
a strict time frame. The legislation also sets out that it is the Stockholm County 
Administrative Court (henceforth ‘the Lower Court’) which will rule on an appeal, 
followed by the Administrative Court of Appeal in Stockholm (henceforth ‘the 
Appellant Court’) and the Supreme Administrative Court (‘the Supreme Court’).
In comparison to the fairly detailed procedural regulation of the appeals process, 
the substantive basis for judicial review of the Pharmaceutical Benefits Board’s 
decision-making is less clear-cut. The legislation does not specify in detail what it 
means for a pharmaceutical to have a ‘reasonable’ cost of use. Some clarification 
is provided in the legislative bill (New Pharmaceutical Benefits Bill 2001). How-
ever, this document also includes repeated references to the need for imprecise 
instructions for the TLV due to the difficulty of specifying practice for an organi-
zation with a new and complicated task. The onus is therefore on the TLV to make 
decisions that can be justified and judged as being in accordance with the TLV’s 
governing legislation. It is to a consideration of these justifications, and the court’s 
judgements, to which we now turn. These can be briefly summarized as follows:
2003: The TLV denies subsidy for Viagra
In its decision justification document from March 2003, the TLV acknowledges 
that Viagra may be a reasonable drug to subsidize for patients with severe ED. 
However, the judgement is that the agency does not have the means for ensur-
ing that subsidy is restricted only to those patients whose treatment needs fulfil 
the legal criteria for publicly funded pharmaceutical use (Pharmaceutical Ben-
efits Board 2003c, 4); the risk that non-worthy patients would receive subsidized 
medicine and opening the door for diagnostic bracket creep is such that all use is 
denied subsidy.
2004: The Lower Court approves restricted subsidy to ‘reasonable’ 
patients with certain medical conditions or a treating specialist
In 2004, the Lower Court rules to reverse the TLV’s denial of subsidy, and approves 
subsidy with restrictions to patients with certain medical conditions such as diabetes 
or cardiovascular diseases, or who were prescribed the drugs by a urologist. Unlike 
the TLV, the Lower Court concludes that the scientific studies the pharmaceuti-
cal companies submitted show the pharmaceutical to be generally cost-effective, 
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and therefore reasonable. In contrast to the TLV, the Lower Court also judges that 
the two other pharmaceutical-based treatments of male impotence – Caverject and 
Bondil – are relevant comparisons. Viagra (and Cialis and Levitra) was deemed 
cost-effective in comparison to Caverject and Bondil, which had been approved 
for subsidy in the intervening year between the TLV’s decision on Viagra and the 
Lower Court’s decision (see also Länsrätten in Stockholm 2004b; 2004c, 13, 25).
The TLV immediately appealed this decision. While the appeal was pending, 
Viagra (and Cialis and Levitra) was not subsidized.
2005: The Appellant Court approves restricted subsidy  
on different grounds: specialists to make appropriate  
diagnosis of ‘reasonable’ patients
The Appellant Court did not uphold the TLV’s subsequent appeal of the Lower 
Court’s ruling. However, the Appellant Court did change the definition of the 
restrictions for approved subsidy. In the Appellant Court’s ruling, Viagra was 
granted restricted subsidy for: ‘patients with the [medical condition] severe erec-
tile dysfunction, regardless of underlying illness. Initial prescription [is] to be 
made by a physician with specialist competence in urology’ (Kammarrätten in 
Stockholm 2005, 18).
In contrast to the Lower Court’s conclusion, the Appellant Court agreed with 
the TLV’s initial conclusion that the cited clinical studies showed that only patients 
with severe male impotence were reasonable to treat. However, the Appellant Court 
agreed with the Lower Court’s argument that medical practitioners could depend-
ably identify patients who were ‘reasonable’ to subsidize. Yet the diagnosis-based 
restriction the Lower Court set was not deemed to correctly identify those patients 
who should receive subsidized treatments. Rather, the Appellant Court argued that 
restricting subsidy to initial prescription by a medical specialist on male reproductive 
organs (urologist) was a (more) dependable way of determining ‘reasonable’ patients.
The TLV also immediately appealed this decision. It would take three years for 
the Supreme Court to make its decision in the case.
2008: The Supreme Court denies all subsidy
Based on the existence of Bondil and Caverject, the uncertainty of a ‘severe ED’ 
diagnosis, the imagined behaviours of patients and doctors and the risk for diag-
nostic bracket creep, the Supreme Court denied all subsidy of Viagra (and Cialis 
and Levitra) in 2008. We will now discuss this decision.
Discussion: conniving patients, beguiled  
doctors and disciplining drugs
Diagnostic dilemmas: identifying the right patients to  
treat with subsidized drugs
In the final Supreme Court decision that Viagra would not be subsidized, the TLV 
argued it would be impossible to limit the subsidization of Viagra to appropriately 
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needy and deserving patients, and therefore the drug should not be subsidized at 
all. As the TLV puts forward in its argument:
Doctors will rely upon the patient’s responses and understandings [to ques-
tions about their ED], which in practice means that it is impossible for the 
individual doctor to deny the patient a subsidized prescription if the patient 
demands it. Likewise, the patient can nearly always be expected to want to 
have the medication subsidized.
(Regeringsrätten 2008a, 3)
The implication is that all, or at least a significant number of, patients with mild 
ED – those not considered deserving of the subsidy – could be expected to con-
nive and wile their way into a diagnosis of severe ED, beguiling their doctors into 
making this diagnosis and thereby receiving subsidized Viagra instead of paying 
for it themselves.
Why are patients and doctors represented this way? Why does the TLV (and 
apparently the Supreme Court, which agreed to its arguments) distrust patients 
and declare doctors incapable of withstanding a patient’s wishes in the clini-
cal setting, implying that the layperson/expert relationship has broken down?6 
Other research has shown this dynamic does occur in the patient/doctor meet-
ing (cf. Hirschauer 1998, 16; Timmermans and Berg 2003, 121; Friberg 2006). 
And empowered, knowledgeable patients who make demands on their health care 
providers exist, and are cultivated by both patient groups and care providers. But 
one would assume the belief still exists that doctors are capable of objectively 
diagnosing disease. Yet, actually, the (in)ability of doctors to assess the severity 
of ED was already questioned and debated in the original TLV decision document, 
although three board members disagreed with this, stating:
The only ones who can determine if a patient has severe ED are the patient, 
his partner, and his doctor. This type of decision occurs daily and repeat-
edly for all sorts of illnesses in a doctor’s day-to-day practice, with varying 
degrees of certainty. To determine ED can hardly be more difficult than to 
determine if a patient is suffering from depression, pain or any other state for 
which the doctor must primarily rely on information from the patient.
(Pharmaceutical Benefits Board 2003c, 5)
But they were in the minority. The idea of conniving patients and beguiled doctors 
continued to appear and became one of the important framing arguments in the 
Supreme Court decision. We suggest that when it appears in the arguments put 
forward to the Supreme Court, the construction of conniving patients and beguiled 
doctors is relating and responding to earlier arguments about the reasonableness 
of Viagra and prior decisions to subsidize other medical treatments of ED.
It is important to keep in mind that throughout the debate about subsidies, it 
was generally agreed that Viagra was a ‘reasonable’ drug to subsidize for severe 
ED.7 The Supreme Court, for example, stated that it was ‘uncontested that medical 
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treatment of severe ED is to be considered urgent and that treatment with Viagra 
in these cases is cost-effective’ (Regeringsrätten 2008a, 9). And in the original 
decision justification document, the TLV formulated its views on the ‘reasonable-
ness’ of treating patients with severe ED as follows:
[T]he diagnosis [of] ED is so wide that one can include everything from com-
plete inability [to achieve an erection] to the occasional inability [to achieve 
an erection]. The Board can therefore determine that the degree of suffering 
for all individuals who are affected by ED is not so great that it can dictate 
that the group as a whole has a large need of care in relationship to many 
other patient groups. In addition, a gradual reduction in erectile ability is a 
natural part of aging. According to the Board’s understanding, it can hardly 
be the general public’s (allmännas) task to ensure that a person can live with 
the same functionality for the entire life. . . . The Board has considered if it 
would be possible to adopt a qualified decision which would allow Viagra to 
be subsidized only for those who suffer from severe ED, which can be more 
appropriate to treat medically and where one can assume that the medicine 
would be cost-effective. The Board cannot, however, find appropriate restric-
tions which would make it possible in this case to limit the subsidy to only 
those who have a socioeconomically reasonable need of subsidized treatment.
(Pharmaceutical Benefits Board 2003c, 4)
Thus, already in the original decision document the TLV admits it may be reason-
able to subsidize Viagra for patients with severe ED, but that existing medical 
practice is not capable of or trusted enough to provide diagnoses that meet the 
level of certainty that the TLV as a bureaucratic institution demands, that is to 
distinguish without a doubt which patients have mild ED and which have severe 
ED. The problem was, for the TLV and the Supreme Court, there was no reliable 
way to determine if a patient suffered from severe or merely mild ED.
Debates over diagnostic tools: questionnaires,  
urologists and patients’ accounts
A tool exists for measuring ED: the International Index of Erectile Function (IIEF). 
However, in the various decision-making processes involving the subsidization 
status of Viagra disagreement recurred about its ability to actually determine the 
severity of ED. According to the TLV in the court documents, this questionnaire 
was developed for other (research) purposes and is only really used as a support 
or crutch in the patient meeting, and not as a diagnostic instrument (Regeringsrät-
ten 2008a, 3). The TLV’s position, as described in the Supreme Court ruling, is 
that: ‘the questionnaire provides no guarantee that the information provided by 
the questions is a mirror of reality’ (Regeringsrätten 2008a, 3). Furthermore, the 
TLV does not see the IIEF as a necessary diagnostic tool because doctors can 
diagnose their patients’ ED without it. Yet when making this diagnosis, doctors 
will have to rely on patients’ information and experiences, rather than a scientific 
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tool. Therefore, the TLV claims that doctors are powerless to deny the truth of 
patients’ stories, thus making it impossible to deny the patients subsidized Viagra 
if the patients demand it (presumably by telling doctors they have severe ED) 
(Regeringsrätten 2008a, 3).
Expert testimony, particularly in the Lower Court, supported the claim that the 
IIEF was primarily used as a conversational aid, not a diagnostic tool, and that 
doctors did have to rely on conversations with patients to determine the sever-
ity of the ED. Like in the dissenting opinion of the original decision document, 
arguments were put forth through the entire debate that this type of diagnosis is 
something doctors are qualified to do, and do in their daily practice with many 
other diseases. However, these arguments did not provide sufficient reassurance 
to the TLV or the Supreme Court that the diagnosis of severe ED was being made 
on certain, scientific grounds.
The difficulty of diagnosing severe ED also carried with it another problem for 
the TLV. According to the Supreme Court documents, because it was impossible 
to identify objectively, scientifically and with certainty the group of patients who 
should be covered, it would also be impossible to develop bureaucratic structures 
which could check that the subsidy was correctly applied. Following on from this 
was a series of arguments against the use of specialist doctors to regulate the pre-
scription of Viagra to those with severe ED, which the Appellant Court decision 
had dictated. However, one of the biggest problems with relying on specialists to 
diagnose severe ED was an uneven distribution of specialists in the country, which 
meant many people would not have access to a specialist. If patients were forced 
to rely on visiting a specialist for the prescription of the drug, those patients liv-
ing in areas without access to them would be discriminated against by the health 
care system, which would go against the principle of equal access to health care 
guaranteed by law (Swedish Book of Statutes 1982, 763). Additionally, the TLV 
argued that restricting prescription rights to specialist doctors could only be moti-
vated for control reasons, not medical reasons, which would not lead to an optimal 
use of resources within the health care system (Regeringsrätten 2008a, 3–4).
Likewise, when discussing the use of specialist doctors the TLV asserted that 
because the disease of ED is flexible and patients’ experience of it variable, both 
over time and from patient to patient, it is not a sufficiently stable condition to war-
rant one initial truth-determining moment with a specialist. An initial prescription 
by a specialist would, therefore, not guarantee that the medicine would only be used 
for the most severe cases over an extended period of time (Regeringsrätten 2008a, 
4). A man with severe ED at one appointment may get better and have mild ED 
later. Thus there was no trusting that even a specialist could apply the criteria for 
subsidizing the medication appropriately. However, we feel that the most interest-
ing element in the debate is the existence of and subsidy for Bondil and Caverject.
Pharmaceuticals as alternative tools for  
resolving problems of diagnosis
The TLV granted subsidy for Bondil and Caverject a few months after the agency 
denied subsidy for Viagra (Pharmaceutical Benefits Board 2003d; 2003e). Bondil 
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is a medication in ‘dissolvable stick’ form inserted into the urethra. It can be 
administered by the man himself, after initial training by a medical professional, 
and produces an erection after about ten minutes. Caverject is injected directly 
into the erectile tissue of the penis. It is also possible for the man to inject him-
self with Caverject, although training with a medical professional is also rec-
ommended. Both Caverject and Bondil were, at the time, more expensive than 
Viagra, although they now cost about the same per dose. So, as Pfizer argued in 
the court cases (and as was also noted in the dissenting opinions in both the orig-
inal Caverject and Bondil decision documents; Pharmaceutical Benefits Board 
2003d; 2003e), Viagra was more cost-effective than Caverject and Bondil – all 
else being equal (Länsrätten in Stockholm 2004, 9; Kammarrätten in Stockholm 
2005, 16). As previously noted, whether all else was equal was very hotly con-
tested. For both the TLV and the Supreme Court, it was important for the decision 
to deny subsidy for Viagra that neither Caverject nor Bondil was particularly easy 
or pleasant to use. Notably, the Supreme Court justified its decision to uphold the 
TLV’s decision to deny subsidy for Viagra since:
It is true that the drugs Caverject and Bondil are subsidized. In the decision 
regarding these two substances, however, it was assumed that because of 
the methods of use, they will primarily be used to treat patients who suf-
fer from the most severe forms of ED. The general subvention decision is, 
therefore, in practice limited to only those cases of ED for which would also 
be reasonable to subsidize Viagra. The subsidy for Caverject and Bondil 
can therefore not be used as an argument that Viagra should also be granted 
general subsidy.
(Regeringsrätten 2008a, 8)
Also in the Lower and Appellant Court rulings it was implied, and sometimes 
stated outright, that a patient with mild ED might be tempted to try Viagra, but he 
would not be tempted to try injecting or inserting medicine directly into his penis. 
Repeatedly in the documents it is claimed that Bondil and Caverject have built-
in mechanisms that prevent their ‘misuse’ or at least their ‘mis-subsidization’ by 
patients suffering from only mild ED, and the TLV can thus claim that it is provid-
ing a subsidized treatment for patients who suffer from severe ED, which will not 
be misused (Länsrätten in Stockholm 2004, 9). Thus, one could assert that when 
the TLV argues before the Supreme Court that Viagra should not be subsidized, it 
is really saying that there is no sufficiently reliable medical tool in clinical prac-
tice to determine the severity of ED which would fulfil the objectivity demands 
of the bureaucratic subsidy system. According to the TLV’s arguments, patients 
can be expected to exaggerate the severity of their problem in order to receive 
(desirable) subsidized drugs. Doctors will probably be beguiled or bullied into 
agreeing with the patients. And the diagnostic questionnaire the industry and cer-
tain medical practitioners suggest for determining severity is not a reliable tool, 
either. Instead, in the case of ED, the bureaucracy that regulates subsidies relies on 
the physical characteristics of two other medicines to discipline the patients and 
determine the severity of disease. Bondil and Caverject become ‘bitter pills’ that 
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only a sufficiently ill person could reasonably be expected to swallow. Thus, their 
use by a given patient reifies a diagnosis of severe ED.
Reliance on the physical characteristics of a technology (pharmaceutical) 
to prevent misdiagnosis and mis-subsidizing of drugs against ED is important 
because it is thought to reduce the risk of diagnostic bracket creep, that is to limit 
the risk that the drug will be prescribed for a larger group of symptoms or for less 
severe symptoms that were previously untreated. There are other examples where 
the TLV pinned its hopes on a technology that might serve to remove ambiguity 
related to the correct diagnosis of ‘treatable’ patients, such as the organization’s 
review of pharmaceuticals for the treatment of stomach acid–related disorders 
(Pharmaceutical Benefits Board 2003b; see also Sjögren 2006).
The assertion of a risk of diagnostic bracket creep goes back to the argument 
that a patient is always going to want to have his medication subsidized, even if 
he knows that he really only has mild ED (or a stomach ache), and will therefore 
pressure his doctor into agreeing that he actually has severe ED. Since, in this 
scenario, the patient’s description of ED is not to be trusted, alternative methods 
for creating unambiguous knowledge about the condition must be used. Doctors, 
in the TLV’s ideal world, must be able to rely on scientific diagnostic tools to help 
them make correct decisions in their clinical practice. But since the available tool 
(the IIEF) is deemed unreliable, instead the TLV relies on the drugs themselves to 
do the disciplining work.
Conclusion
The TLV was purposefully created to decide the subsidization status of prescrip-
tion pharmaceuticals and to take part in shaping the use of public funds for phar-
maceutical spending. In this chapter, we have focused on how the TLV and the 
courts conceived of patients, doctors and subsidized pharmaceuticals when deter-
mining the subsidization status of Viagra. Notwithstanding the legal criteria for 
approving subsidy, we have argued in the previous section that the ultimate denial 
of subsidy in the Viagra case relied on a construction of imagined behaviours 
and roles for patients, doctors and drugs as recipients and enforcers of subsidy 
decisions. A comparison of the various decision justifications points to a suspi-
cion of patient misuse of the subsidy, difficulties for doctors to deny subsidy and 
an organizational concern for bracket creep, all of which could potentially lead 
to unreasonably high public spending on Viagra. In this section, we will reflect 
on the consequences of these observations, against the organizational remit of 
the TLV and the role of pharmaceuticals in fulfilling the regulatory ambitions of 
the organization. In particular, we will touch on the use of pharmaceuticals as 
disciplining technology and a possible differentiation between bureaucratic and 
treatment compliance.
Use of pharmaceuticals as disciplining technology
The term disease mongering is often used for the process by which the existence 
of a drug (or other form of treatment) is used to create and/or promote the notion 
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of a disease meriting treatment. Marshall (2002; 2006) and Tiefer (2000; 2006) 
have shown this development using the case of erectile dysfunction and the mar-
keting of Viagra, but other drug–disease pairs have also been connected to dis-
ease mongering: the development of SSRI inhibitors and the increased diagnosing 
of depression (cf. Healy 2004), and lifestyle drugs and diseases like hair loss 
(Rogaine), wrinkles (Botox) and shyness (beta-blockers) (Elliott 2003; Moynihan 
and Cassels 2005). In these cases, the existence of a treatment serves as a motiva-
tion behind the medicalization of a particular state of being and the definition of 
a disease.
Studies within science, technology and medicine have examined how medica-
tions can be ascribed even stronger ontological roles. For example, in his explo-
ration of bronchodilators, Willems demonstrates how these drugs work within a 
network of researchers, laboratory assistants and measurement devices to create 
disease classifications. In this example, the drugs ‘define diseases and reorganize 
the body by creating new identities for it’ (Willems 1998, 118). Similar events have 
been detailed for arteriosclerosis (Mol 2002), liver disease (Law and Singleton 
2005) and IUD contraception practices (Dugdale 2000). Medical technologies can 
be silent and unrecognized actors that take part in producing particular configura-
tions of diseases or patients, as an outcome of the technologies’ use in a network 
of actors. In the present case, however, we understand the TLV’s use of Caverject 
and Bondil as a conscious and explicit deployment of technologies to this purpose.
As described earlier, the TLV deemed Viagra reasonable to subsidize for 
patients with severe ED. However, the tools necessary to identify and sort patients 
based on the severity of ED were deemed insufficiently reliable. This highlights 
that the clinical practice involved in prescribing Viagra is messy. That clinical 
practice is messy makes it difficult to regulate, difficult to define and certainly 
difficult to standardize (Berg and Mol 1998; Timmermans and Berg 2003). So 
when a bureaucratic body such as the TLV is confronted with obvious examples 
of how that messy clinical practice is going to be difficult to regulate (and difficult 
to enforce any regulation within), the organization looks for other means of dis-
ciplining it. By granting Bondil and Caverject subsidy while denying subsidy for 
Viagra, the TLV is relying on particular physical characteristics of these two drugs 
to replace the diagnostic responsibilities and perceived shortcomings of medical 
doctors in clinical practice.
We suggest that the way that the TLV searches for (and finally finds in the case 
of Caverject and Bondil) an ‘objective’ tool to define and diagnose severe ED can 
be related to the two different types of objectivity explicated by Porter (1995). 
Porter differentiates between disciplinary objectivity and mechanical objectivity. 
The former is found in specialist communities and can be characterized by con-
sensus between equals, trust, tacit knowledge and the artful application of insight. 
It is also associated with a disdain for standards. In many ways, disciplinary 
objectivity is what the expert witnesses relied on when they claimed throughout 
the various decision documents analyzed in this chapter that doctors are entirely 
capable of diagnosing severe ED when meeting patients, with or without the assis-
tance of the IIEF. It is also what the Appellant Court decided to rely on when it 
ruled that subsidized Viagra should initially be prescribed by urologists.
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Mechanical objectivity, on the other hand, replaces trust in experts with 
mechanical rules, procedures and numbers, and is what the TLV is trying to find 
when relying on Caverject and Bondil to define severe ED. Porter argues that 
mechanical objectivity through independently verifiable rules and procedures can 
be used by an expert community (like the TLV) to create legitimacy. It ‘is a way of 
making decisions without seeming to decide; [it] lends authority to officials who 
have very little of their own’ (Porter 1995, 8). Perhaps it is no surprise, then, that 
the TLV, which was created only in 2002, would rely on this type of mechanical 
objectivity. Not only does its young age mean that it needs to create legitimacy 
for its decision, but also the very fact that the agency is being taken to court over 
its decisions indicates that the TLV’s authority is being questioned. Furthermore, 
the TLV is looking to intervene in what has historically been an activity (treat-
ment choice) that has constituted an important part of the mandate of a strong 
professional group (physicians) (cf. Porter 1995, 228). Taken together, this would 
arguably encourage reliance on mechanical objectivity, rather than the trust and 
legitimacy of an expert community, and the Supreme Court decision supports the 
employment of this kind of mechanical objectivity.
Bureaucratic versus treatment compliance
Given how the process of determining Viagra’s subsidization status unfolded, 
there was no move to adopt any kind of more flexible version of objectivity. As a 
parallel to Porter’s differentiation between disciplinary and mechanical objectiv-
ity, we would posit that the TLV’s deployment of Caverject and Bondil is intended 
to take part in creating circumstances that minimize the risk of non-compliance. 
But it is non-compliance in a particular manner and mode.
As a consequence of the TLV’s formal and delimited task to make knowledge-
based decisions about the subsidization status of prescription pharmaceuticals, 
we see a concern with the bureaucratic compliance to these decisions. This is in 
contrast with the general compliance to the agency’s individual decisions within 
medical practice. This contrasts with what we would loosely term treatment com-
pliance, by which we refer to compliance that involves consideration of multiple 
rules, decisions and principles in an individual case. The latter form of compli-
ance is typically inferred in relation to treatment guidelines, for example, where 
it is common practice to state that the guideline is a standard, which is discretion-
ary to follow, rather than a directive, which must be adhered to (cf. Brunsson 
and Jacobsson 2000). These two ideas of compliance imply very different ver-
sions of what constitutes ‘good practice’, where the latter is more malleable and 
ambiguous. It is worth reminding the reader here that the decisions the TLV takes, 
and its desire for objective diagnostics and disciplining tools, come at a point in 
time when the Swedish health care and social insurance agencies are under fire 
for excessively permissive long-term sick leave in what the media presented as 
unreasonably large segments of the populations, thereby draining the coffers of 
the social welfare state.
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The more ‘singular’ version of bureaucratic compliance constructs a differ-
ent scope and means for balancing judgement and distributing responsibility 
between patient/doctor/TLV and the state than does the idea of treatment compli-
ance. Notably, scholars have argued that regulation, which maintains ambiguity 
over the conditions for appropriate use, contributes to moving responsibility away 
from those with the formal power to regulate use (cf. Rappert 2001).
We therefore see certain parallels between how the TLV itself is regulated and 
evaluated, and how the agency seeks to regulate medical professionals. In the 
case of the TLV, there are precise procedural requirements for the organization’s 
decision-making process and comparatively loose substantive criteria. Due to 
the manner and means of oversight – primarily through the requirement for pub-
lic accounting of the grounds for every decision outcome, and further through 
appeals – it is the mechanical objectivity of the TLV that is emphasized rather than 
the expert judgement that the agency is encouraged to use.8 That the TLV is evalu-
ated for how it makes and justifies decisions could arguably serve to emphasize 
the organization’s procedural, bureaucratic compliance (cf. Power 1997). This 
could, in turn, shift the responsibility for perceived shortcomings in how bounda-
ries for public fiscal responsibility for pharmaceutical use are drawn to the TLV 
(and, by extension, individual medical practitioners) – and away from the national 
policymakers who have given the organization this challenging task.
How the TLV was tasked with regulatory responsibility and how it perceived 
its role as a regulating body are examples of local, nation state–specific responses 
to the integration of international pharma within an allegedly culturally neutral, 
objective and scientific medical knowledge paradigm. While of course, the TLV 
exists within an international pharmaceutical regulatory framework, especially 
the EU one, as Abraham and Lewis (2000) explore, it and its decisions are none-
theless indelibly tinted by the cultural aspects of the Swedish medical system. 
The introduction of a drug like Viagra refracts uniquely within it as the drug and 
framework encounter each other. A new drug and a new regulatory body led to 
new regulatory tools and, because of local structures (like the uneven distribution 
of urologists throughout the country) and the culturally specific ideology of the 
health care system’s framework (with the principle of equal access to health care 
guaranteed by law), the drug precipitated a debate and decision about subsidy 
based on local structural and ideological aspects of the Swedish health care sys-
tem. The glocal of Viagra is inseparable from the local of the TLV and erectile 
dysfunction. This chapter articulates the construction of a Swedish Viagra col-
oured by the TLV and value judgements about what ED is within the ideology of 
the Swedish health care system. This glocal Viagra becomes a drug with uniquely 
Swedish diagnostic and prescription values, practices and concerns.
Notes
 1 An earlier version of this chapter has been published as Sjögren, E. and Johnson, E. 
(2012). Conniving Patients, Beguiled Doctors and Disciplining Drugs: Justifying the 
Denial of Subsidy for Viagra Use in Sweden. In Martin Letell, Bengt Larsson and 
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Håkan Thorn, Re-engineering the Social? Transformations of the Swedish Welfare 
State. Basingstoke: Palgrave, 181–96.
 2 For a discussion of this process, see Christensen and Lægreid (2002); Lindbom (2002); 
Premfors and colleagues (2003).
 3 As of 1 September 2008, the TLV broadened its scope of responsibility, which now 
also includes the evaluation of dental treatments.
 4 From the TLV’s webpage, www.tlv.se, accessed 5 June 2008. This and all other transla-
tions are the authors’ own.
 5 When the pharmaceutical benefits scheme was first launched, the inclusion of a drug 
in the scheme was determined by the medical condition(s) it was approved to treat. 
Medicinalstyrelsen, a precursor to the National Board of Health and Welfare, was 
responsible for deciding which medical conditions were granted subsidized pharma-
ceutical treatment. Whether an individual patient’s pharmaceutical use was subsidized 
then depended on the diagnosis set by the treating medical professional. The diagnosis-
based system for deciding subsidy was abandoned a few decades later in favour of 
a product-based system, which was in place at the time of the TLV’s creation. The 
overarching principle of a product-based system is that subsidy is decided by product: 
either a pharmaceutical is approved for subsidy or it is not. And since the inception of 
the TLV, a pharmaceutical is not subsidized unless the TLV has reached the decision to 
approve subsidy. See Sjögren (2006).
 6 Our analysis builds in part on the assumption that doctors/experts are not asking for 
this steering from above. Studies of the emergence of evidence-based medicine (EBM) 
note that it has its ideological and practical foundations in intra-professional qual-
ity improvement efforts (see, for example, Claridge and Fabian 2005; Hult 2006). 
However, attempts to exercise control of medical treatment choice decisions based 
on standards of best treatment have since been appropriated by actors and agendas 
beyond the medical professions, such as administrators, politicians and third party spe-
cial interests (Pope 2003; Timmermans and Berg 2003).
 7 The documents we have seen all seem to agree that at least severe forms of ED are 
a medical condition worthy of treatment. There were no references to the morality 
debates that surrounded Viagra when it was introduced, probably because the docu-
ments we have analyzed were from 2003 and later, at least five years after the initial 
introduction of Viagra.
 8 Notably, the legislative bill that was submitted to Parliament explicitly states that the 
precise interpretation of the law is left to the TLV as it ‘develops practice’ (New Phar-
maceutical Benefits Bill 2001, 47).
3  ‘A few good men’ are  
not enough
Upsetting general categories with 
specific knowledge when making 
reimbursement decisions1
Ebba Sjögren
Two overarching arguments in this volume are that situating pharmaceuticals in 
any particular locality recasts the identities and actions of various actors and forges 
new relationships between health problems and pharmaceutical-based solutions. 
The other chapters trace various avenues through which ostensibly globally stand-
ardized drugs become enmeshed in local discourses and socio-technical arrange-
ments. However, the localization of pharmaceuticals does not automatically give 
rise to increased pharmaceuticalization. The cases of Viagra and alpha-blockers 
discussed in Chapters 4 and 5, respectively, highlight differences in the trajec-
tory of pharmaceuticalization when drugs are introduced into areas with varying 
degrees of medicalization. In the previous chapter, the protracted legal battle over 
the reimbursement status of Viagra was ultimately resolved by a broadly exclud-
ing court ruling which denied all public funding.
This outcome was argued on the basis of structural and ideological aspects of 
the Swedish health care system, notably including the principle of equal access 
to health care. Here, I extend the analysis of how pharmaceutical treatment 
changes forms of governance and I argue that the possibility for making broadly 
exclusive or inclusive decisions may be strained by the widespread ambition to 
make pharmaceutical treatment more individualized, notably through technical 
advancements in the targeting of pharmaceutical-based treatment. To date, such 
commercially available products are rare. However, their introduction will argu-
ably add to existing challenges with addressing subcategories of users and uses in 
the regulation of access to pharmaceutical treatment. I use the examples of man-
agement of reimbursement for Viagra and other conventional drugs to suggest that 
a greater precision in delimiting and linking categories of treatable patients and 
reimbursable drugs can make existing arrangements for defining the boundaries of 
fiscal responsibility for pharmaceutical use less robust. This nuances the promis-
sory discourse around widespread access to individualized pharmaceutical-based 
treatment in particular, and the sustained momentum of pharmaceuticalization in 
general.
In the past decade, detractors have aimed intensified critique against the revo-
lutionary model of biotechnology previously espoused by many researchers, poli-
cymakers and representatives of the pharmaceutical industry. Notwithstanding 
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the formative influence of such expectations on the development trajectories of 
the field (Hedgecoe and Martin 2003), a growing body of research brings into 
question the linear model of innovation based on observations of an incremen-
tal spread of so-called pharmacogenomic technologies ‘from bench to bedside’ 
(Hopkins et al. 2007). A recurrent conclusion is that ‘[t]he translation of this sci-
ence into new technology is far more difficult, costly and time-consuming than 
many policy-makers believe’ (Nightingale and Martin 2004, 564).
While pharmacogenomics has many definitions, a recurrent core claim is that 
increased knowledge about the human genome and the genetic precursors of dis-
ease can contribute to greater certainty of diagnosis and improved effectiveness of 
treatment. Thus, in addition to generically promoting the continued possibility of 
drug-based treatment for a growing number of health problems, the pharmacog-
enomics project seeks both to reconfigure how patients, diseases and treatments 
are characterized and categorized, and how categories of patients, diseases and 
treatments are linked. One overarching explanation for the difficulty of devel-
oping and implementing pharmacogenomic technologies is that they – like all 
pharmaceutical-based treatments – must be embedded in existing organizational, 
professional and financial arrangements. New socio-technological networks 
emerge as incumbent structures that are reconfigured by the introduction of new 
technologies and attendant material and discursive practices (Callon 1987; Bijker 
1995; Jasanoff 2004). This chapter seeks to contribute to an understanding of 
how pharmaceuticals shape governance by foregrounding one setting in which 
such technologies must be situated: decision-making about health care coverage, 
specifically pharmaceutical reimbursement.
Determining the scope of coverage is a generic concern for both private insur-
ers and health care systems, which operate with public funding. Unsurprisingly, 
the matter of health care provision, and especially the evaluation of products’ 
cost-effectiveness, has been identified as an important contributing factor to the 
integration of any new pharmacogenomics product into local health care systems 
(Hedgecoe 2004, 179–80; Hopkins et al. 2006; Gurwitz et al. 2009). The use 
of evidence-based evaluation mechanisms has been seen as an important means 
of resolving the economic challenges expected to arise from the treatment pos-
sibilities more personalized therapies afford (Phillips et al. 2004). A dominant 
research theme has been the development of techniques for analyzing the eco-
nomic impact of pharmacogenomic technologies. To date these studies have been 
largely exploratory (for example Flowers and Veenstra 2004; Dervieux and Bala 
2006; Payne and Shabaruddin 2010). Relatively few pharmacogenomic technolo-
gies have reached the development stage where the matter of coverage is raised. 
Thus, the actual practices of deciding the scope of health care provision have 
garnered comparatively little attention from scholars, as compared to the impact 
of pharmacogenomics on drug development (Lesko and Woodcock 2004; Gins-
burg et al. 2005; Phillips and Van Bebber 2006; Pendergast 2008) and clinical use 
(Hedgecoe 2004, 2008; Kirchheiner et al. 2005; Lakoff 2006). However, scholars 
have previously posited challenges with incorporating the results of tools such as 
cost-benefit analysis into existing regulatory systems. For example, Raj (2002) 
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notes that many existing systems for deciding coverage for so-called orphan drugs 
generally fail to acknowledge the problem of scarce resources.
With the advent of pharmacogenomics technologies, he argues, these arrange-
ments will have difficulties addressing the likely emergence of a larger number of 
‘new orphan groups’, that is, categories of patients for which it is commercially 
unattractive to develop tailored therapies. In anticipation of a growing number of 
pharmacogenomic products that allow for more individually targeted drug-based 
treatment, a purpose of this chapter is to inquire into the workings of one critical 
regulatory setting where evaluations of such technologies’ cost-effectiveness will 
be used as part of determining coverage. This is done through a detailed inquiry 
into the activities of one of the many governmental health care assessment bodies 
that have been created in Western welfare states over the past decades (Jost 2005).
In studying the Swedish governmental agency tasked with deciding the scope 
of the public pharmaceutical benefits scheme, I engage with an issue that previous 
research has identified as pivotal to the development and implementation trajecto-
ries of biotechnology in general and pharmacogenomics in particular: the politics 
of classification (Bowker and Star 1999; Miller and Rose 2008). It is well known 
that the delineation and management of populations as objects of knowledge and 
intervention is a political project with significant material impact (Hacking 1999; 
Foucault 2007, 2008). A growing number of studies highlight the considerable 
commercial, clinical and ethical stakes that a geneticization of disease classifica-
tions (Hedgecoe 2002), and the possibility and practice of patient stratification 
(Hedgecoe and Martin 2003; Hedgecoe 2004; Reardon 2004; Egalite and Godard 
2007; Prainsack 2007), bring to the fore.
This chapter focuses on how categories of ‘treatable patients’ and ‘reimburs-
able pharmaceutical use’ are constructed. Crucially, these categories are inter-
dependent: patients are treatable if they can be linked to a functioning treatment 
regime. Similarly, a pharmaceutical use is only reimbursable if it treats patients in 
a medical and economically viable manner. An evaluation of viability takes into 
consideration various forms of knowledge about pharmaceuticals’ medical and 
economic effects, derived from clinical studies and clinical practice. I will illus-
trate how this knowledge is articulated at different levels of aggregation and with 
varying degrees of accuracy, which gives rise to recurrent ambiguity as to how 
patients and interventions should be characterized and categorized. This ambi-
guity must be addressed in order to construct stable categories of patients, dis-
eases and drugs that can serve as objects for regulatory intervention. I suggest that 
knowledge at lower levels of aggregation and the increased degree of accuracy 
that pharmacogenomic technologies may provide could strain the means by which 
decisions about pharmaceutical coverage are currently made.
That more precise and accurate knowledge poses a challenge to an existing 
regulatory setting is somewhat contrary to the findings of Lakoff. His study of 
efforts to identify genetic markers for bipolar disease in Argentina makes vis-
ible the close intertwining of fundamental notions of disease causality with the 
regulation and production of knowledge about psychiatric treatment regimens 
and the organization and undertaking of clinical care. Notably, he highlights the 
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pervasive influence of ‘pharmaceutical reason’ (Lakoff 2006, 6–7) on a wide 
range of actors. This strategic logic operates with the underlying rationale of link-
ing drugs directly to diagnosis. Citing Rosenberg (2002), Lakoff characterizes 
this rationale as ‘disease specificity’ (2006, 158–9), according to which illnesses 
are understood as stable entities which can be explained through universal causal 
mechanisms that are identifiable in the bodies of sufferers. Of particular relevance 
is my understanding of disease specificity as a tool of administrative management 
that makes it possible to rationalize health practices through the production of 
standardized evidence of treatment efficacy (a development discussed by Berg 
1997; Pope 2003; Timmermans and Berg 2003). Lakoff concludes that pharma-
cogenomic technologies support the norm of specificity as evoked in regulatory 
arrangements since ‘genomic technology seeks to make the [specificity] model 
more accurate. Pharmacogenomics serve as a mechanism of adjustment between 
drug and disease entity – a way of calibrating intervention more closely to illness’ 
(Lakoff 2006, 174). This characterization of pharmacogenomics suggests that the 
momentum of pharmaceuticalization could be further enhanced by a more wide-
spread availability of individualized drug-based treatments. While Lakoff goes 
on to illustrate how more precise calibrations of drugs to diseases may clash with 
other configurations of functionality – notably those found in clinical practices; 
see also Hedgecoe (2008) on the usefulness of pharmacogenomic technologies as 
a situated achievement – I argue that disease specificity is also a difficult norm to 
adhere to in a regulatory setting. A widespread commercial availability of individ-
ualized pharmaceutical treatments is therefore likely to have more diverse impli-
cations for the manner in which pharmaceuticals are situated and the momentum 
of pharmaceuticalization.
The following empirical account will inquire into how the Swedish Dental and 
Pharmaceutical Benefits Agency (henceforth ‘TLV’, the same agency discussed 
in the previous chapter) makes decisions about conventional drugs. The organi-
zation’s classification of pharmaceuticals as included or excluded from the pub-
lic pharmaceutical benefits scheme mobilizes particular modes of characterizing 
and categorizing patients, diseases and drug-based therapies. Foregrounding the 
means by which the TLV characterizes and categorizes ‘treatable’ patients and 
‘reimbursable’ pharmaceutical use contributes to the final purpose of this chapter: 
to articulate the versions of solidarity that are produced. Previous studies illustrate 
how the regulatory setting can have a considerable influence on how legitimate 
uses and abuses of biotechnology are defined and materialized (see, for example, 
Jasanoff 2005; Prainsack and Firestine 2006). As previously mentioned, the delin-
eation of coverage is a practical concern in both publicly and privately funded 
local health care systems. This is because a balance between individual and aggre-
gate needs for treatment is a fundamental problem for any attempt to undertake a 
just distribution of limited resources – irrespective of how this justice is defined. 
Nevertheless, this matter arguably has particular salience in welfare systems with 
espoused ideals of ‘universal coverage’. Here the boundary for collective fiscal 
responsibility2 for individuals’ health care needs must be drawn in a manner that 
is perceived as just and equitable. This is part of the construction and maintenance 
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of a systemic solidarity, on which any such health care system depends. It is 
therefore important to understand the mechanisms whereby patients, diseases and 
pharmaceuticals are categorized in the process of determining coverage, as the 
scope of the public pharmaceutical benefits scheme has direct consequences for 
what manner of solidarity is achieved.
In the forthcoming empirical account, I follow how the TLV evaluates the 
reimbursement status of various non-pharmacogenomic pharmaceuticals. The 
decision to study conventional pharmaceuticals is partly premised on the limited 
experience of evaluating pharmacogenomic technologies’ coverage. However, the 
evaluation uncertainties related to pharmacogenomic technologies are similar to 
other innovations (Ling and Raven 2006). Furthermore, previous sociologically 
informed studies of pharmacogenomics in practice lend support to the supposition 
that such technologies become ‘ordinary’ when embedded in existing organiza-
tional arrangements (Hedgecoe 2004, 7). Thus, the difficulties faced when evalu-
ating conventional pharmaceuticals can be used to indicate potential challenges to 
ambitions of a more widespread introduction of pharmacogenomic drugs.
The remainder of this chapter is organized as follows. The next section will 
introduce the empirical setting of the study and then account for four controversies 
centred on the evaluation of pharmaceutical-based treatments for stomach acid–
related disorders, migraines and erectile dysfunction. In each case, the focus is 
on incoherence between the level of aggregation and the degree of accuracy with 
which patients, diseases and pharmaceuticals are characterized, categorized and 
linked. The following section will discuss how these incoherencies are addressed 
and what forms of solidarity this produces.
Different categories or not? Dealing with incoherent 
characterizations of patients and pharmaceutical use
The Dental and Pharmaceutical Benefits Board:  
an organization to set boundaries for publicly funded  
pharmaceutical spending in Sweden
Whether patients must pay for their prescription pharmaceutical use can have 
potentially far-reaching effects on usage patterns. This is perhaps most obviously 
the case in welfare states, where patients’ out-of-pocket expenditure for drugs has 
historically been low and the reimbursement of pharmaceutical use relates to an 
overarching concern with fair and equitable resource allocation. How to prioritize 
resources is an enduring concern in the field of health care. In recent decades, the 
debate over resource allocation within health care has tended to take its point of 
departure in the perception of a widening gap between the supply and demand of 
health care intervention. This has brought the question of prioritization to the fore, 
whether between different forms of medical interventions or between different 
therapy areas and patient groups.
One way many Western welfare states have sought to address the question of 
which treatments to provide and reimburse is through the creation of central health 
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care technology assessment (HTA) organizations. These organizations typically 
have instructions which emphasize the use of scientific facts in decision-making 
(Jost 2005). The organized collection and evaluation of evidence about treatment 
effects is conceived as a means to achieve a more fair and effective prioritization 
of limited resources (Cuyler and Newhouse 2000; Mitton and Donaldson 2004). 
The creation of HTA organizations as such is therefore in line with the pervasive 
idea that the evidence-based standardization of treatment decisions and medical 
clinical practice can secure broadly defined better outcomes (Drori et al. 2003; 
Pope 2003; Timmermans and Berg 2003).
In Sweden, a governmental agency was created in 2002 with the task of deter-
mining the reimbursement status of all prescription pharmaceuticals.3 Prior to 
the creation of the TLV, all use of prescription pharmaceuticals in Sweden was 
‘automatically subsidized’ (New Pharmaceutical Benefits Bill 2001, 1).4 Accord-
ing to the TLV’s governing legislation, pharmaceuticals should now be granted 
reimbursement when:
the cost for using the pharmaceutical . . . is reasonable from medical, humani-
tarian and socio-economic perspectives.
(Act on Pharmaceutical Benefits, Section 15)
When a pharmaceutical is excluded from the pharmaceutical benefits scheme, 
patients must pay for all outpatient use of the product.5 In contrast, the cost of 
a pharmaceutical that has been approved for reimbursement is carried by the 
patients’ counties of residence.6 The legislation gives the TLV the option to 
approve reimbursement for restricted uses of a drug. However, this alternative is 
to be used sparingly in order to uphold the principle of a product-based reimburse-
ment system (Act on Pharmaceutical Benefits, Section 11).
The work of the TLV to decide pharmaceuticals’ reimbursement status is 
divided between the Board and the Bureau. The Board has the formal decision-
making power. The government appoints its eleven members to reflect different 
interest groups within the health care sector (Ordinance with Instructions for the 
Pharmaceutical Benefits Board, Section 8). Present and previous Board mem-
bers include practising general physicians, health economists, medical special-
ists, medical ethicists, individuals with experience from patient organizations and 
county health administrators. The role of the Bureau is to undertake evaluations 
to support the Board in its decision-making. The Bureau employs approximately 
fifty individuals, many of whom hold doctorates in pharmacy or health economics.
By law, the TLV must publicly justify its decision outcomes in so-called deci-
sion justification documents. However, as it is not specified what it means for a 
pharmaceutical to have a reasonable cost of use, the onus is on the TLV to make 
decisions that can be publicly justified as being in accordance with the agency’s 
governing legislation. The legislative bill submitted to Parliament provides some 
guidance for interpreting the legal framework. As mentioned in the previous 
chapter, the bill instructs the TLV to adopt ‘a broad approach’ (Pharmaceutical 
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Benefits Bill 2001, 46) and to take into consideration the three principles of pri-
ority setting that Parliament approved in 1997. These are: equal human value, 
meaning all people have an equal right to life and health; need solidarity, that 
those with greatest need of treatment have priority over those with lesser need; 
and cost-effectiveness, that the benefit of treatment must be reasonable in relation 
to its cost (Socialutskottet 1997). There are no detailed instructions about what 
it means in practice to take these principles into consideration. However, the 
agency is explicitly encouraged to use health economic techniques for evaluat-
ing drugs (New Pharmaceutical Benefits Bill 2001). Notably, the TLV must not 
take into consideration the budgetary impact of implementing its decisions. Nor 
does the agency have any targets to fulfil as regards the level of pharmaceutical 
spending.
The following section describes four instances of conflicting characteriza-
tions and categorizations of treatable patients and reimbursable pharmaceutical 
use. Three of these accounts are based on a detailed study of the evaluation of 
pharmaceuticals for the treatment of migraine and two stomach acid–related dis-
orders. These decision-making processes were followed using a combination of 
fifty-seven semi-structured interviews with members of the TLV’s two project 
groups and members of the organization’s decision-making Board, analysis of 
working documents and decision justification documents and participant obser-
vation (described in greater detail in Sjögren 2006, 59–67). Following the com-
pletion of this study, the resulting controversy concerning one decision outcome 
was opportunistically identified and followed via articles selected through key 
word searches in a proprietary media database (Mediearkivet). The fourth account 
looks at the legal appeal of the TLV’s denial of reimbursement for Viagra. The 
empirical material derives from the TLV’s decision justification documents and 
the various court rulings in the case (for a more detailed discussion of methodol-
ogy, see Chapter 2).
In each account, the focus is on how the TLV deals with incoherencies which 
emerge between different levels of aggregation and degrees of accuracy when 
characterizing and categorizing patients, diseases and drug use. The first account 
is from the stomach-acid group, where the TLV had to address the significant 
prescription of certain pharmaceuticals to ‘untreatable’ patients.
Identifying ‘untreatable’ patients: sorting similar  
symptoms into different diagnosis categories?
The stomach-acid group was one of two pilot projects for the TLV’s review of the 
existing pharmaceutical assortment. It was launched in October 2003. At an early 
stage, members of the stomach-acid group described a ‘well-known’ problem of 
off-label prescription. The specific suspicion was that physicians were prescrib-
ing a class of drugs called proton pump inhibitors (PPIs) to patients who had 
stomach-ache rather than gastro-oesophageal reflux disease (GERD). These two 
conditions could have similar symptoms. However, numerous sources agreed that 
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only patients with GERD could be successfully treated with PPIs. Unfortunately, 
it was often difficult for clinicians to determine whether a patient had GERD:
Everything else is clear-cut . . . you have a bacterial infection; you have an 
ulcerous sore, and so on. With GERD, there is so much variation. . . . You 
have symptoms with sores, sores but no symptoms, symptoms with no sores.7
It was considered problematic that the means of identifying ‘treatable’ patients 
was so ambiguous.8 In an attempt to resolve this ambiguity, the stomach-acid 
group proposed that the Board restrict reimbursement of PPIs to patients with 
a confirmed diagnosis of GERD. In order to ensure a confirmed diagnosis, the 
suggestion was to make reimbursement of treatment for patients with GERD con-
tingent on a gastroscopic examination. However, the Board ultimately discarded 
this and other suggestions to delimit a smaller category of treatable patients linked 
to reimbursed drug use. Instead, all of the PPIs were included in the pharma-
ceutical benefits scheme. Informants explained that this outcome was largely a 
consequence of the Board’s recognition that it was not possible for the TLV to 
intervene in diagnostic practices in the manner needed to make a more specific 
category of ‘reimbursed pharmaceutical use’ stable and feasible to implement in 
clinical practice:
The Board took a pragmatic view and said that we can’t tell the doctors how 
they should make a diagnosis . . . we don’t know enough about what it would 
mean, what kind of equipment they have access to today.9
Had the Board chosen to include a restriction in line with the Bureau’s original 
proposal, this could have become a ‘hard strike in the air’.10 This would have been 
potentially problematic for the perceived legitimacy of the TLV’s work.
Furthermore, informants noted that if the Board were to take differences in 
diagnosis-related treatment regimens into consideration for the case of PPIs there 
was a strong likelihood that more reimbursement decisions would have specific 
inclusion criteria. The widespread use of diagnosis-based reimbursement restric-
tions was not in line with the principle of a product-based system for pharma-
ceutical reimbursement, which the TLV’s governing legislation instructed the 
organization to uphold (New Pharmaceutical Benefits Bill 2001, 37–8). One 
informant noted that it was a principal problem that a product-based system 
inferred that all pharmaceuticals had only one cost and effect, which could be 
clearly measured and systematically evaluated.11 That a pharmaceutical in prac-
tice might have multiple effects (and costs) related to the treatment of different 
patient groups was not in line with the legislation’s basic premise.
In summary, the TLV discarded the possibility of formulating more specific 
inclusion criteria for patients with GERD in the face of epistemological prob-
lems with delineating a correct, stable and clinically feasible category of patients 
with this diagnosis. Formulating a more specific inclusion criterion was also at 
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odds with the principle of a product-based reimbursement system. By approving 
reimbursement for all the PPIs, the TLV constructed a broadly inclusive category 
of treatable patients. The ambiguity concerning who belonged to this category 
and should have their pharmaceutical use reimbursed was delegated to medical 
practitioners. A similar strategy of delegating ambiguity was used to resolve 
incoherency in the comparison of treatment effects for products in the migraine 
group.
From one comparison to none: the failure to match the treatment 
effect of migraine drugs to stable patient groups
In the preceding account, the identification of specific ‘treatable’ patients was del-
egated to medical practitioners. The challenge in the migraine group was some-
what different, since there were no perceived problems for clinicians to diagnose 
patients with migraine. Therefore, the TLV’s migraine group initially intended to 
evaluate the treatment effects of different pharmaceuticals using data from vari-
ous clinical trials. However, it soon became apparent that this data was incoher-
ent. Notably, the studies used different measurements of treatment effect and also 
defined different categories of ‘comparable’ drugs. This made it impossible to 
make a general comparison of all the drugs using a common metric. To resolve 
this problem, the Bureau’s project group decided to use the golden standard for 
measuring treatment effect as defined by the International Headache Society. As 
most clinical trials included this metric, it could be used to compare some – if not 
all – results from the studies.12
Once the comparable effect metric had been defined, the subsequent evaluation 
was initially couched as a matter of deciding how many pharmaceuticals were 
needed to ensure adequate product diversity. One project member likened this to 
an analysis of ‘marginal rate of return’, where the first product might treat a certain 
percentage of patients and subsequent pharmaceuticals could treat an increasingly 
smaller group of new patients.13 However, the project group’s seconded medical 
experts and various other parties soon highlighted a critical problem: it was not 
possible to foresee which patient would respond to which pharmaceutical within 
a chemically similar group of drugs called triptanes. This meant that ‘[i]n practice, 
doctor and patient must test until a triptane with good effect and acceptable toler-
ance is identified’ (TLV 2005a, 23). Since the triptanes were not interchangeable 
treatment alternatives for identifiable groups of patients, it was not possible to 
compare their treatment effect using the chosen metric.14 The failure to compare 
treatment effects, in combination with the high-calculated cost of not treating 
migraine, was described by informants as a strong contributing factor behind the 
TLV’s subsequent approval of reimbursement for all the triptanes. Yet, while the 
TLV approved reimbursement for all of these drugs, the agency’s final report for 
the migraine group also included a ranking of the evaluated pharmaceuticals in 
order of calculated cost-effectiveness. It was stressed that the ranking was not a 
general treatment recommendation and the TLV would not monitor compliance 
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to the ranking, However, the intention was that the ranking could guide medical 
practitioners in choosing an order in which to test the triptanes.
If one took cost-effectiveness into consideration. But there are other things 
that need to be taken into account as well, of course.
(Interview project manager migraine 
group, 22 February 2005)
The preceding example from the stomach-acid group revealed problems with 
defining a stable category of ‘treatable’ patients using a diagnosis-specific inclu-
sion criterion. In the present case, the migraine group struggled with how to estab-
lish a stable and coherent characterization of the evaluated pharmaceuticals. An 
intended comparison of treatment effects was thwarted due to a failure to achieve 
comparable data. This failure resulted from the lack of a stable object of knowl-
edge: there was no aggregate of patients for whom the treatment effects of dif-
ferent drugs could be compared. Instead of identifiable patient groups, there were 
individual patients with different and unforeseeable responses to treatment. The 
TLV’s solution to this ambiguity was to forego any specific inclusion criteria that 
might risk the exclusion of pharmaceuticals that were potentially the only treat-
ment alternative for certain patients. Instead, a broad category of reimbursable 
drug use was established. The work to characterize and categorize a particular 
tripane as appropriate to reimburse when used by a specific patient was delegated 
to medical practitioners.
In summary, both of the preceding cases saw the delegation of ambiguity over 
the characterization and categorization of treatable patients and reimbursable drug 
use to medical practitioners. In the following example, concerns over the feasi-
bility of implementing reimbursement restrictions in clinical practice meant that 
such delegation was not considered appropriate.
‘A few good men’ are not enough: the exclusion of Viagra from the 
pharmaceutical benefits scheme
As detailed in the previous chapter, in March 2008, the Supreme Administrative 
Court of Sweden ruled to exclude Viagra (and two other pharmaceuticals used 
for the treatment of erectile dysfunction) from the public pharmaceutical benefits 
scheme. This decision ended a process that had started seven years earlier, when 
the Swedish government decided to immediately cease general reimbursement of 
Viagra. In the aftermath of a heated public debate, the government took steps to 
reverse its decision. Less than six months later, the TLV began its operations. The 
reimbursement status of Viagra was one of the first cases the new agency decided. 
In March 2003, Viagra was once again excluded from coverage. The decision 
justification document issued by the agency gave two reasons for this outcome.
The first argument was that Viagra was not generally reasonable to reimburse 
for treatment of all forms of erectile dysfunction. Notably, the TLV argued that the 
medical studies cited in the application for reimbursement showed neither that the 
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product was generally cost-effective nor for which particular patient groups the 
drug was cost-effective (TLV 2003, 4). The second argument was that no depend-
able way exists to identify specific groups of treatable patients that could be 
deemed societally reasonable to provide with reimbursed treatment. Had this been 
possible, the TLV might have approved reimbursement for Viagra to patients with 
severe erectile dysfunction. However, the perceived inability of medical prac-
titioners to determine the medically treatable and societally reasonable patients 
made it necessary to deny reimbursement to all patients.
As described in Chapter 2, the company marketing Viagra appealed the TLV’s 
decision and a series of court battles ensued. Prior to the Supreme Court’s rul-
ing, two lower courts overturned the TLV’s decision and approved restricted 
reimbursement for Viagra for a specific category of patients. The Lower Court 
defined this category as patients with certain medical conditions such as diabetes 
or cardiovascular diseases, or patients who were prescribed the drug by a urolo-
gist (Stockholm County Administrative Court 2004). While the TLV’s subse-
quent appeal of the Lower Court’s ruling was not upheld, the Appellant Court did 
change the category of patients to be included in coverage. Instead of a primarily 
diagnosis-based categorization, the Appellant Court restricted reimbursement to 
initial prescription by a medical specialist on male reproductive organs. The court 
described this as a more dependable way of identifying the medically treatable 
and societally reasonable patients (Stockholm Administrative Court of Appeals 
2005).
Three years later, the Supreme Administrative Court justified its denial of 
all reimbursement on three grounds (Supreme Administrative Court of Sweden 
2008):
1 The existence of two alternative treatments for patients with severe erectile 
dysfunction [i.e. those patients who were both treatable and reasonable to 
provide with reimbursed treatment; author’s note]
2 The uncertainty of a diagnosis for severe erectile dysfunction, and
3 The imagined behaviours of patients and doctors that created a clear risk for 
off-label prescription of Viagra to patients other than those whom it was ‘rea-
sonable’ to treat with reimbursed pharmaceuticals.
The Supreme Court’s second and third arguments are similar to those the TLV 
made in its original decision justification document. The perceived risk, that med-
ical practitioners would be too inclusive when categorizing patients as eligible for 
reimbursed Viagra, justified the exclusion of all Viagra use from coverage.
In summary, the first two cases centred on various problems that the TLV had 
with creating correct and stable categories of treatable patients and reimbursable 
drug use that were feasible to implement in clinical practice. In both the migraine 
and stomach-acid groups, the epistemological problem of characterizing, cat-
egorizing and matching patients, diseases and drugs was delegated to medical 
practitioners through the delineation of broad, inclusive categories. As argued in 
Chapter 2, the case of Viagra further illustrates how the basis for characterization 
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and categorization needed to be stable and feasible to implement in clinical prac-
tice. The fourth and final example elaborates further on the issue of clinical fea-
sibility by looking at the implementation of a TLV decision for a specific patient 
group.
Ensuring reimbursed pharmaceutical use for a deserving few: 
implementing the decision to exclude all Losec use from coverage
Since its inception, the TLV has evaluated hundreds of products. While most deci-
sions have met with few public reactions, this account concerns one case which 
did become a matter of some public attention: the general exclusion of Losec 
from coverage. Losec, a brand-name pharmaceutical in the stomach-acid group, 
was deemed unreasonable to subsidize on the grounds that other products with 
the same active substance had a significantly lower price. These drugs were inter-
changeable with Losec, according to the list maintained by the Swedish Medical 
Products Agency. Thus, the TLV argued that patients could receive another prod-
uct when filling their Losec prescriptions. The result would be significant cost 
savings, without a loss of treatment quality.
However, in the aftermath of the TLV’s decision in February 2006, reports sur-
faced about an unforeseen consequence of excluding Losec from coverage. The 
TLV’s decision was based on the fact that patients using Losec could remain in 
treatment with another brand of drug. This premise was derived in part from an 
analysis of data from clinical trials and sales statistics, which suggested that a 
number of products were interchangeable for the patient population using Losec. 
However, information now surfaced about a group of patients for which Losec 
was the only treatment option. This patient group was young children with GERD. 
They had difficulties swallowing capsules and therefore needed to take the active 
ingredient in a form that could be broken apart and softened.
The exclusion of this group of patients from reimbursed treatment was not 
considered a reasonable outcome. Several counties’ solution was to finance this 
particular use of Losec through an alternative route. Specifically, the Losec these 
patients used was re-categorized as inpatient use. By doing so, the counties man-
aged to put in place a number of extra routines so that the National Corporation of 
Pharmacies could directly bill the cost to the counties.
In summary, this final case makes visible the incoherence between different 
levels of aggregation and degrees of accuracy in both the characterization and 
categorization of patients, and the matching of patient categories with pharma-
ceuticals. The data the TLV used crafted a large category of patients for whom 
the active substance – not a particular brand or dosage form – was important 
for treatability. But this category was not stable in other settings. Specifically, 
it clashed with a more fine-grained category of patients in medical practice for 
whom dosage form was a key component of treatability. To ensure that the treat-
ment of these patients remained reimbursed, a new organizational arrangement 
was put in place. This involved the re-categorization of Losec from outpatient to 
inpatient use. Thus, the inclusion of the specific category of patients in coverage 
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was achieved outside the regulatory arrangements of the pharmaceutical benefits 
scheme.
The following section will compare and contrast the four accounts of how inco-
herent and unstable categorizations of treatable patients and reimbursable drugs 
were addressed. The focus is on the mechanisms for resolving ambiguities, and on 
the consequences for inclusion and exclusion that these solutions provide.
Discussion
The four preceding accounts illustrate various detailed and case-specific prob-
lems related to the evaluation of reimbursement status for pharmaceutical-based 
treatments of stomach acid–related disorders, migraine and erectile dysfunction. 
However, the examples also highlight common challenges in the TLV’s work 
to appropriately and reliably create and maintain stable categories of ‘treatable’ 
patients, and link these patients with ‘societally reasonable’ pharmaceutical use in 
line with the legal criteria for reimbursement. I will now discuss how perceived 
epistemological problems in this categorization work were addressed. The sec-
ond part of the section will elaborate on the difficulty of achieving high disease 
specificity when making decisions about coverage. The final part of the section 
will relate the observed processes of decision-making about pharmaceutical reim-
bursement to the production of different modes of solidarity.
Making decisions with ambiguous knowledge  
by delegating ambiguity to others
In the first case, the TLV struggled with how to differentiate between ‘treatable’ 
and ‘untreatable’ patients in its reimbursement decisions for drugs in the stomach-
acid group. The Bureau project group made various proposals to delimit a more 
specific category of patients with the ‘treatable’ disease GERD. One example was 
the suggestion to make reimbursement contingent on a ‘confirmed diagnosis’. 
This was defined as a diagnosis made after a gastroscopic exam. However, the 
Board discarded these suggestions. In part, this behaviour can be attributed to 
the Board’s recognition of a lack of supporting technologies. Notably, the Board 
was aware that lack of access to gastroscopes could impede the implementation 
of such a restriction. In foregoing more specific inclusion criteria in its decision 
outcome, the TLV delegated ambiguity over which specific individuals were to be 
categorized as treatable patients to medical practitioners.
The second account of the migraine group described work to characterize and 
categorize pharmaceuticals using a comparison of treatment effect. By deciding 
to use the International Headache Society’s metric, the TLV defined an ostensi-
bly common means of measuring treatment effect. This opened up the possibil-
ity of formulating more narrowly defined criteria for what could be categorized 
as ‘reimbursable’ drug use. Yet this means for comparing drugs broke down in 
later stages of the decision-making process, when the TLV was unable to sustain-
ably link the measurements of treatment effect to a stable and identifiable patient 
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population. The subsequent decision to approve reimbursement for all the trip-
tanes can also be described as delegation to medical practitioners: this time of the 
work to determine whether a given pharmaceutical made a patient treatable, and 
thus made the drug reasonable to prescribe with reimbursement.
The first two cases illustrate how attempts to craft more specific categories of 
treatable patients and reasonable drugs were abandoned in favour of broadly inclu-
sive decision outcomes that delegated the ambiguity of categorization to medical 
practitioners. The story of Viagra reads differently. Despite a widespread agree-
ment about the existence of a specific group of patients that merited reimbursed 
use of Viagra (individuals with severe erectile dysfunction), this characterization 
of patients was not deemed stable and feasible in clinical practice. The agency 
doubted the ability of medical practitioners to appropriately limit the prescription 
of Viagra to these deserving few. Rather than the broadly inclusive category in 
the previous two cases, the outcome in the Viagra case was a broadly exclusive 
category that made it necessary for all patients to take private fiscal responsibility 
for their Viagra use.
While this chapter does not consider what responses the denial of Viagra may 
have triggered, the final case of Losec offers insight into how an ostensibly stable 
category of treatable patients was upset after the TLV had made its reimbursement 
decision. The agency’s decision to exclude Losec from the pharmaceutical ben-
efits scheme was premised on the comparison of treatment effects within a patient 
population for whom the active substance defined treatability. The subsequent 
breakdown of this category of patients – which had been sourced from clinical 
trials – came in the intersection with a particular clinical practice. Suddenly there 
was a specific group of patients whose treatability was closely entwined with 
Losec as a specific product. This group of patients had not been rendered visible 
for the TLV. Following the TLV’s decision, efforts were made by other parties to 
de facto include the specific patient group in coverage.
The four accounts provide examples of how the TLV dealt with ambiguity to 
reach a decision outcome. To make a decision that could be justified, there was a 
need for the characterization and categorization of patients, diseases and drugs to 
be correct, stable and feasible to implement in clinical practice. If this was diffi-
cult to achieve, then an alternative recourse was for the TLV to remove ambiguity 
about who was a treatable patient and what was reimbursable drug use through 
delegation to others, notably medical practitioners (see also Rappert 2001). In the 
first case from the stomach-acid group, members of the TLV’s Bureau and Board 
expressed a practical understanding of the socio-technical network of clinical 
work. Thus, the requirement to have a confirmed diagnosis in order to reimburse 
pharmaceutical treatment of GERD was discarded since it was dependant on a sup-
porting network of elements, such as a gastroscope, which the agency could not 
mobilize. The justification that certain Viagra use could not be granted restricted 
reimbursement due to concerns over compliance similarly reflects an understand-
ing of diagnosis as a situated accomplishment, which can be malleable to the 
influence of different actors. These examples thus illustrate how more precise and 
detailed knowledge about patient subgroups and their treatment responses did not 
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immediately and automatically resolve the challenge of justifying decisions based 
on correct, stable and clinically feasible knowledge.
‘Specific’ concerns in crafting categories of included  
and excluded patients and pharmaceuticals
The preceding section discussed the TLV’s responses to ambiguity in the charac-
terization and categorization of patients, diseases and pharmaceuticals. Arguably, 
one foundation for the aforementioned epistemological problems is the codified 
norm of disease specificity (Rosenberg 2002, cited in Lakoff 2006). This is most 
clearly made visible in the description of the legally sanctioned product-based 
reimbursement system as a model which assumes each drug has one set of treat-
ment effects which can be attributed to a clearly defined patient population. This 
assumption is recurrently challenged in the preceding four accounts. Nevertheless, 
the option of formulating more specific inclusion criteria for coverage appears to 
be a comparatively weak one. This might be the case for several reasons.
One obvious reason is that the legislation governing the agency’s work instructs 
it to strive to uphold a product-based reimbursement system. However, a further 
explanation is that the agency lacks the means of influencing the work practices of 
medical practitioners. The TLV has no mechanisms to ensure compliance to any 
more specific restrictions it might set out. A third reason, highlighted by the prob-
lem of diagnosing GERD and prescribing migraine drugs with treatment effect, 
is that adhering to the underlying assumption of disease specificity when making 
decisions about coverage makes it problematic for the TLV to both justify deci-
sions based on evidence, as is required by law, and reach outcomes that can be 
appropriately implemented in clinical practice, in line with its intended task of 
setting priorities for public pharmaceutical spending. This dual imperative makes 
it difficult to disregard knowledge from either clinical trials or clinical practice. 
This creates a basis for clashes between the level of aggregation and degree of 
accuracy with which patients and pharmaceuticals are possible to characterize 
and categorize. It is against this backdrop that the advent of pharmacogenomic 
technologies should be considered.
What this chapter suggests is that a greater accuracy at lower levels of aggrega-
tion than pharmacogenomic technologies could provide would further strain the 
construction of stable objects of regulatory intervention. The difficulties of ren-
dering stable representations of patients that can encompass variation – notably 
as regards diagnosis practices and treatment response – contributes to blurring the 
category of medically treatable, societally reasonable and therefore regulate-able 
patients. Thus, in contrast to earlier conclusions about the capacity for pharma-
cogenomic technologies to support a further calibration of health care rationali-
zation (Lakoff 2006, 174) and provide momentum to pharmaceuticalization, the 
present study suggests a potentially more destabilizing effect. Disease specificity 
is a difficult norm to adhere to in the current regulatory practice. A more precise 
knowledge about how to characterize and categorize treatable patients and rea-
sonable drugs is not obviously more useable and useful when reaching a decision 
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outcome. Rather, one could argue that the possibility of articulating a greater form 
of disease specificity in certain forms of knowledge could further contribute to the 
need for delegation of ambiguity and the attendant distribution of responsibility 
that this entails. However, the viability of this practice can be questioned. First, 
the possibility for ad hoc tinkering in those situations where unreasonable out-
comes result from decisions about coverage, as exemplified by the case of Losec, 
does not provide – much less guarantee – a systematic treatment of such prob-
lems. Second, an increased ambition to standardize, control and direct the content 
of medical practice using evidence-based policy would make tinkering difficult 
to maintain (Berg 1997; Berg and Mol 1998; Timmermans and Berg 2003). The 
present inquiry into the construction and workings of a particular ‘redistributive 
machinery’ thus provides a basis for reflecting on both the existing production of 
solidarity, and what the advent of more individualized treatment and diagnosis 
could portend.
Inclusive forms of evidence-based solidarity?
This chapter highlights a possible underlying ‘dysfunctional norm of disease 
specificity’ in decision-making concerning resource allocation in the Swedish 
health care system. These findings suggest that pharmaceuticals which allow for 
more individually targeted therapy could make it even more complicated and 
potentially controversial to make such a local ‘redistributive machinery’ work. 
However, it would appear to be a difference of degree, rather than kind. The four 
accounts discussed earlier concern the evaluation of reimbursement status for 
conventional drugs. By analogy, it could be argued that technological advances – 
in particular when paired with more knowledge claims about matters such as 
individual patients’ drug responses – might exacerbate the prevalence of upset-
ting precision in the Swedish context. This argument is supported, in part, by the 
results of a comparative study of how Germany, the Netherlands and the United 
Kingdom have incorporated three kinds of genetic technologies (Aarden 2009).
Based on a comparison of the local regulatory and medical practices by which 
medical technologies become available to individuals, Germany has a reticent 
pattern of provision for such technologies due to the relative importance of policy 
decision-making about health care provision. In these processes, cost-effectiveness 
and efficacy play an important role, such that the requirement for inclusion is 
tangible proof of disease or risk (Aarden 2009, 145). In a broader setting in which 
evidence-based decision-making is emphasized, this would tend to exclude groups 
of patients or pharmaceuticals for which evidence is unavailable or incoherent or 
where diagnosis and treatment in clinical practice remains complex and variable. 
This contrasts with the case of the Netherlands and the United Kingdom, where 
other forms of solidarity are achieved through practices that lead to the emphasis 
of alternative levels of specificity, for example of niche communities that match 
patients and technologies in the case of the Netherlands (ibid., 146).
The current study in Sweden suggests a tendency to forego the incorporation of 
more specific knowledge and inclusion criteria into decision outcomes in favour 
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of broadly inclusive or exclusive categorizations of patients and pharmaceutical 
use. This could be taken to suggest that the solidarity such arrangements produce 
remains true to a principle of universal coverage. However, such a judgement must 
also take into consideration the settings into which decisions are implemented. As 
previously mentioned, at the time of the study the TLV had no responsibility for 
considering the financial impact of its decisions. A changed requirement that eval-
uations of public coverage should consider not only cost-effectiveness but also 
economic feasibility would arguably also limit the possibility of making broadly 
inclusive decisions at the policy level (see also discussion in Rai 2002). Similarly, 
the linking of remuneration to health care service providers to compliance with 
treatment guidelines and reimbursement decisions would arguably contribute to 
limiting the room for interpretation when implementing decisions in clinical prac-
tice. Such developments could become topical in a setting where the widespread 
expectation and fear is that conventional and pharmacogenomic technologies will 
continue to drive the direct cost of pharmaceutical-based treatment.
Conclusions
This chapter has inquired into a national governmental agency’s efforts to include 
or exclude prescription drugs from a national pharmaceutical benefits scheme. 
I draw attention to the challenge ambiguous knowledge poses in the work of craft-
ing stable categories of treatable patients and reimbursable drug use with which 
to justify local coverage decisions. The effort on the part of the studied agency to 
craft correct, stable and clinically feasible categories within a regulatory frame-
work premised on disease specificity resulted in decisions with broadly inclusive 
or exclusive categories. The former type of decisions involves a delegation of 
ambiguity regarding the characterization and categorization of treatable patients 
and reimbursable drug use to medical practitioners. I have argued that different 
levels of aggregation and degrees of accuracy in knowledge claims about patients, 
diseases and pharmaceuticals are a potential source of ‘upset’ in categorization 
work. The observed delegation of ambiguity balances the dual need to make and 
justify evidence-based decisions which are feasible to implement in clinical prac-
tice. However, such outcomes are not obviously in line with the legislative ambi-
tions to centrally prioritize resource allocation.
This study illustrates how a governmental agency’s efforts to include or exclude 
drugs from a national pharmaceuticals benefits scheme is normative work that takes 
part in a wider politics of distribution for health care resources. A critical issue is 
how the dynamic tensions which emerge in the work of constructing locally rea-
sonable and legitimate coverage decisions are addressed. This arguably requires 
an understanding of the mutual constitution of medical technologies and the dis-
tributive practices embedded within any local health care system. In particular, it 
implies sensitivity to the broader range of mechanisms and arenas through which 
new technologies in health care practices are situated, beyond the clinical setting. 
A related concern is how to make visible the normative work of organizations 
such as the TLV. Little visible public debate concerning the TLV’s work exists in 
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Sweden. This contrasts with the experience in many other countries, where the 
work of HTA organizations has prompted controversy. For example, several deci-
sions by the British National Institute for Clinical Excellence (NICE) have been 
the target of public outcry and the visible involvement of various advocacy groups 
(Moreira 2010). The lack of conflicts and visible interest group involvement in the 
Swedish case is partly a methodological artefact of the study, which focuses on the 
internal workings of the TLV. However, it is also an empirical finding that has the-
matic antecedents linked to the localization of technologies. In a comparative study 
of regulatory responses to agricultural biotechnology and GM food in Germany, 
the United States and the United Kingdom, Jasanoff (2005) she observed differ-
ences in the topic and manner of controversy within each country. He explained 
the observed differences in part by differences of civic epistemology, the ‘cultur-
ally specific, historically and politically grounded, public knowledge-ways’ that 
encompass shared understandings of how knowledge should be ‘presented, tested, 
verified, and put to use in public arenas’ (Jasanoff 2005, 249, 256). In a similar 
vein, Prainsack and Firestine (2006) have argued that the absence of public contro-
versies concerning biobanks in Israel is due to a series of narratives that construct 
biotechnology as crucial for the continuity of Jewish existence in the region.
The lack of visible conflict about TLV decisions in Sweden can also be attrib-
uted to the workings of a ‘machinery’ of social technologies and devices, which 
renders the TLV’s decision-making processes opaque (Casula and Sjögren 2011) 
and formats the participation of interest groups (Sjögren and Fernler 2010). 
A publicly funded health care system is ultimately dependant on the boundaries 
for public fiscal responsibility being set in a manner that is perceived as legiti-
mate. The present chapter highlights the complex interplay between scientific and 
clinical knowledge claims with different levels of aggregation and with varying 
degrees of accuracy, which gives rise to recurrent ambiguity as to how patients 
and interventions should be characterized, categorized and linked. This ambiguity 
must be addressed in order to construct stable categories of patients, diseases and 
drugs that can serve as objects for regulatory intervention. Building on previous 
chapters, the examples of Viagra and other conventional drugs highlight that the 
future of pharmaceutical access is not limited to enrolling participants in clinical 
practice but enrolling society to subsidize access to situated understandings of 
‘legitimate’ drug use. Thus, even with a more incremental introduction of indi-
vidualized technologies for diagnosis and treatment, there is an ongoing need to 
follow the avenues whereby they become embedded in existing local systems for 
deciding the scope and content of health care provision.
Notes
 1 Substantive parts of this chapter have been previously published as Sjögren, Ebba 
(2010). Upsetting Categories? The Consequences of Pharmacogenomics for Making 
Knowledge-based Decisions in Sweden. New Genetics and Society, 29 (4), 389–411.
 2 Public funding of health care can be supplied in various ways. One such method, which 
is in place in Sweden, is the direct provision or third party financing of health care 
services using taxes. An alternative model, which is used in Germany and Holland, is 
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based around statutory health insurance schemes (see Wagstaff et al. 1999 for a brief 
overview).
 3 The term pharmaceutical reimbursement is commonly used in the literature. How-
ever, the term subsidization status more accurately captures the structure of the Swed-
ish pharmaceutical benefits scheme. This scheme is designed to minimize private 
expenses in connection with illness. In the current set-up, a patient pays the full cost of 
prescription pharmaceuticals up to 1,100 SEK (approximately 112 Euro). A graduated 
subsidy then reduces the patient’s direct cost for prescription medication so that (s)he 
never pays more than 2,200 SEK (approximately 225 Euro) in a twelve-month period.
 4 The term was used to describe how a drug was included in the public pharmaceutical 
benefits scheme once the Swedish Medical Products Agency (or its European equiva-
lent, EMEA) had approved it for use.
 5 ‘Outpatient use’ refers to pharmaceutical use, which takes place outside of monitored 
hospital care. This can include pharmaceuticals which have been prescribed during 
inpatient care, but which are intended for use after discharge from hospital. When a 
pharmaceutical is excluded from the pharmaceutical benefits scheme, this in no way 
limits the right of physicians to prescribe the drug. The use of pharmaceuticals for 
inpatient treatment is not subject to centralized regulation by the TLV. This coverage is 
decided by the individual counties.
 6 The twenty-one counties finance the majority of health care services directly through 
an income tax levied on all county residents who are in paid employment. The cost of 
the pharmaceutical reimbursement is billed to patients’ resident counties by the state-
owned National Corporation of Swedish Pharmacies, which held a legally sanctioned 
monopoly on the distribution of pharmaceuticals in Sweden until 1 July 2009.
 7 Interview project manager stomach-acid group, 17 May 2005.
 8 Interview project manager stomach-acid group, 2 September 2005; interview health 
economist, 16 November 2005.
 9 Interview project manager stomach-acid group, 23 November 2005.
 10 Interview project manager stomach-acid group, 23 November 2005.
 11 Interview health economist stomach-acid group, 28 September 2004.
 12 Interview project manager migraine group, 10 June 2004. See also discussion about the 
lack of ‘ideal effect metric’ (TLV 2006, 41–2).
 13 Interview project manager migraine group, 19 April 2004.
 14 Interview health economist migraine group, 22 February 2005.
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4  The Swedish medical 
discourse
Impotence, erectile dysfunction 
and Viagra in Läkartidningen1
Ericka Johnson
Medicalizing the ageing male
The inability to achieve and maintain an erection has had many causes and many 
cures. Ancient Greeks attributed it to a diet of dry, cooling foods. During the 
European Middle Ages, impotency could be the result of a curse – dealt out by 
one’s enemies, a witch or a slighted lover who tied knots in a string. Later, sexual 
excess, youthful indulgences and masturbation were blamed. During the nine-
teenth century both a wife’s aversion to sex and her desire for it could cause 
impotence, as well as a glimpse of her ‘unattractive’ female genitals. The stress 
of modern, urban living was (and still is) made a culprit. Then, of course, comes 
the litany of Oedipal urges, domineering mothers, incestuous fixations and the 
Freudian analysts needed to cure these. In the mid twentieth century, especially 
in the United States, therapists looked to relationship issues for a cause and the 
point of treatment, while in a wider arena impotence was variously attributed to 
feminism, the sexual revolution and the contraceptive pill. And most recently, 
impotence has become a vascular issue (for a cultural history of impotence, see 
McLaren 2007).
Tracing the changing expectations of men’s potency and vitality in Europe and 
North America shows how male sexuality has, with time, become more and more 
medicalized. This is true of sexuality in general. It has slowly gained recogni-
tion as a field in medicine: conferences are being held about various aspects of 
sexuality; medical journals on the subject are sprouting up; medical schools are 
offering courses in sexuality and some are even opening entire departments in 
the field; doctors are being encouraged to speak with their patients about sexual 
histories during routine medical exams; and pharmaceutical solutions to sexual 
‘problems’ help define these problems as medical (Fishman and Mamo 2001, 181; 
Tiefer 2006, 274f). At the same time, non-medical experts are flourishing, offer-
ing sexual advice on the Internet, radio talk shows and TV, in magazines and 
newspapers (Tiefer 2006, 275). But while female reproductive health has tradi-
tionally been a focus of medical intervention (see Martin 1992; Oudshoorn 1994; 
Dugdale 2000), for men it has been virility, with strength and vitality instead of 
reproductive capacity, that has long attracted medical attention (Sengoopta 2006; 
McLaren 2007).
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Sexuality is not the only area of life to be medicalized and later pharmaceutical-
ized with the development of pharmaceutical solutions to health ‘problems’. The 
processes of medicalization and pharmaceuticalization depend on the social and 
technical networks within which people and diseases are placed. As Oudshoorn 
states, ‘health problems can only be classified as illness and be medicalized if 
there exists a cultural climate and a medical infrastructure that actively transforms 
health complaints into diseases’ (Oudshoorn 1997, 143). Thus, solutions to prob-
lems like depression, anxiety, obesity, hair loss and ageing can become medical 
solutions when both the medical community and general population recognize 
them as such. This process is not uncontroversial, however, and the pharmaceuti-
cal solutions to obesity, hair loss and ageing can be grouped together with the 
treatment for erectile dysfunction in the category of drugs sometimes called life-
style drugs (Mamo and Fishman 2001, 16; Elliott 2003; Loe 2004a; Moynihan 
and Cassels 2005; Williams et al. 2011a). While some of these cures address prob-
lems that most people would at least nowadays call diseases (like depression), the 
disease status of others is more contested and their development has spawned the 
term disease mongering to denote the process of medicalization that uses medical 
practice and medical technologies to promote a concept of improvement unto per-
fection and the idea of medication for instant, scientific solutions for physiologi-
cal and psychological distress (see Fishman 2004, 193; Tiefer 2006, 274). Disease 
mongering not only serves the purposes of pharmaceutical companies looking for 
conditions that can fit their pharmaceutical cures, it also expands the areas of life 
that doctors can claim as their territory – and for which they can charge consulta-
tion fees and sell drugs (Elliott 2003).
Some of these lifestyle drugs and diseases are related to a change in attitudes 
towards activity, sexual and otherwise, in older age. The concept of successful 
ageing allows the medical community to offer medical solutions to health prob-
lems traditionally associated with ageing, problems like hair loss, menopause and, 
as will be discussed in this chapter, erectile dysfunction. As the medical com-
munity claims these areas as its domain (rather than the domain of diet, witch-
craft, antisocial behaviour or psychoanalysis, for example), the problems become 
diseases and the solutions are often decidedly medical, in the form of surgeries, 
drugs and physiological treatments. Because these solutions to ageing are creating 
diseases out of changes during the life span, the idea of getting older successfully 
has been critiqued for promoting an idea of ageing that really means not ageing 
at all (Marshall 2006, 350). Viagra and its promise of returning male sexual per-
formance to a youthful, erection-on-demand state so that anyone can have sexual 
intercourse at any time and any age is currently one of the most talked about treat-
ments for successful ageing.
This development should be placed in the history of medicalized male vital-
ity. In the early part of the twentieth century, it was thought that the secret to 
masculine vitality was found in the sex glands, and much research about these 
glands, in both people and animals, was conducted (see Oudshoorn 1994; Mar-
shall 2006; Sengoopta 2006). One of the medical treatments developed during 
the 1920s (sometimes called the decade of the testicle because of the intensity of 
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research into testicles during this time) to treat a loss of vitality in ageing men was 
the Steinach operation. Developed by Austrian Eugen Steinach, and said to have 
been performed on both Freud and Yeats, the operation redirected fluid from the 
testicles to be reabsorbed into the body rather than released outside. This fluid was 
then thought to help revitalize the patients (Marshall 2006, 347; Sengoopta 2006; 
McLaren 2007). In the 1930s and 1940s, male rejuvenation treatments moved into 
more mainstream medical practices and began to reflect new knowledge about 
testosterone. Hormone therapy, that is testosterone treatment, was developed as 
a treatment for the ‘male climacteric’. But again, the goal of treatment was gen-
eral male vitality as displayed through physical and mental, but not necessarily 
sexual, prowess. In fact, increased sexual function was sometimes seen almost as 
an undesired and slightly embarrassing side effect of treatments (Marshall 2006, 
347–8).
In the middle of the twentieth century, new research into sexuality and sexual 
behaviour changed the way sex and sexual dysfunction was perceived and treated. 
No longer was sexual decline in the male thought to be a natural part of ageing. 
Experts asserted that sexual activity and sexual intercourse were important parts 
of healthy ageing (Marshall 2006, 349). Impotence was thought to be caused by 
a fear of impotence. It was perceived as something that could be avoided and 
treated through therapy, often involving the partner, rather than through biomedi-
cal interventions (Tiefer 2006, 283). During the middle of the century and up into 
at least the 1980s, it was generally agreed that in 80% of impotence cases the 
problem was psychological and therapy was the best treatment.
According to feminist sex therapist Tiefer (2006), the psychology-based 
approach to sexuality in general and sexual dysfunction in particular changed 
during the 1980s. She notes that in the United States, several different factors 
contributed to a shift. For one thing, the American Psychiatric Association (APA) 
decided to define sexual problems as disorders in performing a sequence of geni-
tal functions, which coincided with a broader acceptance of a biomedical and psy-
chopharmacological model of mental health. At the same time, the health industry 
began to use the Diagnostic and Statistical Manual of Mental Disorders and its 
definition of sexual (dys)function when determining which diseases would be eli-
gible for reimbursement (Tiefer 2006, 283). Shortly thereafter, urology specialists 
began to take on more sexual dysfunction cases, which served to cement the idea 
that impotence was a biophysical issue of the penis, and led to examinations and 
treatments for sexual dysfunction that did not include the involvement of wives or 
partners (Tiefer 2006, 285).
Thus, impotence, which only a decade before had been called a psychological 
problem with physiological results, began to be seen as a physiological problem 
that could lead to psychological suffering (Marshall 2006, 350). The 1990s also 
saw other changes in the view of sexual dysfunction. Impotence became known 
as erectile dysfunction (ED), specifically located in the penis. By the late 1990s, 
largely thanks to research and advertising funded by Viagra’s maker, Pfizer, the 
new reigning explanation for impotence stated that 70–80% of cases stemmed 
from physical causes, a direct reversal of the earlier ideas and one which supported 
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medical consultations and prescription-based solutions rather than behavioural 
therapy or couples counselling (Plante 2006, 379). Sexual function was no longer 
seen as a controversial side effect of anti-ageing treatments; it was now the main 
goal.
The narrative of impotence and ED within the US context is also relevant to 
what has happened in Sweden, although with a bit of delay on some points. To 
examine the pharmaceuticalization of erectile dysfunction in this discourse in 
Sweden, I have analyzed articles dealing with impotence and erectile dysfunction 
in the generalist medical journal Läkartidningen.2 I have looked at the articles 
published between 1990 and 2015, starting eight years before Viagra’s introduc-
tion in 1998. Doing so shows that the construction of impotence, erectile dysfunc-
tion and male sexuality in Läkartidningen in some ways follows very closely 
with how these ideas have been framed in the international medical community, 
despite the framework of socialized medicine within which Läkartidningen pub-
lishes and the debates about subsidies of Viagra which have surrounded its intro-
duction to the Swedish market. For example, in Läkartidningen the discourse has 
moved from social causes of impotence to a focus on mechanical and molecular 
aspects of ED, as has also happened in English-language journals. Reports in 
Läkartidningen from studies about impotence are also frequently linked to phar-
maceutical funding after the introduction of Viagra, and there seems to be more 
column space granted to these discussions than there was before Viagra. In 2006, 
a study was published in Läkartidningen which reaffirmed that social aspects of 
ED contribute to individuals’ treatment options. This suggests that a broader defi-
nition and re-evaluation of male sexuality could have appeared in the Swedish 
discourse. But it is rather unique. The local structures of health care provision also 
influenced the Viagra discourse in Sweden, framing it in debates about chronic 
medical conditions that produce ‘legitimate’ and severe ED. These debates are 
particularly Swedish in that they stem from questions about subsidizing Viagra 
with tax money.
Later I will present my analysis drawn from a careful reading of the Läkartidnin-
gen articles. In examining the articles, I have looked at the construction of patients 
and symptoms associated with impotence, as well as how the authors define and 
propose impotence and its cure(s). I have then contextualized this against results 
of similar analysis of the international discourse on impotence and ED. The arti-
cles studied have been found using the search words: impotence, impotence treat-
ment, penis erection, erectile dysfunction, erectile difficulties, potency treatment, 
Viagra and Sildenafil.3 A total of fifty-three articles was sourced for the years 
1990–2015. Forty-five of these were published after Viagra was introduced.
Impotent patients before and after Viagra
Prior to Viagra, impotence was presented in Läkartidningen as a combination 
of psychological and physiological conditions. It was also something ‘natural’. 
This understanding of the condition is reflected in a 1993 book review which 
asserts: ‘Approximately ten percent of western men suffer from sexual difficulties 
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associated with impotence, and if men can stay healthy and live long enough, 
they all become old-age-impotent’4 (Mellgren 1993, 984). Old-age impotence, 
my translation for åldersimpotent, can be read as a specific type of impotence, 
and one that seems to disappear from the discourse after the arrival of Viagra and 
the presentation of the term erectile dysfunction. Also of note is that this number, 
10%, is very low compared to Pfizer statistics that began to appear with the intro-
duction of Viagra. (On the Viagra website,5 ED is said to afflict more than half of 
men over fifty.)
Impotence, if natural, was, however, already a medicalized condition before 
Viagra arrived, although for fewer people. Pre-Viagra, impotence was also very 
complex in Läkartidningen. In an article about the causes of impotence from 1990, 
the authors spend an entire section speaking about feelings. They discuss the way 
men, particularly after not engaging in sex for a longer period of time, can want to 
have sex, but still not have sexual urges. They explain this by stating that ‘many 
people interpret desire as the same thing as libido. But desire and libido are not 
the same thing’ (Olsson et al. 1990, 4456). Five years later, in an article written by 
two of the same authors, the pre-Viagra discourse denied the feasibility and benefit 
of distinguishing between physical and emotional causes of impotence, something 
Viagra relies on. ‘To create a distinction between somatic and psychological cases 
of impotence has been shown to match poorly with reality. Instead, one must for 
every patient evaluate biological factors and his feelings, his relationship to his 
partner, his family and work’ (Olsson et al. 1995, 313). Thus, pre-Viagra, impo-
tence is a result of a combination of (mostly social and emotional) factors.
It is not just the number of impotent patients and the emotional causes of impo-
tence that change through the 1990s in Läkartidningen; the definition of an impo-
tent patient also proves flexible. In the 1995 pre-Viagra article about impotence 
(Olsson et al.), impotent patients are constructed as a heterogeneous group, within 
which one finds some patients easier to treat than others. Those most likely to 
respond successfully to treatments are men in long-term relationships, and when 
discussing them, this ‘patient’ is frequently spoken about as the couple. More dif-
ficult to treat are single men, of which the authors identify three types: the young, 
shy man; the older man who has been sexually inactive for a while; and the loner 
carrying a secret. Of these, the older, sexually inactive man is seen as the easiest 
to treat (Olsson et al. 1995, 314). This typology of patients is based on social fac-
tors, and focuses on the men’s relationships with others, not on the biological or 
mechanical causes of impotence. Respect for the social aspects of impotence also 
appears when, in the same article, the authors discuss reasons it can be difficult 
to treat impotent patients: because some impotent men can have rigid stereotypes 
about normal sexuality; they can find intimacy threatening; they think sex is about 
performance and thus develop performance anxiety; they are unable to recognize 
their own emotional signals; they see the ability to have intercourse as a sign of 
power; and/or because some of them experience impotence as shameful (Olsson 
et al. 1995, 314). And, as the authors later go on to say, the most difficult thing to 
deal with as a doctor is the rage that some patients feel and can at times project 
upon the doctor when treating impotence.
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After the appearance of Viagra, types or groups of patients are still discussed 
in association with ED in Läkartidningen, but usually these are connected to indi-
viduals who have diseases whose symptoms can include, or whose treatments can 
induce, impotence, that is diabetes, multiple sclerosis, anxiety attacks and heart 
disease. Thus patients are distinguished into categories based on medical diseases 
rather than social factors. This later discussion of the types of ED patients in 
Läkartidningen was probably triggered by the debates raging after the introduc-
tion of Viagra over who should receive subsidies for the prescriptions of Viagra 
(see Landtblom and Ertzgaard 2000; Örn 2001). Using Viagra in these cases is 
presented as a solution to ED for patients with a legitimate need for the drug. I use 
the word legitimate because it is in these cases that the Swedish courts have heard 
arguments for and against the subsidized use of Viagra as a treatment for severe 
ED (see Chapter 2).
Sexual problems and pharmaceuticals
From their studies of US cases, sociologists Mamo and Fishman note that pre-
scribing drugs like Viagra can, in some cases, lead to and justify polypharmica 
(Mamo and Fishman 2001, 27). Läkartidningen takes up the occurrence of poly-
pharmica as well. Three years before the introduction of Viagra, the discussion of 
sexual difficulties and pharmaceuticals was raised in Läkartidningen in an article 
called ‘Sex life and pharmaceuticals’ (Lundberg 1995). In it, Lundberg discusses 
both how pharmaceuticals have been developed to treat sexual problems, and how 
pharmaceuticals taken for other reasons can influence one’s sex life. Thus, by 
1995, pharmacological sources of, and solutions to, sexual problems were gain-
ing acceptance within the Swedish medical community. But it also shows that the 
understanding of the concept of sexual problems was very broad before Viagra. In 
this article, a great deal of time is spent discussing the influence of other drugs (i.e. 
dopamine and serotonin blockers) on desire rather than on the mechanical ability 
to have sex, for both men and women. Most interesting, however, is the way sex is 
defined more widely than it often is in post-Viagra discussions. For example, sex 
is presented as involving not just intercourse but also orgasms, even for women. 
And after noting that serotonin blockers can make orgasm difficult for women, the 
author states, ‘There are, however, few reports of orgasm difficulties in men using 
this type of antidepressant. We do not know if there is a sex-specific difference 
or if the problem is hidden in men because of the difficulties in differentiating 
between ejaculation and orgasm’ (Lundberg 1995, 2745). The idea that men could 
experience ejaculation without orgasm is completely absent from any later discus-
sions of Viagra, as is the possibility of having an erection without ejaculation. But 
in the 1995 article, a nuanced way of discussing pharmaceuticals and sexual health 
is presented, one that involves desire, ability and pleasure. Much of this nuance 
is lost with the arrival of Viagra, and discussions about libido and desire also 
tend to disappear in the literature about ED, in Läkartidningen and other medical 
journals, despite the fact that the makers of Viagra insist that it will not produce an 
erection without sexual stimulation. But, as many social scientists and critics have 
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noted about Viagra in general, it relies on the traditional understanding of male 
sexuality, that men always want sex (see Fishman and Mamo 2001, 183; Mamo 
and Fishman 2001, 23; Marshall 2002, 2006; Loe 2004b; Tiefer 2006).
Returning to the discourse in Läkartidningen, libido appears only in connection 
with impotence post-Viagra in two articles. One is the 2004 column ‘Pharmaceuti-
cal questions’ (Kimland and Ståhle 2004), which is a brief compilation of topics 
discussed at regional pharmaceutical information centres. There, in 2004, the terms 
libido and impotence appear together when reporting a study that examined these in 
connection with the use of lithium (as the 1995 Lundberg article did when talking 
about sexual problems and pharmaceuticals). The other is a 2008 article that dis-
cusses the benefits of off-label use of Sildenafil for women suffering from sexual 
dysfunction as a result of antidepressants (Bodlund 2008). But these two articles 
can be read as special cases dealing with the effects of psycho-pharmaceuticals 
rather than the use of Viagra for a wider population.
Pharmaceuticals and erectile dysfunction
Pharmaceutical solutions for impotence existed prior to Viagra’s arrival in 1998, 
although most of these involved needles or pellets inserted directly into the penis 
and were therefore not as easy to administer as a pill. However, in a Läkartidnin-
gen article from 1997 (Hedelin and Abramsson), the use of orally ingested medi-
cines for erectile dysfunction is discussed and their pending introduction to the 
market predicted. In this article, the term erectile dysfunction,6 rather than impo-
tence, is first used in Läkartidningen.7 With this term, the discussion is shifted to 
the mechanical aspects of blood flow, vascular systems and muscle cells. Men 
have ‘erectile difficulties’ and these can be treated. The authors start the article 
with the statement, ‘The ability for a man to have an erection that facilitates inter-
course and insemination is a prerequisite for the continuation of the human race’ 
(Hedelin and Abramsson 1997, 2548), and then go on to discuss various possibili-
ties for treatment to be subsidized by the Swedish state, a discussion that later 
takes on enormous proportions in Läkartidningen (Hedelin 1998; Sjöstrand 1998; 
Beerman 2000; Byström 2000a, 2000b; Landtblom and Ertzgaard 2000; Landtb-
lom 2004; Ströberg et al. 2006).
In 1998, Viagra appears in Läkartidningen, with articles about the drug itself 
and about the way it is being received in the United States (Bergström 1998; 
Branke 1998), its introduction to Sweden, specifics of its use, questions of its 
costs to the individual and society (Hedelin 1998) and warnings that it is being 
sold illegally through the mail (Aldstedt 1998). It is at this point that impotence, 
which in the 1990 and 1995 articles was broadly defined, often with social causes, 
and which occurred in many different types of patients, including couples, is now 
directly equated with ED. In the introduction to his 1998 article ‘New treatment 
for impotence’, aforementioned urologist Hans Hedelin articulates this discursive 
coupling: ‘Erectile dysfunction (impotence), that is the inability to achieve and 
maintain an erection for a sufficiently long period for sexual activity, is the most 
common form of sexual functioning problems’ (Hedelin 1998, 4558).
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To better contextualize his use of the term erectile dysfunction, it is important 
to note that the discursive sliding between, and in some cases conflation of, impo-
tence and ED has a history outside of the Swedish context, largely in the field of 
urology and closely connected to the development of pharmaceutical therapies. 
Social scientist Barbara Marshall, in her work on Viagra, relays the story of how 
Dr Giles Brindley in 1983, in front of an audience of medical peers, injected his 
penis with phenoxybenzamine and obtained an erection, essentially removing the 
connection between emotional or tactile stimulation and erection. Ten years later, 
in 1993, the US National Institute of Health created consensus around the use of 
the term erectile dysfunction (Marshall 2002, 136). In Sweden, in the 1998 Hedelin 
article, erectile dysfunction becomes equated with impotence in Läkartidningen.
Susan Bordo claims that impotence as a term reflects a characteristic of the per-
son, not a disease – one says of a man, ‘he is impotent’ while one would not say ‘he 
is a headache’ (Bordo 1998, 87). And, as Loe (2004a) has noted, the shift in Eng-
lish from impotence to ED can be quite comfortable for the individual. ED allows 
the man to maintain his identity and self untainted, and treat only the penis. Potts 
notes this as well: ‘This term [impotence] infers that a man loses power through 
his “failure” to achieve an erection, and demonstrates how important a notion of 
“potency” is in constructions of conventional masculine sexuality. Consequently, 
an inability to produce erections may be perceived as tantamount to a destruction 
of the male self’ (Potts 2004, 23). With the introduction of ED and Viagra, a medi-
cal term and a pill exist that can prevent damage to the individual and erase blame 
for the failure to produce an erection on demand. These comments on terminology 
are also applicable to the Swedish usages of impotence and erectile dysfunction.
Another interesting observation in connection with the use of the term erectile 
dysfunction is that, in the 1998 Läkartidningen article, Hedelin asserts that ED 
is ‘the most common form of sexual function problems’ around the world. This 
statement was very common in 1998, internationally. That ED became the most 
common form of sexual function problem just when a medicine to cure it was 
introduced has been discussed elsewhere in relation to medicalization, biomedi-
calization and pharmaceuticalization (Mamo and Fishman 2001, 16; Elliott 2003; 
Loe 2004a; Moynihan and Cassels 2005; Williams et al. 2011a). In Läkartidnin-
gen, articles after 1998 spend a great deal of time talking about the physiology 
of erections and their molecular and biological aspects, and very little, if any 
time discussing counselling, couples therapy and the social or relationship issues 
related to impotence.
Perhaps most indicative of the direction articles about impotence and ED in 
Läkartidningen took after the introduction of Viagra is the 2000 article ‘Viagra is 
the first option for treating erectile dysfunction,’ co-authored by urologist Hans 
Hedelin (who defined erectile dysfunction as impotence) and Pfizer employee 
Lena Jacobsson. In this article they discuss a study which compared treatments 
for ED in Sweden. Gone from this study are all questions about the emotional 
or social aspects of impotence, or even the fact that sexual problems can take 
other forms than ED. Instead the study only focuses on how ED can be treated 
pharmacologically. The authors start their article by stating, ‘In the last few years 
different methods to successfully treat erectile dysfunction (ED) have appeared, 
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methods which work largely unrelated to the cause of the erectile problems and 
which demand a minimum of evaluation before the treatment can be initiated’ 
(Hedelin and Jacobsson 2000, 2616). Thus, the treatment for ED (which impo-
tence had become) is suddenly a relatively simple procedure, rather than one 
which, as suggested in a 1995 article, demands an empathetic doctor who can 
give hope and understanding, and who can spend sufficient time with the patient 
to discuss his/their problems, often over a period of several consultations (Olsson 
et al. 1995, 313). Likewise, in articles appearing prior to Viagra, references to 
alternative treatments like self-injections to the penis and the use of penis pumps 
and surgical implants appear, often as later-stage complements to couples therapy 
(see Olsson et al. 1995). This is particularly true with the penis implant, which is 
discussed with the warning:
Those patients who expect that an implant will not only create erections but 
also improve their relationship with their partner and bring them closer to a 
harmonic life are often disappointed.
(Olsson et al. 1995, 316)
However, this is exactly what Viagra promises, as noted in a 1998 Läkartidningen 
article, which argues for subsidies for Viagra because its use cures two patients, 
not just one, that is also the partner of the man suffering from ED (Sjöstrand 
1998). Potts and colleagues (2006) have shown how this idea is also prevalent in 
English-language commercials for Viagra, and the partner in the Swedish com-
mercial discourse is discussed in Chapter 6.
The shift in the use of the term impotence to erectile dysfunction occurs in 
Läkartidningen and the post-Viagra articles written largely by urologists, and is 
not unique to the Swedish discourse. It is in line with what has occurred in other 
journals and media outlets internationally. As Tiefer notes in her critique of the 
English-language use of the term, ‘erectile dysfunction, a condition in the man’s 
genitalia, has become the only acknowledged focus of interest, focus of evalu-
ation, and focus of treatment. This represents a substantial narrowing from sex 
therapy – erasing the partner, erasing subjective meaning, and, ironically, perpetu-
ating the obsession with penile hardness, which many sex therapists have argued 
is itself a primary cause of sexual unhappiness’ (Tiefer 2000, 278).
Examples of the same refocusing of the discourse in Sweden can be seen in 
Läkartidningen. Prior to Viagra, mention is made of another closely related sexual 
problem: premature ejaculation (Olsson et al. 1990). But after Viagra, this prob-
lem is not discussed again in connection with sexual difficulties until 2006, when 
a notice about a new drug treatment is presented (Hansen 2006) which mentions 
that 20–30% of men suffer from premature ejaculation. (Compare with the pre-
Viagra book review that states an estimated 10% of men suffer from impotence 
(Mellgren 1993).) This seems to confirm Marshall’s assertion, drawn from her 
analysis of English-language articles about Viagra, that ‘even though premature 
ejaculation (an “orgasmic disorder”) has higher prevalence rates than “erectile 
dysfunction” in many studies, we do not hear of an “epidemic” of premature ejac-
ulation’ (Marshall 2002, 137). Viagra has shifted the focus onto ED, and redirected 
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attention away from other sexual difficulties, including early ejaculation and a 
lack of libido, internationally and also in the Swedish medical discourse.
The impotent man, the partner patient  
and a woman’s responsibility
Before Viagra, in several of the Läkartidningen articles about impotence, the 
patient is presented as the partner unit. For example, in an article from 1995, the 
roles of each partner in dealing with impotence are narrowly defined. ‘Conversa-
tion with the couple is the most important diagnostic and therapeutic instrument. 
One should strive to work with the couple rather than the man alone, though one 
should never try to force the partner’s cooperation. Men and women have differ-
ent ways of expressing themselves and therefore misunderstandings can easily 
arise. Women must learn to be clearer and men to be more receptive’ (Olsson et 
al. 1995, 313). In addition to charging each partner with a specific way of com-
municating and the responsibility to change this, the article notes: ‘The best help 
for a man with disappointing erections is, besides his own courage to speak about 
it, an understanding and sensual partner who is sexually keen but not demanding’ 
(Olsson et al. 1995, 314). Although, as the authors go on to say, ‘of course, this 
isn’t always enough’ (Olsson et al. 1995, 314).
The couple-patient is also present when talking about other sexual problems 
pre-Viagra, as here, when discussing early ejaculation: ‘Naturally, the sexual act 
can easily be a failure in these situations unless the female partner is wise and 
possibly experienced, and can focus primary attention on physical contact and 
intimacy, and reduce the importance of genital contact’ (Olsson et al. 1990, 4456). 
The woman is charged with responsibility for ensuring that the sexual act is a 
success, despite the man’s sexual problems. This is slightly different than when 
speaking about impotence as a partner issue or presenting the impotent patient 
as a partner constellation. Instead, the solution to the sexual problem is in the 
hands of the female partner. This same shift of responsibility for curing the patient 
occurs in the discussion about (male) libido. When expanding on the difference 
between desire and libido, and their relationship to impotence, the authors state 
that, ‘Naturally, even here the female partner’s behaviour is very important’ (Ols-
son et al. 1990, 4456). Also of note is the distinct sense that impotence occurs only 
in heterosexual relations. And, as the earlier discussion about men and women’s 
communication issues implies, not only is the patient a heterosexual couple, it is a 
couple with very stereotypical, gender-specific interaction patterns.
In 1998, after the introduction of Viagra, the definition of the patient with ED 
shifts from the couple to the man in Läkartidningen. The only articles which sug-
gest the presence of a female Viagra patient is the aforementioned 1998 article 
which argues that the debate about whether to subsidize Viagra should take into 
consideration that the pill helps two patients, not one (Sjöstrand 1998) and the 
2008 article about using Viagra for women on antidepressants (Bodlund 2008).8 
Other than these, however, the post-Viagra ED patient is primarily the man pre-
scribed the pills, and often only the genitals of that man.
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The assumption of heterosexual patients in the Swedish case is not unique and 
mirrors a wider heteronormativity in the English-language discussions about Via-
gra and impotence, this despite the widespread use of Viagra within homosexual 
communities, and despite the use of the gender-neutral term partner in Pfizer 
advertising (see Chapter 6). For further discussion, see McLaren (2007) and Vares 
and Braun (2006).
Reopening the debate
Not until 2006 does the partner-patient unit of ED appear again in the post-Viagra 
Läkartidningen. In this year the partner becomes one of the people who should 
be asked about evaluation of the treatment and one of the reasons patients chose 
to discontinue treatment (Ströberg et al. 2006, 1107). While the integration of 
the partner in the discourse can be related to his/her presence in the pre-Viagra 
articles, this is a somewhat new role for the partner. Rather than being part of the 
cure, as in the articles from the early 1990s, now the partner is part of the wider 
context that influences a patient’s decision to follow a medical cure. It is also in 
this 2006 article that the social factors behind ED are finally reintroduced to the 
discourse, after having been absent for eight years. In the discussion about the dis-
continuation of pharmaceutical treatments for ED, the results of the Pfizer-funded 
study showed that more than half of the patients prescribed Sildenafil stopped 
using it within two years. To explain this, the authors report that ‘Often the rea-
sons are multi-factoral and factors like increasing age, diminished libido, rela-
tionship problems, health problems, social and cultural background all together 
can influence the decision to stop treatment’ (Ströberg et al. 2006, 2866). Issues 
concerning the physiology of ED were not the only, or even primary, answers they 
received from patients. This article in Läkartidningen shows that when a study 
is conducted which actually asks Viagra patients about their experiences and the 
reasons for their use or disuse of the drug, a disjuncture of the drug’s patients and 
their medically prescribed sexual identities and practices begins to (re)appear.
That international medical research about the use of pharmaceutical treatments 
for ED is focused on biological, mechanical or molecular aspects of erections 
has been noted. As Tiefer wrote in 2000, ‘There’s little attention to the person or 
couple attached to the penis, or recognition that relational factors might modify 
the meaning or importance of penile rigidity or sexual intercourse in a couple’s 
sexual script. It would appear that industry-sponsored research wishes simply to 
wave away the complexities introduced by the psychosocial context of sexuality’ 
(Tiefer 2000, 278). As an example of pharmaceuticalization, the case of Viagra 
in Sweden before the 2006 study complicates the medicalization hypothesis that 
general medicine is trying to constantly expand the domain over which it reigns. 
The examples of medical intervention for impotence in the pre-Viagra articles in 
Läkartidningen suggest that doctors were willing to intervene in the biomedical 
and social aspects of their patients’ sexuality, but that after Viagra’s appearance, 
medical intervention is narrowed to the biomechanical functions of a man’s penis. 
This narrowing runs counter to some expected processes of medicalization, but 
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shows how pharmaceuticalization tries to confine the condition of impotence to 
one disease (ED) with a universal, pharmaceutical treatment.
This tendency makes the Pfizer-funded Ströberg, Hedelin and Bergström 
(2006) study in Läkartidningen even more noteworthy, as it perhaps suggests that 
Viagra has not successfully reduced impotence to ED. Their article reopens the 
discussion of factors that can influence sexual health and simultaneously remedi-
calizes the larger context of patients’ sexual health. One could have hoped that this 
signalled a return to a more nuanced discussion of sexual problems and their treat-
ments within Läkartidningen and that acknowledging that there may be diverse 
reasons for patients to discontinue treatment with Viagra and similar medications 
may lead the medical discourse to include aspects from the early 1990s, that is 
recognition that there are different types of patients who have different reasons 
for and understandings of their impotence, along with the existence of a pill. By 
comparison, it is relatively uncomplicated to assert that women’s sexualities are 
complex and context dependent, and that they are influenced by feelings and emo-
tions, even with older women (see, for example, Loe’s (2004b) study). One could 
have hoped that the 2006 article in Läkartidningen was a sign that soon Swed-
ish men, too, would be granted the right to (once again) own a complicated and 
context-dependent sexuality influenced by feelings, emotions and social situa-
tions, not just kicked into action with a drug. But in the years that followed, little 
seemed to change. Viagra continued to be discussed in articles about subsidies and 
in relation to other medical conditions, like cardiovascular and prostate problems. 
Thus, in the Swedish medical discourse, the local structures doctors and health 
care providers worked in combined with Viagra’s global traits to create a glocal 
Viagra in Läkartidningen, one which presented and maintained a pharmaceutical 
solution to erectile dysfunction.
Notes
 1 An earlier version of this chapter has been published as Johnson, E. (2008). Chemis-
tries of Love: Impotence, Erectile Dysfunction and Viagra in Läkartidningen, NORMA, 
3 (1), 31–47.
 2 Läkartidningen is the trade journal of the Swedish Medical Association (Läkarför-
bund). It is published about once a week and covers international and Swedish devel-
opments in medicine and medical care.
 3 In Swedish: Impotens, impotensmedel, peniserektion, erektil dysfunktion, erektil 
svårigheter, potensmedel, Viagra, Sildenafil.
 4 All translations are the author’s.
 5 www.viagra.se (October 2015).
 6 Much later, in 2005, an interesting shift is made when erectile dysfunction, which had 
been a side effect of some diseases, also becomes a symptom. Läkartidningen reported 
that erectile dysfunction may be a symptom of undiagnosed heart disease and encour-
aged doctors who have a patient with ED to find out if that patient actually has heart 
disease (Gunnarsdottar 2005).
 7 Masters and Johnson used the term erectile dysfunction in the 1950s (McLaren 2007, 
221). However, it was generally not taken up by the medical community until adopted 
by urologists and popularized by Pfizer (see Marshall 2002; Loe 2004a).
 8 See Loe (2004b) for an analysis of senior women in the United States and the drug.
5  Alpha-blockers and a weaker 
pharmaceutical influence on 
medical discourse
Ericka Johnson
As Illich pointed out many years ago, a drug’s commercial and medical success is 
not terribly dependent on its chemical effects on the body (Illich 1976, 72). This 
observation has given impetus to critical work on pharmaceuticals that explores 
factors which make drugs as varied as Viagra, antidepressants and Botox so suc-
cessful (Fishman and Mamo 2001; Elliot 2003; Moynihan and Cassels 2005; 
Marshall 2006; Petryna and Kleinman 2006), and spawned studies of the way 
pharmaceuticalization influences medical and social practices (Williams et al. 
2011a). In this body of work it becomes clear that one important factor, among 
many, that can impact a drug’s success is the way it is constructed and situated 
in the professional medical discourse and the medical infrastructure of a specific 
country, a trait pharmaceuticals share with many other medical technologies (see 
Healy 2000; Löwy 2015).
This section of this book explores local examples of a pharmaceutical’s ability 
to influence the treatment of established medical conditions and redefine health 
problems as issues with a pharmaceutical solution. The previous chapter explored 
the influence Viagra had on the medical discourse in Sweden. In this chapter, I am 
again relying on an analysis of the medical discourse in the Swedish-language 
medical journal Läkartidningen. From it, I have retrieved research articles and 
debate pages that appear when the journal’s online archive is searched for the 
Swedish words associated with lower urinary tract symptoms secondary to benign 
prostate hyperplasia (LUTS/BPH): BPH, prostatahyperplasi and prostatahyper-
trofi.1 I have conducted a search for the years between 1990 and 2015, since 
alpha-blockers started to become a more common treatment method in Europe for 
LUTS/BPH in the 1990s (EUA 2006, 35) and were registered as a treatment for 
BPH in Sweden in the early 1990s (Carlsson and Spångberg 1996a, 4549; Hallin 
1999, 3520). This time frame mirrors that used for Viagra in the previous chapter.
Alpha-blockers are an interesting case for a book about glocal pharmaceuti-
calization because they show an example of incomplete change in the medical 
discourse and clinical practice for the treatment of LUTS/BPH, as opposed to 
Viagra, which completely changed the face of a disease and its treatment. Alpha-
blockers are also related to an analysis of Viagra because one of their side effects 
is impotence and/or erectile dysfunction. Medical guidelines suggest that men tak-
ing alpha-blockers may experience decreased desire and erectile and ejaculatory 
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difficulties (EAU 2006; AUA 2010; SBU 2011). Many men who receive a pre-
scription for alpha-blockers will also receive a prescription for Viagra, although 
probably to very limited success, given that Viagra does not address desire.
Alpha-blockers are being prescribed to treat LUTS/BPH in Sweden as in other 
developed, Western countries. In fact, some Swedish experts assert that they are 
being overprescribed. Yet, despite their presence in the Swedish cadre of treat-
ments for close to twenty-five years, and despite their place as an early course 
of action for LUTS/BPH, according to an official Swedish diagnostic and treat-
ment report (SBU 2011), they have not managed to replace surgical treatments 
as completely as Viagra managed to replace sex therapists in the Läkartidningen 
discourse or out in the urology clinics. By the early 2000s, 40,000 men were 
being treated pharmaceutically for BPH in Sweden (Dahlstrand 2003, 2678), and 
by 2009, this number had risen to approximately 115,000 (Spångberg and Dahl-
gren 2013, 685), a significant increase, even if one considers the possibility that 
pharmaceutical treatments also increased the gross number of patients diagnosed 
with LUTS/BPH. At the same time, surgical procedures had declined, but were 
still relatively high. In 1987, before alpha-blockers, 12,000 surgeries for enlarged 
prostates were performed in Sweden. In 2009, just under 5,000 were performed 
(Spångberg and Dahlgren 2013, 685). This is a decrease, but shows that surgery 
is still the treatment option for thousands of Swedish men each year and is still 
presented as an option in the discourse in Läkartidningen.
LUTS/BPH and alpha-blockers
The search terms I used for this study are the Swedish words which are or have 
recently been applied to what is today known as LUTS/BPH, lower urinary tract 
symptoms secondary to benign prostate hyperplasia in English. This is a condition 
in which the prostate becomes enlarged but without being cancerous. The prostate 
can start to grow again in older men, gradually increasing in size with age, and 
this is thought to happen in the majority of men. For some, it happens around age 
fifty, for others, not until they are seventy or older. It is a normal development, 
but this normal growth can cause problems with urination and is thus considered 
pathological. By the age of seventy, 75% of men will have LUTS/BPH symptoms, 
that is problems urinating (Parsons 2007, 395), and by age eighty, nearly all men 
will have an enlarged prostate (Fall 1999, 2227), 80% of whom will have prob-
lems with urination (Dahlstrand 2003, 2678). These statistics tend to vary a bit, 
but the general understanding is that the prostate gets larger as men get older, and 
that causes problems urinating.
Urologists like to point out that urination issues for men have existed for thou-
sands of years, referring to drawings on Egyptian papyrus from the fifteenth 
century BC and to writings by Hippocrates (Shackley 1999, 776). Medically, 
however, the prostate as a separate organ was not represented in European anat-
omy diagrams until 1536, and not named until 1611 (Marx and Karenberg 2009, 
209). Successful methods of surgically addressing the prostate for urination dif-
ficulties did not really evolve until just more than 100 years ago (Shackley 1999, 
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776). Today, a connection is often made between male urinary problems and an 
enlarged prostate. It is thought that when the prostate gets larger it may also start 
to block the urethra, the tube that lets the urine pass from the bladder and which 
the prostate surrounds, like a straw stuck through a ball. When the prostate begins 
to block the flow of urine through the urethra, its enlargement becomes a problem.
The first step of treatment for LUTS/BPH is currently pharmaceutical. This 
is a relatively recent change and it has complemented but not entirely replaced 
the traditionally more common surgery. Around the turn of the twentieth century, 
surgeries were performed for prostate issues, but with very high risks primarily 
due to infection. These surgeries would access the prostate from the abdomen or, 
more commonly, through a Y-shaped incision behind the testicles. These days, 
the LUTS/BPH prostate is usually surgically accessed through the urethra and the 
most common method is by transurethral resection of the prostate (TURP), which 
sends a tool in through the urethra to scrape away and cauterize the prostate tissue 
from the inside (AUA 2010, 70). There are other mechanical ways of removing or 
destroying a prostate diagnosed with LUTS/BPH, including microwave thermo-
therapy, radiofrequency needle ablation and laser therapies, but besides pharma-
ceuticals, surgery is the most common method in Sweden (SBU 2011).
Pharmaceutical treatment can be traced to the introduction of alpha-blockers in 
the 1970s (Heyns and de Klerk 1989, 226) and their eventual position as a stand-
ard treatment starting in the 1990s. However, even before alpha-blockers, LUTS/
BPH had been treated by suppositories, herbal treatment, chemicals and hor-
mones. Chemical preparations doctors historically prescribed for patients include 
opium, silver nitrate and belladonna suppositories, potassium iodine, potassium 
bromide, ergot (a type of fungi that grows on rye) and large quantities of dis-
tilled water (Marting 1903, 52; O’Shea 2012, 14). Many of these treatments were 
directed at the symptoms the man presented with, primarily urination problems, 
and some of the elixirs irrigated the bladder, but others, like ergot, were actually 
thought to shrink the prostate gland (O’Shea 2012, 14).
At the end of the nineteenth century, it was generally thought that ‘orchidec-
tomy’ (surgically removing one or both of the testicles) and vasectomy could be 
two treatments for the enlarged prostate that may have beneficial effects (Heyns 
and de Klerk 1989, 204; Shackley 1999, 777). This theory was in part developed 
because the then-current surgical methods (primarily suprapubic prostatectomy) 
had a mortality rate of about 20%, so other treatment methods were very welcome 
by patients and doctors alike. But the ideas about using castration and vasectomy 
could also be traced to the observation that eunuchs and those with non-developed 
testicles never presented with ‘hypertrophy’ of the prostate (Ciechanowski 1903, 
91), indicating that the testes were somehow involved in the development of pros-
tate growth later in life. While clinical practice did not really support the use of 
castration for treatment – many doctors reported that it was not successful and 
that patients were not pleased with the results (Marting 1903) – the possibility 
that it could work eventually led to theories about the role of hormones in prostate 
enlargement. However, it took until sometime into the twentieth century before 
hormone therapies were widely developed and used for prostate issues (O’Shea 
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2012, 17; see also Oudshoorn 1994, 2003 and Sengoopta 2006 for general histo-
ries of hormone treatments and their relationship to masculinity). In the 1930s and 
1940s, androgens, especially testosterone, were used to treat patients with what 
was then called ‘prostatism’, but without much success. The next step was to try 
oestrogen and combinations of oestrogen and testosterone. This did not really 
work to reduce the prostate, either, although it did seem to give some relief of 
symptoms and increase urine flow (Heyns and de Klerk 1989, 221). In the 1970s 
and 1980s a series of trials were done on antiandrogens and progestins. Some of 
these showed symptom improvement and others did not, and many of the trials 
had quite a few side effects, like vertigo, shivering, tiredness, loss of libido and 
impotence (Heyns and de Klerk 1989, 221–3). Cholesterol-lowering drugs were 
also tested, but with no significant benefit (Heyns and de Klerk 1989, 23–4).
At the same time, in the 1970s and 1980s, doctors also began to try alpha-
blockers, with more success. They seemed better than placebos at treating peak 
and average flow rates of urination, the amounts of residual urine and even the 
prostatic urethral pressure (Heyns and de Klerk 1989, 226), so much so that it has 
been suggested that their relative success may also have increased the interest in 
diagnosing LUTS/BPH (Ekman 1999, 3504). It is this category of drugs, alpha-
blockers, that I will explore in the Swedish medical literature.
Alpha-blockers
Alpha-blockers’ main purpose as a treatment for LUTS/BPH is to reduce the 
symptoms and bother of urination problems (SBU 2011, 317), and their use has 
steadily increased since the 1990s, probably in part because patients (and their 
doctors) see them as a way of avoiding surgery and in part because of increased 
marketing from pharmaceutical companies (EUA 2006, 35).
Alpha-blockers work on the smooth muscle tissue of the prostate. One the-
ory about the cause of LUTS/BPH is that, as the prostate increases in size, the 
increase in prostatic smooth muscle tissue interferes with urethral constriction and 
impairs the flow of urine (AUA 2010, 13). Reducing this process and changing the 
behaviour of the smooth muscle cells by ingesting alpha-blockers can then help to 
relieve the blockage and enable better urination. However, alpha-blockers, which 
are ingested orally, do not only work on the muscle cells of the prostate; they can 
affect smooth muscle cells all over the body, which leads to side effects like head-
aches, dizziness, hypertension, retrograde ejaculation and, as mentioned earlier, 
sometimes erectile dysfunction. Newer versions of alpha-blockers, which are bet-
ter at targeting the prostate specifically, are being developed and marketed, but for 
the most part, treatment with alpha-blockers is followed by various side effects.
If alpha-blockers are going to work for a man, he should notice a difference 
relatively quickly, some within forty-eight hours, and no longer than a month after 
beginning treatment (EUA 2006, 36). Different ways of measuring the results of 
treatment are commonly used to determine if alpha-blockers are effective, includ-
ing reiterations of the symptom scale questionnaire, pressure, flow and volume 
measures and by measuring the volume of the prostate, to see if it has shrunk at 
Alpha-blockers 67
all. A third of men will not notice any symptom improvement at all (EUA 2006, 
36) and, according to Swedish pharmaceutical registry statistics, two-thirds of the 
men will stop taking alpha-blockers within three years (Spångberg and Dahlgren 
2013, 685). If they do work, the patient can continue taking the alpha-blockers for 
the rest of his life.
Thus, the actual success of treating LUTS/BPH with alpha-blockers is con-
tested. The American Urology Association (AUA) says that alpha-blockers ‘pro-
duce significant symptom improvement compared to placebo that the average 
patient will appreciate as a moderate improvement from baseline’ (AUA 2010, 
28). But what is significant is a matter of debate. In the national Swedish report 
for treatment of LUTS/BPH done by the Swedish Agency for Health Technology 
Assessment, alpha-blockers are said to reduce the symptom bother slightly and 
increase the flow rate slightly better than placebos (SBU 2011, 321). The results 
are statistically significant but rather small (SBU 2011, 335). As the European 
Association of Urology (EAU) guidelines suggest, there are very real placebo 
effects to take into consideration (EAU 2006, 35) and, as the SBU overview noted, 
there is always a publication bias to statistical evaluations based on published 
studies; unsuccessful studies do not tend to be published. Of all the published 
studies that the SBU found to evaluate, none had been financed by independent 
sources; all were funded by the pharmaceutical industry (SBU 2011, 317–18). 
They suggest that it is important to remember that scientific and commercial inter-
ests have influenced the design, conduct and evaluation of the studies on which 
conclusions about alpha-blockers are based (SBU 2011, 325). My analysis of the 
medical discourse in Läkartidningen would suggest that resource distribution and 
professional hierarchies implicit in the structural organization of professional 
health care in Sweden are also relevant factors in the moderate success of alpha-
blockers within the process of pharmaceuticalization of LUTS/BPH. They are not 
the only factors, but they are involved.
Alpha-blockers for LUTS/BPH in Läkartidningen
Treatment for LUTS/BPH in Sweden can take one of three paths – and sometimes 
all three through the course of the disease. One can engage in ‘watchful wait-
ing’, which means the patient is sent home and told to keep an eye on things and 
come back if his urination problems become more serious. If the patient is already 
so bothered by his LUTS/BPH that watchful waiting is not an option, the treat-
ment can either be lifelong medication, beginning with the use of alpha-blockers, 
potentially combined with 5-Alpha-reductase inhibitors (5-ARIs), or the problem 
can be addressed surgically or through other means of removing or destroying the 
prostate. (There are natural dietary supplements, herbal medicines and exercise 
programmes which are also said to help, but these are not covered by the urology-
dominated discourse in Läkartidningen.)
Alpha-blockers could have been a game changer for the treatment of LUTS/
BPH when they were introduced in the 1990s. And to some extent, they have 
been, but not entirely. When they started being used, the main treatment for severe 
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BPH was surgery. The surgical removal of parts of the prostate through the urethra 
has been in general use in Sweden since the end of the 1960s (Hedelin et al. 2003, 
2441). However, the introduction of alpha-blockers has not removed surgery as an 
option for treatment, even if the official diagnostic and treatment overview (SBU 
2011) suggests that alpha-blockers are a first-step treatment, to be tried before 
surgical removal or reduction of the prostate. Yet surgery for an enlarged prostate 
and the urination problems it is thought to cause is still a very widely used method 
in Sweden (and in other countries), and the surgical techniques are continually 
being advanced technically, with hospitals purchasing expensive robotic surgery 
systems, partly as recruitment tools to attract urology surgeons (Lindgren 1999), 
and TURP simulators for training purposes are being developed and used (Käll-
ström 2010). The most recent articles in Läkartidningen mention both surgery and 
pharmaceutical treatments on equal grounds (Degerblad et al. 2014). So, as an 
example of pharmaceuticals changing the treatment practices of already medical-
ized diseases, alpha-blockers are only partially successful.
When they arrived on the scene, alpha-blockers did not have to do any con-
vincing about the ‘realness’ of LUTS/BPH or its presence in the enlarged prostate 
diagnosis. Problems with urination had already been accepted, both the legiti-
macy of patient suffering and the legitimacy of paying for treatment with tax 
money in Sweden. LUTS/BPH was an established disease with established treat-
ments that were costly and that cost was not controversial. What was controversial 
in the Swedish medical discourse was shifting that cost from surgery provision 
to pharmaceutical distribution. In 1996, an article about new, expensive pharma-
ceuticals for urological treatments, written by a leading urologist, compared their 
increasing costs (and potential share of a limited health care budget) with the cost 
of more traditional urology care, claiming that the increased costs for medicines 
for prostate cancer, BPH and erectile dysfunction ‘would equal the annual costs 
of running between five and six medium sized urology clinics’2 (Carlsson and 
Spångberg 1996a, 4552). In this argument the cost of medication is directly com-
pared to the cost of funding clinical treatments in urology. Resources for drugs 
are rhetorically placed in direct competition with urologists’ salaries and clinical 
costs.
The concern about cost is particularly relevant to the local context of alpha-
blockers in Sweden, reflecting both the tax-based structure of health care funding 
in Sweden and the fact that LUTS/BPH treatments are accessed within a health 
care system that has designated specialists – urologists – who treat LUTS/BPH 
and gatekeepers to those specialists, general practitioners. With alpha-blockers, 
there was debate and concern about cost in general, although the concern seems 
to be more related to the fact that use of alpha-blockers for the treatment of LUTS/
BPH is a lifelong medication, whereas the (arguably expensive) surgery it is some-
times thought to replace is a one-off cost (Hedelin et al. 2001, 2441). However, 
in the debate about whether to treat with alpha-blockers or to treat with surgery 
also lurked an implication of which type of doctor was allowed to treat LUTS/
BPH and where the state resources for it would then go. In Sweden, a man with 
suspected LUTS/BPH cannot make an appointment with an urologist on his own; 
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he must receive a referral to the urology specialist from his general practitioner. 
General practitioners are not allowed to conduct TURP surgeries, but they can – 
at least theoretically – prescribe alpha-blockers (Hassler 2002, 2174). By shifting 
the first line of treatment to alpha-blockers, there is the potential that LUTS/BPH 
patients will become a case for general practitioners but not urologists. To some 
extent this has happened, but not entirely, and here, too the medical discourse has 
focused on how alpha-blockers can potentially shift cost and resource distribution 
within the health care system (Carlsson and Spångberg 1996b, 4557). In the early 
2000s, it was estimated that one in four patients was beginning treatment with 
alpha-blockers or other pharmaceuticals before visiting a urologist (Hedelin et al.  
2003, 1435). This does not mean that urologists have lost 25% of their LUTS/
BPH patients – on the contrary. There has been a dramatic rise in the number of 
patients presenting with LUTS/BPH since the early 1990s, probably due to the 
existence of alpha-blockers and their use as a treatment at an earlier stage in the 
disease. But nonetheless, the discourse in Läkartidningen shows a concern about 
patients being treated outside of, and prior to, consultation with a urology spe-
cialist, despite that the Swedish urology field is currently understaffed and there 
are long waiting lists for meeting a urologist, as the field is very occupied with 
prostate cancer.
For the treatment of LUTS/BPH, a shift from being a disease treated by special-
ists to one managed by general practitioners can also carry with it a step down 
the prestige ladder (see Witz 1992; Lindgren 1999), and one which could mean 
a transfer of resources from the more prestigious speciality (urology) to the less 
prestigious world of general practitioners, as the comparison of increasing costs 
of pharmaceutical treatments to clinic costs could suggest. This competition 
between GPs and urologists has been articulated elsewhere, like in the debate 
about whose finger is better at conducting the digital rectal exam of the prostate, 
the general practitioner’s or the urologist’s (see Kirby et al. 1995). It may have 
had an influence on the extent to which alpha-blockers replaced surgery in the 
Swedish context.
The final words in the debate between alpha-blockers and surgical treatments 
for LUTS/BPH may yet remain to be written. One of the urologists I interviewed 
suggested that the new framing of BPH as primarily LUTS in the 2013 European 
Association of Urology clinical guidelines (Oelke et al. 2013) is a result of alpha-
blockers – or lobbying by their producers and supporters – to change the focus 
from the enlarged prostate to the lower urinary tract symptoms and thereby shift 
the focus from potentially removing an enlarged gland and instead treating the 
muscles in and around it with pharmaceuticals.
More recently, there has been little debate about the use of alpha-blockers in 
Läkartidningen, which would suggest that the usage has stabilized. Alpha-blockers’ 
place in treatment practice has also been formalized in the 2011 overview pub-
lished by the Swedish Agency for Health Technology Assessment. The chair of 
the committee who authored this report is the same urologist who raised the com-
parison of costs in relation to urology clinics in 1996, and who wrote a 2013 
article in Läkartidningen reviewing the overview. His voice, together with the 
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health care policy analysts he co-authored with, raised concerns about the (over)
use of alpha-blockers, while simultaneously noting their relatively small success 
rate (Spångberg and Dahlgren 2013, 683).
Strong and weak pharmaceuticalization:  
alpha-blockers and Viagra in Läkartidningen
As discussed in Chapter 4, Viagra changed the concept of ED and impotence, its 
treatment and even who its patient was in the Swedish medical discourse, as it did 
in the international discourse. Yet particularly local Swedish aspects appeared in 
the discourse around Viagra, related to local (nation state) health care provision 
specificities, particularly the division of labour between GPs and specialists, and 
the funding structures for clinical care and pharmaceutical provision. There are 
some similarities here to what happened with alpha-blockers in the Läkartidnin-
gen discourse, but also some significant differences.
One similarity between the Viagra discourse and that surrounding the use of 
alpha-blockers is the concern about cost, yet there are some significant differences 
between them, too. This was a very heated debate about Viagra, and dealt primar-
ily with the potential costs a state subsidy of the pharmaceutical would entail, an 
argument that spilled over into the court system, as Chapter 2 detailed. The Viagra 
cost debate focused on the sheer (potential) cost of the drug for a desiring public 
and its legitimacy within a tax-funded system, based on the question of whether 
old-age impotence was a legitimate disease to spend tax resources on. Within the 
alpha-blocker debate, the question of cost was framed as one of where within the 
health care system the disease would be treated, and whether resources should be 
used to support clinics or pharmaceuticals. The legitimacy of spending tax money 
to treat LUTS/BPH was never questioned.
Viagra also changed the way impotence (now ED) was treated, which alpha-
blockers only partially managed to do. Here the most interesting difference with 
alpha-blockers can be found. Perhaps the incompleteness of the shift from surgery 
to pharmaceutical treatment is because the representatives of the other method of 
treatment (surgery) are not from a less prestigious and weaker field of medicine. 
In the Viagra case, when Viagra was introduced it shifted the event of impotence 
from a problem for sexual and couples therapists to a disease (ED) under the remit 
of urologists. The urologists were able to claim this territory from the sex thera-
pists without much visible resistance. However, LUTS/BPH was already a disease 
of urology when the pharmaceuticals arrived on the scene and despite indica-
tions that general practitioners may be beginning to prescribe alpha-blockers for 
it, urologists are trying to keep LUTS/BPH in their remit. Rather than facilitating 
a shift from one medical field to another, alpha-blockers merely created two dif-
ferent factions within urology: those who were still using surgery, and those who 
were willing to treat LUTS/BPH with pharmaceuticals.
Given that the introduction of alpha-blockers could have replaced an expen-
sive, invasive surgical procedure, one could have expected it to cause a change in 
treatment practices more readily and thoroughly, as Viagra did. But this was not 
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the case. Surgical procedures are down significantly from their occurrence rate 
before alpha-blockers were officially part of the treatment cadre, but there are still 
many thousands conducted each year in Sweden. Perhaps one clue to why can be 
found in the fact that with Viagra there was no actor who/which had traditionally 
received large resources for the treatment of impotence. Sexual therapists existed 
(and still exist) in Sweden, but their branch of medicine was peripheral compared 
to urology, and not nearly as well funded. The occurrence of impotence was medi-
calized, but its treatment costs were minimal and it was somewhat considered a 
natural part of getting older that men should just accept (see McLaren 2007). This 
was not the case with urination problems. The shift of ownership of impotence 
from sex therapists to urologists that Viagra facilitated was from a low-prestige 
field to a higher-prestige one. But for alpha-blockers, the potential shift was from 
a surgical branch of urology to a non-surgical branch of urology. This can either 
be considered two equal branches in the same field, or envisioned as a shift from a 
high-prestige to a lower-prestige branch in the same field of medicine, depending 
on how one sees it (cf. Lindgren 1999). Alpha-blockers were not a tool that could 
be used to capture the right to diagnose and treat a problem from one specialty 
to another. Urologists were already conducting surgeries for LUTS/BPH, and it 
is primarily urologists who are prescribing alpha-blockers. Increasing their use 
could potentially allow GPs more space in the game, but the urologists seem to 
be a more powerful voice in the discourse. In fact, no GPs were authoring arti-
cles about LUTS/BPH and alpha-blockers in Läkartidningen during the period 
studied, unlike the Viagra discourse, which saw a shift in who was the author of 
most of these texts. In the alpha-blockers for LUTS/BPH discourse, nearly all of 
the articles are written by or giving the opinions of urologists – eleven of them – 
throughout the entire time period searched, with the exception of a few pharma-
cists and pharmaceutical policy analysts. This is different than the authors, who 
were given space in the Viagra discussion, where sex therapists and sexologists 
were writing about impotence before Viagra, and urologists were writing about 
erectile dysfunction after Viagra’s arrival.
The case of alpha-blockers in Sweden can nuance our understanding of phar-
maceuticalization by showing that the existence of the drug and its acceptance 
into the official retinue of treatment options is not enough to predict the success of 
a new pharmaceutical treatment. Success is also related to which actors (individu-
als, commercial interests and medical practitioners, a heterogeneous category) use 
the drugs to make the shifts that occur. Locally, with the case of alpha-blockers 
in Sweden, the specific concerns with cost and resource distribution related to 
the government-financed organization of speciality clinics may have impacted 
the amount of success the alpha-blocker treatment has had in replacing existing 
therapies, and seems to certainly have influenced the way it was presented in the 
medical discourse.
Alpha-blockers have become an earlier step in the disease trajectory, a sort of 
middle stage before eventual treatment with surgery, even though many men are 
prescribed alpha-blockers with the idea that they will have to take them for the rest 
of their lives, and may avoid surgery by doing so. The ability of alpha-blockers to 
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shift the treatment paradigm of an existing medical condition from surgery to phar-
maceutical has been weaker than that of Viagra. But they have still managed to 
take over some of the patients and, perhaps more important, they have managed to 
increase the number of patients identified as having LUTS/BPH. Alpha-blockers 
have been part of a process of pharmaceuticalization of an existing medical condi-
tion, but this process has been only partially successful.
Notes
 1 There has been a more recent debate about the dangers of using an anti-inflammatory 
drug for BPH because of its negative effect on heart patients already taking glucosa-
mine, a debate that has primarily been related to Pfizer’s heavy marketing of Artrox, 
its alleged influence on Swedish safety and side-effect recommendations to doctors, 
Pfizer’s alleged attempts to debunk studies which criticize its effectiveness and safety, 
and its increased cost, compared to other drugs (see Beermann 2003; Fuberg 2003a, 
2003b; Järhult and Lindahl 2003a, 2003b, 2003c; Lohm and Lindh 2003;; Nilsson et al.  
2003; Lohm et al. 2003; Järhult 2005). This is not an alpha-blocker and is therefore not 
analyzed in this chapter.





6  Enrolling men, their  
doctors and partners
Individual and collective 
responses to erectile dysfunction1
Ericka Johnson and Cecilia Åsberg
This chapter examines how men, their doctors and their partners are enrolled by 
the Pfizer-sponsored website for potential Swedish Viagra customers. We read 
this enrolment as an example of how new techno-social identities are created by 
a drug, in this case, Viagra. The Swedish-language site www.potenslinjen.se2 (in 
English, ‘potency hotline’) is framed as a source of information for laypeople 
concerned about erectile dysfunction.3 We have examined how the site’s text and 
imagery address different audiences in the construction of the Swedish Viagra 
man. Our analysis builds on existing literature about the promotion of Viagra 
which addresses the construction of erectile dysfunction (ED) and masculinity in 
other national contexts, and we therefore make mention of alternative images and 
readings in other contexts throughout our analysis. Like previous critical stud-
ies of Viagra (Fishman and Mamo 2001; Marshall 2006; Tiefer 2006; Vares and 
Braun 2006), we are examining the construction of an ideal user of Viagra, but we 
also discuss the way the enrolment of doctors and partners serves to position ED 
in the man and define its treatment as a solitary act of taking a pill while simulta-
neously involving the other actors to help the medicine function.
Our contribution delineates the specific roles the various subjects are granted in 
the commercial discourse, in particular by looking at the invisible work the ‘pas-
sive’ female partner is tasked with as she is told to actively guide and support her 
partner in the Viagra trajectory. To think through the creation of the Viagra-specific 
techno-social identities within the pharmaceuticalization framework (Williams et 
al. 2011a), we use the Actor Network Theory (ANT) concept of enrolment, which 
articulates the roles given to various actors as they are enrolled into a network that 
discursively constructs ED as an illness and Viagra as a cure.
The global and the local become relevant in this chapter when the empirical 
material is read against the framework of regulations regarding DTC marketing of 
pharmaceuticals. The legality of DTC advertising of prescription pharmaceuticals 
in the United States and New Zealand has spawned much of the critical research 
about Viagra and its role in the media climate (see Mamo and Fishman 2001; 
Elliot 2003; Loe 2004b; Moynihan and Cassels 2005; Potts and Tiefer 2006). And 
the illegal advertising with near impunity of pharmaceuticals in countries which 
do ban DTC advertising has been detailed by Zetterqvist and Mulinari (2013) and 
Zetterqvist and colleagues (2015). Our study, looking at Viagra in the Swedish 
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context, which bans DTC advertising for prescription drugs, confirms the results 
of much of this work but contributes an important insight to the strength and flex-
ibility of Viagra marketing in a globalized pharmaceutical market. There is a good 
deal of harmonization between the Swedish site and other Viagra sites, yet also 
local adaptation (see also Chapter 7). And as we show here, the local adaptation 
of Viagra marketing that is not considered DTC advertising relies on the construc-
tion of subjectivities for the man, his doctor and his partner. The Swedish site is 
a ‘purely informational’ site about erectile dysfunction (although it is obviously 
advertising Viagra) and therefore has information explaining what sex therapy 
can offer men suffering from impotence in addition to pharmaceutical solutions 
to ED. The site has previously (2009) listed the telephone number to a sexual 
medicine centre at a large hospital in Stockholm that receives undirected funds 
from Pfizer and recently (2015) suggests that men use sexual or psychological 
therapy for cases when erectile problems have psychological or social causes. In 
these cases, the site suggests men turn to The Yellow Pages. Despite the DTC ban, 
Viagra figures largely on the website in its colour schemes and Pfizer branding, 
even if the word Viagra is generally absent.
Viagra has figured largely in the ‘collective psyche’ in Sweden both as a sub-
ject of newspaper articles (some reading as if they have been taken directly from 
drug company PR sheets) and of public debate, thanks in large part to the drawn-
out discussions and court cases about whether the Swedish health care system 
should or would subsidize Viagra (see Chapters 2 and 4). Despite the ban on DTC 
advertising, a wide range of commercially produced informational material about 
Viagra is available in Sweden: free pamphlets and booklets which men or their 
partners can order from Pfizer; literature for doctors and other medical profession-
als; press coverage in local and national newspapers; informational material on 
publicly funded webpages about men’s health. We have, for this chapter, focused 
on the website www.potenslinjen.se for a number of reasons: it is produced by 
Pfizer for a Swedish audience in the Swedish language; it is easily accessible 
to anyone with an Internet connection and does not require interfacing with a 
medical practitioner; it focuses on impotence and erectile dysfunction rather than 
men’s health in general; it can be accessed by and addresses individuals not fac-
ing impotence personally, like partners and friends. Additionally, the website is a 
good example of how Pfizer tweaks its material to localize a global message for 
its global product. Viagra is available in Sweden, but falls outside of the state-
subsidized pharmaceutical scheme, which means patients must pay for the drug 
themselves, creating challenges for marketing the drug. This is addressed by a 
short film on the website, encouraging men to avoid dangerous, black market pur-
chases and explaining how easy it is to get a prescription and buy the ‘real thing’ 
at a drugstore. By analyzing the discourse on www.potenslinjen.se, we argue that 
the challenge of encouraging men to buy Viagra has been met on the website in 
part by enrolling men, their doctors and their partners in the ways we detail later 
in this chapter.
In analyzing the text and images on this site, we have been inspired by the criti-
cal studies of Viagra mentioned earlier in this book as well as Foucault’s idea of an 
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economy of discourses about sexuality. We are looking at the material presented 
on the website as an example of an economy of discourses in an attempt to articu-
late ‘the necessities of their operation, the tactics they employ [and] the effects 
of power which underlie them and which they transmit’ (Foucault 1987 [1976], 
68f). We also draw inspiration from studies of scientific discourse and naturalized 
embodiment that feminist scholars have produced since the late 1970s on power-
ful ideological processes (cf. Merchant 1980; Haraway 1989; Butler 1990; Martin 
1991; Fox Keller 1992; McClintock 1995; Bryld and Lykke 2000; Franklin et al. 
2000; Braidotti 2006). These researchers have used feminist critiques to inves-
tigate how science as a discourse and notions of the natural are used to support 
dominant ideologies.
In our final discussion, we ask what this enrolment says about social, rather 
than individual, aspects of ED, drawing inspiration from early medical sociology 
work on community responses to mental health (Eaton and Weil 1955) and recent 
qualitative studies of men’s responses to ED (Oliffe 2005; 2006). By exploring 
alternative narratives of illness, we suggest, an alternative reading of erectile dys-
function and its subjects could be told.
Background
Science and technology studies use the term enrolment within ANT to denote how 
human and non-human agents are called on and woven into complicated networks 
(Latour 1993; 1998). Although it has been rightly criticized for implying a heroic, 
entrepreneurial actor in the process of enrolment (Star 1991), the concept is use-
ful for our study because it articulates the sense that there are actors with specific 
interests (here, the pharmaceutical company Pfizer and its marketing experts) who 
use specific methods (those described in this chapter are discursive strategies) to 
involve heterogeneous constellations of human and non-human actors in the con-
struction of a Swedish Viagra man. We will be using the concept of enrolment to 
examine how a specific web of actors – potential users, their medical doctors and 
their partners – is woven together by a discrete discourse to construct an identity 
and agenda for the Swedish Viagra man.
In Sweden, Viagra has been available by prescription since its approval in 1998, 
but, like the similar drugs Cialis and Levitra, it is not covered by the national sub-
sidy programme for medicines. Thus, men can get a prescription for the drug, 
but they must pay for it out of their own pockets, which is unusual for the Swed-
ish consumer. Produced and sold by the pharmaceutical company Pfizer, Viagra 
works physically in some men and in some situations by blocking the return of 
blood flowing out of the penis. Thus, if a man becomes aroused and blood flow to 
the penis increases, Viagra will help keep it there and produce an erection.
Discursively, however, Viagra does many other things. Viagra has, for example, 
changed our language about impotence in both English and Swedish. The market-
ing around Viagra has helped to introduce the term erectile dysfunction (ED) to 
the general public, replacing the more negative term impotence (Bordo 1998, 90; 
Potts 2004, 23). Masters and Johnson used the term erectile dysfunction in the 
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1950s (McLaren 2007, 221). In psychiatric discourse, erectile dysfunction has 
been articulated as a problem of arousal since the 1970s, when ED is defined as a 
problem of attaining and maintaining an erection sufficient for intercourse (APA 
2000). Sexual response models within sex therapy have taken foremost physiol-
ogy, but also behaviour (penetration) into account in defining healthy or non-
healthy sex, which coloured the term impotence pejoratively, and later replaced 
it with the term erectile dysfunction. However, the medical community did not 
generally take up the term until it was adopted by urologists and popularized by 
Pfizer (see Bordo 1998; Marshall and Katz 2002; Loe 2004b; see Chapter 4 for the 
Swedish example). This rhetorical shift narrows the definition of what impotence 
is from a condition of the psyche, the emotions or the relationship, to a biomedi-
cal complaint (Marshall and Katz 2002; Tiefer 2006; McLaren 2007; Johnson 
2008). Pfizer marketing has also introduced the concept of erectile quality (EQ) to 
expand the market to include younger men (Fishman and Mamo 2001, 181; Mar-
shall 2002, 139), playing on ‘erectile insecurity’ (Tiefer 2006, 279). And, impor-
tantly, Viagra has been a phenomenon around which multiple, different, vested 
interests have gathered to sell it and construct the disease of ED, as Loe articu-
lately shows in her examination of the US case (Loe 2004b).
As has been noted widely, Viagra has reinforced the definition of sex as penetra-
tion, and masculinity as the ability to achieve penetration, relying on a reworked 
version of the notion Sigmund Freud previously had reserved for the female mind: 
the ‘anatomy is destiny’ determinism of the naturalized body in the construc-
tion of the late modern male identity. The physicality of male embodiment boils 
down to the sexual (and not necessarily reproductive) performativity4 of the vis-
ible sexual organ. Thus, within the Viagra discourse, as Baglia’s (2005) study of 
Pfizer promotional material in the United States has shown, sexual performance is 
defined by a narrow sexual function model starting with arousal and progressing 
through erection, penetration and ejaculation. As long as a man can perform this 
penetrative sex, his masculinity is intact. The idea that penetration produces (or at 
least proves) masculinity reinforces the importance of penetration for both the sex 
act itself and the concept of sex-life expectancy. As sociologist Barbara Marshall 
notes, this concept of sex-life expectancy, with its calls to vigilant self-monitoring 
of healthy practices and appropriate sexual behaviour, relies on the disciplined 
individual taking responsibility for managing the risks of lost masculinity (i.e. lost 
ability to penetrate) even before ‘old age’ (Marshall 2006, 335). Viagra connects 
this individual responsibility to the medical and pharmaceutical networks within 
which Viagra is active, which also reinforces the scientism of sex and the natural-
ized body, attaching both to systems of expertise while simultaneously assigning 
responsibility for functionality to the man.
The Viagra discourse of sex relies on a three-step paradigm of arousal, pen-
etration and ejaculation, and then demands Viagra as a solution to (age, stress 
or illness related) declining sexual performance (Plante 2006, 380). According 
to this discourse, a person (or couple) can maintain a successful sex life, as long 
as penetration is possible, that is with the help of Viagra. This idea ignores and 
tends to silence suggestions of alternative sexual practices and a sex life that is not 
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dependent on penetration (Tiefer 2006). In this narrative, emotions all but disap-
pear. And where they do play a role, responsibility for them is given to the partner, 
as we will discuss later.
Enrolling participants in the Viagra discourse
Examining the Swedish website it becomes apparent that Pfizer enrols three dif-
ferent groups of human participants to assist in constructing a subject position for 
men as potential consumers of Viagra: the men themselves; medical doctors; and 
the men’s partners. Throughout the discourse, the Viagra pill is also enrolled as a 
non-human actor, nearly given a hero’s identity.
Enrolling men
Men are enrolled through the information on the pages that constructs them as 
potential patients with ED. They are welcomed in what could be considered a 
respectful and tactful manner: ‘Potency problems can be a sensitive issue in spite 
of the fact that many men – and their partners – are affected,’5 they are told. The 
picture attached to the welcoming sentence, a photo of a tanned, grey-haired man 
in his fifties on his back with hands behind his head, smiling as he looks up into a 
blue sky that matches his blue t-shirt, suggests a relaxed, laid-back attitude. The 
blue colours of clothing and sky seem to allude to the iconic colour of Viagra and 
to Pfizer’s logotype, and are a common feature of Viagra ads, as Loe (2004b) and 
Baglia (2005) have discussed. In the image and text, the cultural stigma of ED is 
mitigated by such a respectful yet relaxed approach. Further, the mode of address 
to the large number of men and their partners who suffer from ED normalizes the 
prevalence of the problem and works to alleviate the concern the visitor to this site 
may be experiencing. The accessibility of an easy, safe and comforting solution 
to erectile problems, in the form of the drug, is also highlighted by the film on 
the first page, complete with dancing, erect penises and reassuring statistics about 
how common ED is.
Aside from the overwhelming discourse of disease associated with erectile dif-
ficulties (including mention of cardiovascular disease, which will be discussed 
later), one of the primary tools used to enrol the men is an interactive quiz in 
which they are first asked to rate their sexual health (by answering a series of five 
questions) then encouraged to talk to their doctor. Unlike much of the other text 
on this site, the quiz is a short version of the International Index of Erectile Func-
tion (IIEF), and is directly translated from the US Viagra site.6 As Marshall has 
discussed, this process of inviting quizzes, generous medical advice and sexual 
education effectively creates an ostensibly benevolent regime of self-surveillance 
on the website for the individual through assisted self-monitoring and remedial 
action (Marshall 2006, 356; see also Mamo and Fishman 2001; Baglia 2005). 
Such a mode of address, and ways of enticing and enrolling potential consum-
ers of Viagra, can be read as part of a larger discourse, a sexual regimen of the 
individual. This sexual self-governance and monitoring, to borrow ideas from 
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Foucault, is centred on male penetration at the Viagra website. Given the flour-
ishing market for self-health guides, books and websites and so forth, this mode 
of address is hardly surprising. This website merges the commercial aims of a 
product-selling site with sexual education and health advice in a manner charac-
teristic of the rather recent new media genre of ‘edutainment’ where entertaining 
features such as quizzes and educational imagery blend for accessible, online dis-
play (Åsberg 2005).
Health matters are, in such genres, firmly placed within the world of consumer-
ism, as detailed in Stacey’s description of self-help literature in her cultural study 
of cancer (Stacey 1997). The Viagra consumer is enrolled into a mode of being 
sustained by the ideal of the self-caring subject position of a health consumer. 
In line with Stacey’s work on health consumerism, this also resonates with what 
Rose and Novas termed ‘biological citizenship’ (Rose and Novas 2005, 14). The 
biological citizen invests heavily in self-education on health matters and develops 
the medical literacy needed to pursue a high-quality, self-sufficient, personally 
and socially ‘responsible’ lifestyle (Rose and Novas 2005, 14). Through the quiz 
on sexual health, the self-surveillance discourse redefines sexual health in a very 
specific, determinist way: sexual health for men is the achievement and mainte-
nance of an erection and ability to complete intercourse. Their anatomy (particu-
larly the functioning of certain parts of their anatomy) becomes their destiny.
The website not only encourages self-surveillance and individual responsibil-
ity, it also provides the tools for individuals to take on the task of monitoring and 
disciplining their erections:
If you are being treated with potency medicine from Pfizer, you can receive 
support and encouragement for your treatment through the web.7
Do you lack the time, desire or opportunity to pick up your medicine from 
the drugstore? Now you can have your impotence medicine delivered to your 
home by mail.
Similarly, in a special section called the Potency Coach, illustrated by an 
animated cartoon figure with a megaphone, one finds that:
The Potency Coach is an easy to use, interactive patient support that will 
help you achieve the expected and pre-determined results with your treat-
ment. Here you can also find information about the underlying causes of 
potency problems and about other patients’ experiences.
Working within a benevolent discursive frame to help him help himself, the web-
site also reveals the assumption of a shy, Swedish man of few words implied by 
such a mode of address. The targeted subject is one who does not easily confide 
in his physician, especially not regarding sexually related matters, and must be 
reassured and coaxed to bring up the topic during a health care visit:
Unfortunately, it is common that men hesitate before seeking help. This is 
a shame, since the vast majority of those who seek help can be successfully 
treated for their problems.
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Perhaps surprisingly, it is not a sexually liberated or outspoken subject who is 
addressed, but someone rather inhibited when it comes to articulating sexual 
problems. From this arises a Swedish man who is non-articulate with respect to 
his own malleable body and sexual health, a man who might need encouragement 
when asking for a Viagra prescription at the doctor’s office since doing so could 
be interpreted as a defeat in the masculinized struggle to control the body. Impor-
tantly, this can be read as a remarkable hands-on approach of Pfizer in facilitating 
the individual and his care of the self.
Enrolling doctors
Medical doctors are also enrolled through Pfizer’s efforts on the Swedish www.
potenslinjen.se website (beyond the infamous drug rep sales techniques [see 
Reidy 2005]). Part way down on the very first page, an anatomical sketch of a 
heart accompanies a text that reads ‘Potency problems – an important warning 
sign’ and delineates how potency problems might be the first ‘useful’ sign of car-
diovascular diseases. It becomes clear that Viagra is not merely a matter of fleshy 
pleasures and an improved sex life, and that the ED Viagra is supposed to allevi-
ate relates to serious health issues and even has a function as a first warning sign. 
Such medical appeals to cardiovascular health issues as linked to ED both play 
to the scientism of the naturalized body and work to medically legitimize Via-
gra. Swedish men seeking medical attention for ED are addressed as upstanding 
citizens taking responsibility for their personal overall health, and doctors are 
encouraged to help them with that. This use of medical complaints other than ED 
to legitimate Viagra can be read against the efforts in Sweden to associate Viagra 
with specific diseases rather than lifestyle choices as part of the debate over state 
subsidies (see Chapter 2).
The medical dimension of Viagra is further enhanced with a figure of author-
ity that confirms both the relaxed personal tone and the urgency of the matter, 
namely a headshot of a physician in scrubs with a hint of a smile on the first page. 
The photo of the doctor creates a close proximity between medical authority and 
the potential Viagra consumer in another sense: the ambivalence of the picture in 
this setting suggests that even a medical doctor can have a use for Viagra. Most 
importantly, however, this small photo, emitting medical confidence and trust-
worthiness, serves a particular function within the website: to illustrate a search 
engine for finding a local, Viagra-friendly doctor. In addition to encouraging doc-
tors to be ‘proactive’ in asking their patients about sexual function during routine 
exams and when taking medical histories,8 Pfizer has included a national database 
of ‘ED-aware’ doctors, or ‘affiliated experts’ as Loe (2004b) calls them, which 
lets visitors to the website submit a query and generates a list of doctors near them 
who can be consulted for information about erectile dysfunction (and, presum-
ably, for prescriptions of Viagra).
A clear example of local manifestations and adaptations of global market-
ing methods, the same type of database can be found on other national Viagra 
sites, also paired with suggested phrases that men can use when speaking to their 
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doctors, addressing the fact that some men may find it difficult to bring up the 
subject of sexual dysfunction during an exam. On the Swedish site, men are told, 
‘When you meet your doctor, she or he will probably interview you and ask you 
questions about previous illnesses and if you are currently taking any medica-
tions. Try to provide as accurate information as possible, including if you still 
have early morning erections or if your erectile ability has disappeared suddenly 
or gradually. It may feel difficult to speak about these issues, but it is completely 
OK to be embarrassed. Remember that doctors are used to speaking about these 
things and their job is to help you.’ In this way the men and doctors are also 
positioned to enrol each other and maintain each other’s investment in the Viagra 
discourse. We suggest that this part of the Viagra website seems to connect bio-
logical citizenship with medical literacy and affiliated experts, to thus secure the 
commercial success of the drug.
Enrolling partners
On the Swedish site partners are also enrolled in the process of positioning men 
as subjects for whom Viagra is the solution to a waning sex life and/or issues of 
sexual dysfunction. Potency issues are continuously addressed as a joint problem, 
for the female partner as well as for the man. In a special section of the Swedish 
webpages, partners are told about the ways ED can affect a relationship, above all 
by letting coldness, distance and worry creep in and replace the sensitivity, near-
ness and trust that had been in the relationship before. On the connecting pages, 
partners are encouraged to be supportive, and then to let their partners know that 
treatments are available for the problem:
Today there are many different treatment methods. There are medicines that 
are prescribed in connection with a doctor’s visit. Apart from medical treat-
ment, sometimes sexual therapy can be the most appropriate approach. It is 
good for you as a relative to know about this and to be able to support and 
encourage your partner to seek help.
The partners are also encouraged to order the free brochure ‘A man’s best support 
is by his side’, published by Pfizer with a smiling, heterosexual couple on its front 
page. The way partners are enrolled to support the men experiencing ED plays 
strongly on the assumption that the partner is steadfastly (unreflectively?) con-
senting to reproduce certain practices and maintain a supportive position within a 
relationship with the man (cf. Potts et al. 2003). There is also information about 
how ED makes a man feel and what sorts of ‘normal’ behaviour it can provoke in 
one’s partner. ‘Many [men with ED] distance themselves from their partners sim-
ply to avoid conflict and to avoid situations which can lead to sex. Many develop 
a new hobby, immerse themselves in their work, or make sure they don’t go to 
bed at the same time as their partner in the evening. Many consciously or subcon-
sciously even create conflicts to avoid being close to their partner.’ As this quote 
implies, sexual intercourse seems to be an active achievement, where ‘success’ 
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needs to be granted. Moreover, the female partner has a supportive rather than a 
leading role in this sexual achievement which combines the traditional, passive 
recipient of penetration (waiting in the bed for her partner with the new hobby) 
with an active subject tasked with leading and directing the man to Viagra and/
or sex therapy. She can guide him on his way, yet he is the doer behind the deed. 
This reverberates with the traditional assumption about heterosexual femininity 
as sexual passivity and masculinity as sexual activity, but more importantly it also 
points to the enormous effort by the woman that in reality lies behind achieving 
the ‘passivity’, which can confirm his active and valuable status as a heterosexual 
male. There are many subtle manoeuvres, enticing practices and persuasive, yet 
necessarily non-direct rhetorical moves a woman must master in order to achieve 
the right amount of sex-inspiring passivity. A lot of hard work lies behind her 
‘passive’ affirmation of his masculinity.
A specific section of the Swedish website is dedicated to the prescriptive dis-
cursive patterns available to the partner. As the main heading on the partners’ page 
suggests, she should ask herself how ‘can I help?’ to receive the answer, ‘Speak to 
and encourage: It is best to speak openly with your partner; support each other’.
In this section of the Swedish webpage one finds a discussion about how ED 
and the normal behaviour it provokes in men can make the partner feel. These 
partner responses build on feelings of guilt and inadequacy. However, the partners 
are encouraged to persevere and help their men seek help because ‘When one has 
received help and solved the problem, many discover that their relationship has 
in fact become stronger.’ Again, the partner’s discursive work is one of maintain-
ing a seemingly effortless and natural attitude that avoids putting pressure on 
her partner and is achieved by another rhetorical strategy here provided by the 
Viagra site text, namely the ‘we’. She can address her sexual needs and his sexual 
problems if they are addressed as a ‘we’ issue, enrolling a sexual dyad, a figure of 
heterosexual complementarity.
Within the Swedish context, it is worth noting that pre-Viagra (prior to 1998) 
medical advice about impotence underlined how important it was for doctors to 
warn their patients that merely solving a man’s inability to produce an erection 
would not necessarily solve relationship problems (Olsson et al. 1995), something 
the Pfizer information seems to belie. Internationally, this assertion can be read in 
light of a Japanese study where a survey on the level of satisfaction derived from 
using Viagra indicated that while the male patient was extremely satisfied, his part-
ner was not satisfied at all. Women reported their husbands’ erections as trouble-
some, that they had to use supplements to increase vaginal lubrication and in some 
cases even take hormones (Castro-Vázquez 2006, 123). Loe (2004a) and Potts and 
colleagues (2003) also provide examples of women’s responses to and concerns 
about Viagra use in the United States, demonstrating a wide diversity in opinions 
and practices. Additional studies on Swedish women’s accounts of Viagra would 
here be needed, but looking at the website it is clear that the female partner, since 
heterosexuality becomes further implied in the illustrative photos of both older and 
younger heterosexual couples that frame the text, is enrolled as responsible for the 
man’s health and for their relationship; she can help him help himself to become the 
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Viagra-empowered, potent man. At the website, her task becomes one of ensuring 
that penetrative intercourse can occur, since sexual intercourse is what consolidates 
the relationship and makes it strong. Through the figure of the sympathetic partner 
conjured up on the website, the responsibility not only for the general health and 
well-being of the man but also for the emotional health of the couple is presented 
as a feminized task.
It is here, in the partner section, that emotions and feelings are mentioned on 
the website with the references to coldness, distance, worry, sensitivity, nearness, 
trust, guilt and encouragement. Physiologically, Viagra only works if a man is 
sexually aroused in the first place, so partners are encouraged to help achieve Via-
gra’s success by ensuring the necessary feelings are in place. Thus responsibility 
for the emotional aspects of sex, not just the relationship, is also effectively given 
to the partner. Partners are reminded that ED is ‘the man’s symptom, the couple’s 
shared problem’, so the partner is directed to ‘speak to and encourage’ the man. 
She is the one who in practice can confirm his potency. Her assignment within the 
Viagra discourse is to manage this talk as she takes the emotional responsibility 
for discussing and reflecting over the role of sex for their relationship. Here, too, 
emotions come into the discourse but so do the co-constitutive agencies of medi-
cal expertise, female partners and Viagra as embodied, chemical effect as well as 
an expectation on virile manhood giving shape to the ideal Viagra man. Partners 
are encouraged to learn about ED because, ‘with knowledge in hand, you will 
find it easier to speak with your partner. Together you can discuss your feelings 
and thoughts, and give each other support, and in the end, solve your relationship 
problems’.
We suggest that this assignment of emotions and responsibility for the relation-
ship’s well-being to the female partner enables her to legitimately address the 
problem of ED as a shared issue. Within the discourse on the Viagra pages, the 
tool she is often given to solve the problem is the little blue pill, but because of 
the particularly Swedish, legally dictated, ‘informational’ role of the website, the 
partner is also provided with information about alternative treatments like sexual 
therapy (even if this information is sparse and even as the site is branded in a very 
Viagra blue). But as we will discuss later, enrolling the partner in the ED discourse 
this way could also open alternative solutions and alternative definitions of the 
problem.
Discussion
In our analysis, we have identified three enrolled participants the website addresses 
to help create a subject position for the consuming Viagra man. The first of these is 
the male patient, for whom anatomy and age become his destiny, but who can con-
sume Viagra to control that destiny and discipline it in line with youthful expecta-
tions. The second is the doctor, both enrolled to help ensure the male patient can 
access Viagra and used to represent scientism, which legitimates the use of Viagra 
by associating it with networks of scientific expertise. And thirdly, the partner 
of the patient is also enrolled in the process of creating a subject position for the 
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Viagra-consuming man. Responsibility for his emotions is given to his partner, 
who simultaneously consents to supporting a pharmaceutical solution for the man 
and the relationship.
The enrolment of these three participants in the commercial discourse creates 
a network of actors who can perform the desire for, distribution of and context to 
contribute to successful use of a pharmaceutical as a solution to impotence. Their 
presence in the commercial Viagra discourse is particularly striking when one 
considers that they all but disappeared from the medical discourse around Viagra 
when it was introduced in 1998. As Chapter 4 discusses, the Swedish medical 
journal Läkartidningen supported a very heterogeneous definition of impotence 
and impotent patients in the early 1990s, one which recognized many different 
types of men with different reasons behind their impotence, and which encour-
aged the involvement of partners during treatment, enrolling the partner in much 
the same way as the Viagra website does (Olsson et al. 1995, 313). This approach 
was not necessarily benign; the imagined partner was a woman in this (also) very 
heterosexual discourse, and she was ascribed a narrow position in the discourse: 
‘Men and women have different ways of expressing themselves and therefore 
misunderstandings can easily arise. Women must learn to be clearer and men to 
be more receptive’ (Olsson et al. 1995, 313). Her ideal sexuality was also lim-
ited: unthreatening, dependent on and receptive to her male partner’s desires. ‘The 
best help for a man with disappointing erections is, besides his own courage to 
speak about it, an understanding and sensual partner who is sexually keen but not 
demanding’ (Olsson et al. 1995, 314). However, with the 1998 advent of Viagra, 
the medical discourse in Läkartidningen narrowed the definition of an impotent 
patient to the male penis and removed the varied social and sexual backgrounds, 
and actors, which had previously been present. Yet, in the commercial discourse, 
the partner and factors like stress and tiredness are present alongside Viagra.
Despite the stigma attached to impotence and the common assumption that 
men would not want to talk about ED (as the nudging encouragement provided by 
www.potenslinjen.se implies), qualitative research (primarily interview studies) 
on men who are dealing with erectile dysfunction shows that not all men deal with 
their ED problems alone and in silence. Many men are already enrolling medical 
professionals and partners in their quest for a solution (Oliffe 2005; 2006; Grace 
et al. 2006). These men turn to medical professionals to procure treatments for 
their impotence (Viagra and similar drugs, but also injections and vacuum pump 
treatments) and some men engage their partners both in treatment therapies and 
as discussion partners with whom they can talk about their difficulties and explore 
alternative sexual practices (Oliffe 2005). As much current research within mas-
culinities studies supports, men’s experience of illness, especially a condition as 
related to masculinity as erectile dysfunction, is influenced by how the men and 
those around them, that is the network of actors enrolled in definition and solution 
work, think about and practise masculinity (cf. Marshall and Katz 2002; Aucoin 
and Wessersug 2006; Sandberg 2011). These studies also suggest that some men 
who experience sexual dysfunction are already comfortable using a network of 
actors to help them both define their problem and seek treatment options.
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We ask, then, how this practice and these enrolled actors (patients, doctors and 
partners) differ from the enrolment we have observed on the Swedish webpage. 
The obvious answer, of course, is that in the conversations detailed in Oliffe 
(2005) the partner pair can explore non-pharmaceutical solutions. But we would 
like to suggest that the type of ‘enrolment’ that the men are displaying is also dif-
ferent in another way. Their enrolment is an activity which creates a community 
of people, all of whom can help to define the medical problem as medical or not 
and as a problem or not. And, importantly, it is also a community that seems to 
at least tacitly recognize that the solution, when there is one, is one that needs 
to be acted on and participated in by more than just the man. In particular, these 
interview studies would seem to highlight the partner’s need to be active in defin-
ing the problem, and also the solution, as co-produced and as something that both 
parts of the couple are actively participating in. This is in contrast to perceiving 
ED as a disease of the penis and the penis alone, and for which responsibility to 
enact a solution (take a pill which will maintain an erection) is the man’s. As we 
have shown, in the Viagra discourse, the partner is enrolled to help the man see 
how important it is for him to take Viagra. This demands a significant amount of 
work on her part, actively enabling the man to recognize the problem as ED and 
the solution as Viagra. An alternative would be for partners to be enrolled as par-
ticipants who can also define alternative sexual practices and solutions.
Thinking about the enrolment of not only new, male patients, but also their doc-
tors and their partners, we were reminded of an early study of mental health by 
Eaton and Weil (1955), which found that relatively isolated, Anabaptist communi-
ties’ responses to patients who developed mental illness were very different than 
the response to mental illness found in the wider American society at the time. 
Rather than isolating the individual, institutionalizing him or her, and stigmatiz-
ing the patient, the Hutterite communities tried to help the individual continue to 
play a role in the community, contributing and working as best they could, and 
being cared for by their family during the course of the illness (Eaton and Weil 
1955, 212). Reading this study today, it is obvious that it was written before the 
pharmaceutical industry had colonized the discourse of mental illness, and illness 
in general. Rather than talking about patient-centred, individualized cures to ill-
ness, the study relied on concepts of social cohesion, social structures and group 
expectations as explanatory models and as treatment options. It pays special atten-
tion to sociological variables, the cultural and social dimensions of health (Eaton 
and Weil 1955, 25).
We are not suggesting that a theory of social cohesion and mental health from 
1955 may be a good way to reinterpret erectile dysfunction. But as a reminder 
that our research material, our observations and our interpretations are influenced 
by the paradigm within which we are working, it is very useful. Going back to 
the material we have discussed in this chapter, and looking at the way patients, 
doctors, partners and pills are enrolled in the production of Viagra consumers, 
we see first that these actors are enrolled to produce pharmaceutical consumption 
as a treatment option. Secondly, the men and their partners are not discussed as 
explanatory factors. Although it may seem unnecessary to reintroduce the part-
ner as the source of impotence (for a discussion of historical, cultural and social 
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explanations of impotence, see McLaren (2007)), this enrolment can explain what 
other critical research on Viagra has shown; that its existence and doctors’ partici-
pation in its prescription practices have created ED. Social structures (the phar-
maceuticalized framework) and group expectations (of lifelong sexual activity 
and successful ageing) have contributed to the ‘epidemic’ of erectile dysfunction. 
The illness, itself, is constructed by the enrolled actors. Only then can they be 
engaged as a network to (help the man) find a solution. Starting from this insight, 
we ask: how might these same human actors be enrolled into creating a different 
solution? If Viagra was not available, what solutions could this cast of characters 
work together to find? Who/what else could possibly be enrolled? And how would 
the concept of ED change?
Like mental illness, impotence has traditionally been a situation that is not gen-
erally flouted or discussed publicly. Therefore we find it interesting that the Viagra 
solution suddenly enrols a wider group of actors to help the man find a solu-
tion. The Viagra solution demands these other actors; the regulatory framework in 
Sweden means that doctors are a gatekeeper to the drug; and Viagra’s reliance on 
sexual desire means that the sexual partner can be important to initiate, develop 
or maintain arousal. What we are asking is: if these three groups of actors (men, 
their doctors and their partners) can be enrolled to address ED through Viagra, 
how could they be enrolled to address ED without Viagra? How would a dis-
tributed response to ED place responsibility for dealing with the problem at the 
relationship(s) and community level rather than only by individual?
We suggest that these examples, both Oliffe’s qualitative research on men with 
impotence (Oliffe 2005; 2006) and the pre-Viagra treatment advice for doctors, 
show that enrolling a wider community to respond to a health issue is possible. 
Enrolling a larger network of actors can involve finding and supporting alterna-
tive behaviours, alternative demands and alternative expectations, both by and of 
the ‘individual’ with a condition, such as erectile dysfunction, and by the people 
around him who are also affected by it.
Notes
 1 An earlier version of this chapter has been published as Johnson, E. and Åsberg, C. 
(2012). Enrolling the Swedish Viagra Man. Science and Technology Studies, 25 (2), 
46–60.
 2 Accessed in October 2007, February and April 2008, November 2009 and October 2015.
 3 This is in contrast to another Pfizer-sponsored website, www.viagra.se, which is 
framed as an informational site for medical professionals. The different readership is 
constructed to legally avoid DTC advertising of Viagra.
 4 We would like to point out that this performativity is more directly connected to spe-
cific physical actions than the discursive performativity often found in gender studies, 
that is Butler’s (1990) work.
 5 www.potenslinjen.se, accessed 4 November 2009.
 6 www.viagra.com
 7 The quotes cited later are (unless otherwise mentioned) taken from www.potenslinjen.
se, accessed 5 November 2009.
 8 This encouragement and advice in how to meet and speak with patients with ED is pre-
sented on the website http://viagra.se, which is directed solely to health professionals 
(Accessed 28 October 2007).
7  Viagra selfhood
Pharmaceutical advertising and 
the visual formations of Swedish 
masculinity1
Cecilia Åsberg and Ericka Johnson
In this chapter, we will investigate the visual configuration of what we term a 
 Swedish Viagra imaginary, a cultural phantasy landscape that produces and repro-
duces certain subject positions of great interest for feminists and other scholars 
invested in social change. More precisely, we interrogate a set of key images pre-
sented by the Pfizer-sponsored website for potential Swedish Viagra customers 
with erectile dysfunction in order to explore how this particular Viagra imaginary 
provides reference points for shared and collective identities. We explore here the 
visual formation, and the naturalization, of the nationally shaped masculinity of the 
potential consumers of Viagra at a Swedish-language site, www.potenslinjen.se/,2 
the same site discussed in Chapter 6. This site is produced by the pharmaceutical 
company Pfizer for the explicit purpose of providing the Swedish public with health 
information on erectile problems.
Drawing on feminist science studies, cultural studies and medical technology 
studies, we argue that Viagra is a cultural phenomenon, or rather a material-semiotic 
node for discursive production and identity formation – one inflected by individual-
ized health concerns as well as by the social authority of medicine and the compel-
ling appeal of so-called lifestyle pharmaceuticals. Following masculinity theorist 
and feminist cultural scholar Graham Dawson, a cultural imaginary, as a kind of 
cultural phantasy landscape, is not monolithic and not hegemonic, but fluid and mul-
tiple. It consists of ‘those vast networks of interlinking discursive themes, images, 
motifs, and narrative forms that are publicly available within a culture at any one 
time, and articulate its psychic and social dimensions’ (Dawson 1994, 48). Cultural 
communities not only mirror but also continually reinvent themselves through cul-
tural imaginaries, as these are sites of identity negotiation and formation.
The reality-producing and identity-constituting effect of such discursive activ-
ities is why it is of the essence to study emerging subjectivities, such as those 
appearing publicly at Viagra websites. Moreover, in line with other critical stud-
ies of pharmaceutical use and promotion,3 we argue that Viagra is a feminist 
issue. The tendency to divide the psychic, the social and the techno-scientific 
into separate domains of knowledge has been resisted in a rich body of work, 
including that of feminist cultural studies of techno-science, and is an interdisci-
plinary mode in which we feel largely at home; see Åsberg and Johnson (2009) 
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and Johnson (2008). We attempt to align and establish cross-disciplinary dia-
logue between cultural theory and gender studies, media ethnography and stud-
ies of science, medicine and technology in society. Our work implies that we 
see sexual difference within a cultural theory setting, understood as the effect 
of the human subject’s entry into the symbolic systems of its culture. While 
subjectivity is neither universal nor ahistorical, it is the product of structuring 
social relations, shaped by materialities and physical embodiment as much as 
by social phantasy. Shared and collective, these phantasies organize a screen 
through which the material world appears and social relations are experienced. 
As cultural imaginaries, they furnish public forms, organize knowledge of the 
social world and give shape to phantasies that are constitutive of, in this case, 
masculine identities. Our method is materialist in that it tries to stay clear of both 
cultural and biological determinisms while approaching material-semiotic phe-
nomena discursively (cf. Haraway 1989). The target of our study here is not the 
lived, sensuous body-self, but the hermeneutic, cultural embodiment of Viagra 
masculinity in discourse.
Our analysis builds on discussions of the promotion of Viagra (a drug mar-
keted by Pfizer since 1998 for men and couples as a cure for erectile dysfunction) 
and the construction of masculinities and sexuality as a lifelong duty and health 
concern of the individual also in other comparative national contexts, such as the 
United States, New Zealand and Japan (see Bordo 1998; Fishman and Mamo 
2001; Marshall 2002; Potts 2004; Marshall 2006; Tiefer 2006; Johnson 2008). 
Like other critical readings of Viagra (Fishman and Mamo 2001; Marshall 2006; 
Tiefer 2006; Vares and Braun 2006), we are examining the construction of ideal 
users of Viagra and especially the nationalized, classed, racialized and sexual-
ized identities they are assigned. This, however, does not imply that we naively 
aim to reveal any kind of Viagra ideology as a singular site of reality distortion 
produced by the discursive operations of Big Pharma (ideology critique). The 
political driving forces of social change are today much more complex and highly 
individualized, which makes us interested in the creation of cultural appeal rather 
than the creation of (hegemonic) consent. In order to investigate in local detail, for 
instance, how retiring sexually became a sign of pathology through the new Via-
gra discourse, we are aligning slightly different insights from feminist approaches 
to intersectionality4 (identity as a crossroad of intersecting social categories such 
as gender, age, ethnicity and embodiment) with the notions of the social imaginary 
and subject positioning (the cultural encouragement for one to take up a specific 
sense of self) from visual cultural studies, and further, with previous work within 
medical sociology and feminist science studies on the ideological processes of 
medicalization and naturalization.
Interrogating the many cultural dimensions of ‘the natural’ as a rhetorical 
device at work in the Viagra imaginary, we consult the work that a range of femi-
nist scholars working on (or in) science, medicine and technology have produced 
since the late 1970s on the powerful, ideological processes of naturalization 
(cf. Merchant 1980; Haraway 1989; Butler 1990; Fox Keller 1992; McClintock 
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1995; Bryld and Lykke 2000; Franklin et al. 2000). It has, through such research, 
become clear that authoritative speech of the natural has maintained stereotypical 
definitions of sex and gender throughout late modernity.
In the case we present, Viagra seems – somewhat oxymoronically – to be natu-
ralizing a hegemonic form of masculinity as closely associated with virility, and as 
determined by erectile capacity for penile penetration of the female body. On one 
hand, such masculine subjectivity is about successful ageing and the maintain-
ing of an autonomous and androcentric, well-defined and impenetrable selfhood, 
one disassociated from health problems and embodiment in general. On the other 
hand, Viagra discourse invites interrogations of volatile masculinity and male 
ageing, pharmaceutical incorporation and prosthetic virility, and of commerce in 
liaison with medical science. These paradoxical Viagra connections function in 
direct opposition to the teleological ethos of science imagined to rationally and 
purposefully promote social development. This is evidenced by the narrative of 
how Viagra, with the active substance sildenafil citrate, came into commercial 
existence as the accidental result of heart medicine trials in which the male test 
subjects reported regained capacities for erectile functioning, and is an example of 
how we see Viagra performing ontologically as a curious material-semiotic node, 
an entangled case of meaning and materiality with some unexpected outcomes, 
especially regarding the choreography of selfhood, which we see as inflected by 
the formative powers of gender, nationality and sexuality.
Delineating the glocal of the creation of new techno-social identities around 
drugs, we discuss what we see as the performance of ‘Swedish’ elements of the 
Viagra man constructed through the text and images on the site, as this collective 
identity is imagined as slightly different from that presented in the advertisements 
that have helped to market Viagra to the US and New Zealand customer base (see 
www.viagra.com and www.viagra.co.nz). US advertising has seen a conceptual 
shift from impotence to erectile dysfunction (ED), and later to erectile quality 
(EQ) – as a much more inclusive category of erectile insecurity. These shifts, 
closely associated to the use of Viagra to maintain masculinity against the threats 
of ageing and other stresses in life, have meant that the potential market for the 
drug has expanded from older men with serious medical problems (as represented 
by early Bob Dole endorsements) to ageing but active, sporty types (presented 
through endorsements by football stars like Pele and baseball stars in the United 
States), to ‘every man’ as in the ads with non-famous, regular Joes (called ‘Sven-
ssons’ in Swedish) in their thirties. Much of the critical research about Viagra has 
so far come from the United States and New Zealand, two countries which allow 
DTC advertising of prescription medicine (see Mamo and Fishman 2001; Elliott 
2003; Loe 2004a; Moynihan and Cassels 2005). DTC advertising of pharmaceu-
ticals creates a media climate that allows drug companies like Pfizer to deliver 
information about their products to the general population through billboards, tel-
evision, infomercials, magazines, newspapers, radio and so forth, pumping out a 
Viagra message and producing a Viagra-primed, ED-aware audience (Potts and 
Tiefer 2006, 268). The messages about Viagra are also mirrored in jokes, televi-
sion programmes and movies, documentaries and news reports, reflecting the fact 
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that the line between paid advertising and media coverage is often blurry. This 
has bearing on our case study as well. Medical and popular imagery (with an 
almost global scope) take part in co-shaping a Viagra imaginary that provides a 
backdrop onto which virility can be measured and masculine subjectivities posi-
tioned. As discussed in Chapter 6, because of the ban on DTC advertising of pre-
scription medicine, the Swedish situation is slightly different (although this ban 
is not always easy to enforce). (Pfizer ran an ad campaign for Viagra on bus-stop 
billboards in 2004, and satellite television broadcasts from abroad have created 
a loophole for television ads as well; see Zetterqvist et al. (2015).) As mentioned 
earlier, Viagra has also figured largely in the collective psyche in Sweden as a sub-
ject both of newspaper articles and of debate, thanks in large part to the drawn-out 
discussions and court cases about whether the Swedish health care system would 
subsidize Viagra.
Concerned with the co-constitutive work of national and global imagina-
tion (Anderson 1983), and with what has been theorized as the unfinished and 
open-ended ‘new universalisms of global culture’ (Stacey 2000), we study how 
digital imagery employed within pharmaceutical marketing positions embodied 
subjects through appeals to both the national and the natural. Appeals to the 
national and the natural are highly potent cultural tropes through which identity 
formation can take place (Williams 1980; Franklin et al. 2000). National dif-
ferences, understood in line with Benedict Anderson’s (1983) anthropological 
notion of nationhood as non-essential imagined communities, are here com-
parative indicators of the glocal dimensions of the Viagra imaginary. While 
Anderson assumed that national media, like everyday print press or museums, 
maintained such a collective imaginary, we propose to investigate how such 
national imagery today also is co-constituted by commercial, sometimes con-
flicting, global flows of imagery in general, and by the pharmaceutical industry 
on the Internet in particular. It is in that vein we closely read the cultural pro-
cesses that produce the subject position of a specific type of Swedish man as a 
potential consumer of Viagra. This ideal consumer, as he is addressed in the web 
text and imagined in the selected photos, is a cultural figuration we refer to as 
the Swedish Viagra man.
Naturalizing the Swedish Viagra man
An example of how Pfizer’s Swedish erectile dysfunction site for the general pub-
lic takes an active part in the public negotiation of the meaning of masculinity as 
related to penetrative sex is a list published on the site of the top ten characteristics 
of ‘a manly man’. This list is based on a public poll and can be read against the 
backdrop of a rather large interest in issues of gender, in what constitutes ‘manli-
ness’ and ‘womanliness’, in Swedish public debate. Gender is a positive notion in 
Sweden, yet the content of such national awareness, informed as it is by decades 
of gender equality policy work, sometimes amounts to no more than an uncritical 
celebration of bipolar difference (Elvin-Nowak and Thomsson 2001, 409). How-
ever, in the summer of 2003, Pfizer hired a nationally renowned polling company 
92 Cecilia Åsberg and Ericka Johnson
to create a top ten list of what Swedish people associated with manliness, and the 
result reads as follows:5
 1 To be practical and handy (a handyman of sorts)
 2 To have good potency (presumed sexual)
 3 To have a well-paying job
 4 To have an attractive partner
 5 To have a physically fit, muscular body
 6 To have an attractive outer appearance
 7 To be interested in sports
 8 To be always ready for sex
 9 To own technical gadgets
10  To have a cool car
The desire to perform an all-around able-bodied, and even enhanced (with cars, 
gadgets or other status-raising attributes) form of masculinity is clearly a defin-
ing feature of the potential Viagra consumer. As an underlying and unarticulated 
assumption, such a notion is, in a commercial, yet serious health informational 
setting like this website, spoken of in terms of ‘good potency’ and visualized 
through imagery of active men appearing in non-erotic, everyday life settings as 
to not risk ‘indecent’, or even homoerotic, associations. This might be regarded 
as somewhat surprisingly prudish in a national setting famous for its high level 
of sexual education. Viagra has, however, been promoted in accordance with a 
class-related sense of ‘respectability’, and such a legitimating mode of address is 
achieved at this site through the staging of health information and references to 
medical professionals.
Next to the list, the visitor is given the opportunity to vote online for which 
of the top four points s/he finds most manly. The results from that direct online 
poll name, unsurprisingly, potency as the number one characteristic and handi-
ness as number two. This poll also indicates how Viagra, while in a limited and 
framed manner on this site, actually is very effective in inviting the addressed 
web visitor to contemplate the meaning of masculinity as strongly linked to, or 
even framed by, erectile capacity. Possible anxieties around potency are also in 
such a benevolent manner (as an open poll) simultaneously alleviated (in how it 
becomes a collective issue) and enforced (by the underlining of potency as the 
most important manly feature). The solution to any private feelings of inadequacy 
is placed in the hands of the individual, as he (or a female partner) on the website 
is encouraged to ask a medical professional for a Viagra prescription. This echoes 
the recurring signature of US television commercials for pharmaceutical products 
where the viewer, at the end of the ad, is always prompted to ask his or her physi-
cian about the new drug. We read this as part of a larger transnational discourse of 
‘biological citizenship’ (Rose and Novas 2005), where the multinational company 
is positioned as a benevolent assistant to the good and healthy sex life that, in the 
website rhetoric, becomes the duty of the individual consumer.
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This able-bodied and individualized ideal masculinity, as it emerges in the list, 
is to a large part construed in antagonist relation to common associations to lived 
femininity (soft embodiment, a low-paid job, dependency, not always ready for 
sex and less interested in male sports, cars and technical gadgets). In turn, this 
points to a phantasy masculinity inflected by class, sexual orientation and age, as 
some of the gendered ideals (owning a cool car) seem formatted already within 
teenage boyhood, although usually only attainable in adult life. Of note is that 
this list is framed and presented at the blue-tinted Viagra website along with a 
picture of a man in a Viagra-blue overall changing a tyre. By analogue, Viagra 
seems an easy solution, as a technical quick fix, to any kind of common feelings 
of insufficient manhood related to being able-bodied overall. The image of the 
man changing the tyre manages to displace a commonplace cultural fetish of abil-
ity where almost everything mundane and less than erotic (like changing tyres) 
that defines such masculinity seems hinged on erectile capacities. While clean 
in design, the website imagery is perhaps not completely devoid of any hints or 
visual reference to intercourse as a forceful male accomplishment, as the man is 
prosthetically enhanced by his phallic jack and tyre iron, screwing wheel lugs on 
an equally Viagra-blue car.
Many of the other images on the site, however, portray romantic couples. The 
Swedish Viagra man seems to predominately appear, whether alone and able-bodied 
or in a relationship, through the discourses of heteronormativity (Butler 1990). 
Nonetheless, there is an ambiguity to the imagery that opens up for slightly differ-
ent interpretations. We found one photo on the Swedish website where a couple’s 
sunlit feet are flirtatiously entangled on a bed with white bed sheets, where the 
gender of the couple is hard to decipher. It could be the feet of two men, or even 
two women, just as well as the feet of a heterosexual couple. As an example of 
erectile desires not being confined to heterosexual men, this picture could in fact 
lend itself to the possibility of portraying a male homosexual couple. Aligning 
the erectile function of the drug with sensuous imagery of couples or active men 
sustains, however, a reductive idea where penetration becomes the sole means 
through which relationships can be confirmed and a sexual act manifested. Also, 
it becomes clear that Viagra is not intended as a drug for the single man wishing 
to enjoy masturbatory sex on his own.
The masculine identity on the Swedish website is marked with nationalized 
signifiers of socioeconomic class in several ways. For example, on one of the 
information pages about facts and myths of impotence, there is the myth that ‘wet 
dreams give early morning erections’. Nocturnal erections are then explained by 
the assertion that ‘When a man is sleeping his penis exercises to keep in shape. 
A healthy man will have an erection approximately every 70th to 100th min-
ute when he is sleeping, regardless of whether he is thinking about sex or tax 
deductibles.’ This same message appears in the short film on the website’s first 
page. The reference to tax deductibles, in a country of progressive income taxes 
and, until recently, high capital gains taxes, could be interpreted as an appeal to 
the interests of the middle and upper-middle classes, or, at least, to the desire to 
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be associated with financially savvy methods of avoiding taxes. Thus, it becomes 
part of respectable upper-middle-class life to consume Viagra.
Perhaps most clearly indicative of Swedishness and its association with healthy, 
physical activity in the outdoors is the dominant imagery of people (men and cou-
ples) in wilderness settings. As a collective phantasy of national belonging and 
camaraderie, the overall use of this imagery can be seen in many commercials 
for a wide range of products in Sweden. We feel that one image on the site in 
particular poignantly plays on a charged version of Swedish nature. This image 
has a blurred, male body jumping into the water in what appears to be a summer 
day in the Swedish archipelago. It draws on a widely viewed beer commercial 
from the 1990s. This commercial, with a distinguishable aesthetic reproduced 
in several versions over the past decades, has come to represent the much-sought-
after, idealized Swedish summer. It is a commercial for Pripp’s Blue Beer which 
shows mixed-sex groups of white Swedes in their late twenties and early thirties 
gathering on the cliffs of the Swedish coast on what is obviously a crisp, yet warm 
and salty afternoon during the summer holidays. This group of Swedes, with their 
well-built, muscular bodies and attractive and slender partners, all wearing swim-
wear and seemingly without make-up, brings with them a large case of Pripp’s Blue 
Beer and spends the duration of the commercial barbequing, sailing or jumping in 
and out of the water while laughing to the background sounds of a then-popular 
Swedish pop-song, ‘Blue, blue winds and water’.6 After more than a decade, this 
advertisement was still running on Swedish television, and the imagery from the 
commercial has fastened in the cultural imaginary of what constitutes Swedish-
ness; namely, naturalness and freedom merged with an aestheticized form of sum-
mer night melancholia. Serendipitously for Viagra, ‘Blue’ is the iconic brand name 
of a particular Pripp’s beer and, for millions of Swedes tuned into popular culture, 
it represents blue water, blue skies and a laid-back, yet youthful attitude of sexual 
yearning (blue as in nostalgic, yet not unhappy, feelings) – all staged within a 
coastal setting very much like that in an image on the Viagra website.
The www.potenslinjen.se site taps into this Swedish imagery of the outdoor 
life, where several other pictures feature men and couples by the seaside. A rather 
simple yet highly effective aesthetic works thus to naturalize Swedish masculinity 
and connect it to Viagra. We would like to emphasize the central role of scenic 
landscapes and visualized Swedish nature as the photographic backdrop in this 
process of naturalizing the Swedish Viagra man. At the same time, class plays in 
the background. Access to the seaside, to a private sailboat that enables access to 
unpopulated islands, cliffs and bathing areas during the short summer, is a privi-
lege that is somewhat restricted to members of the capital-owning classes. Such 
an upper- and middle-class summer lifestyle is thus the iconic ideal and unique 
selling point for both this rather widely accessible beer and the slightly less acces-
sible pharmaceutical. It is a national phantasy of Swedish nature and the yearning 
nature of Swedes as they long for that ‘blue’ summer feeling. We contend that the 
Viagra illustrations on www.potenslinjen.se effectively make use of such a blue 
and youthfully sexual, class-coded and nature-loving, national imaginary of white 
Swedish masculinity.
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This nationalized construction of a middle-class Viagra man in Sweden should 
be seen in light of the prolonged court deliberations over subsidizing Viagra for 
the general public, which was finally decided in March 2008. As Viagra is not 
subsidized in Sweden (see Chapter 2), individuals have to cover the full cost of 
prescriptions. In a country in which all people are covered by state health care 
which substantially subsidizes most pharmaceutical products, the idea of paying 
for a drug, particularly a lifestyle drug, is relatively foreign. Many people would 
probably think twice before purchasing Viagra with their own money when they 
are accustomed to receiving medication much cheaper. Thus, the fact that Viagra 
is not subsidized means that the market for the drug is probably smaller than it 
would otherwise be, at least for Viagra received through a doctor’s prescription, 
which is the method of procurement www.potenslinjen.se promotes. The film on 
the first webpage claims that 100,000 Swedes purchase Viagra illegally over the 
Internet and warns strongly against this. Pfizer has probably therefore consciously 
chosen to market the drug to those social groups with more expendable income.
The image construction of Viagra on the site is also involved in positioning men 
as sufferers of legitimate potency problems related to underlying health concerns, 
thus avoiding connotations to Viagra as a recreational sex drug for party-happy 
youngsters. The target group is instead respectable yet mundane, middle-aged, 
Swedish, middle-class men, perhaps residing in the northern countryside. The 
images on www.potenslinjen.se all depict a very traditional and a very white 
Scandinavian man. This despite the fact that Sweden is, today, a multi-ethnic 
country with a significant urban population.
Among the photos illustrating the claims about potency, health and Viagra, 
there are, besides the medical expert (a white, slightly balding, middle-aged yet 
vital-looking man in glasses and blue scrubs), relatively few portraits of men. One 
exception to this is an image which shows the face of the naturalized, Swedish 
Viagra man in a winter coat in front of an unpopulated and cold, coastal land-
scape. Most photographed people are otherwise depicted with their backs to the 
camera from afar so their faces cannot be discerned, or metonymically repre-
sented through parts of their (tanned, yet white-skinned) bodies, like the entan-
gled feet belonging to the couple in bed. Conversely, the somewhat older man in 
a winter coat looks confidently back at the audience with cheeks blushed by the 
cold. The untamed shoreline in a frosty landscape associates him (and Viagra) to 
the wilderness rather than a cosmopolitan life. It links directly to notions of nature 
and the natural.
Ideas of the natural are often working through a cultural imperative of preser-
vation, of safeguarding the natural as if God-given, and it is probably the most 
powerful trope through which subject positioning and identity formation works 
(Williams 1980; Franklin et al. 2000). The drug Viagra can be conceptualized 
as natural, as it is presented in Pfizer marketing material, since it enables men 
an assumed ‘normal’ control over their bodily functions. It makes naturalized 
masculinity possible. Taking the pill merely enables ‘nature to take its course’ 
(Mamo and Fishman 2001, 20). So at the Pfizer website, the task of the biomedical 
drug industry seems, somewhat oxymoronically, to be one of ‘seconding nature’ 
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(Franklin et al. 2000, 21f). In other words, it is one of preserving naturalized mas-
culinity through the prosthetic virility Viagra can provide.
The imagery online conceptualizes both Swedish nature and Viagra as a drug 
seconding such nature, as a quality of both the inner, personal and outer, physical 
landscapes of the people depicted. From landscapes by the sea in the southern 
coastal areas or winters up north, images of Swedish nature sustain notions of 
Viagra as a normal and natural ingredient through the idea of ‘letting nature take 
its course’. The Swedish man becomes one with the enhanced natural surround-
ings, as Viagra becomes one with the ‘natural’ Swedish man. It is with surpris-
ing ease that the marketing of a pharmacological product can associate ageing 
Northern manhood to harsh and untamed landscapes, as it seems sustained by 
gendered national demographics where women move south to work in the urban 
areas and men stay in the north for the fishing and hunting. Such a phantasy of 
seconded nature remains by implication unsubdued by civilization (gender equal-
ity discourse or multiculturalism) as it takes on the oppositional characteristic of 
feminized and multicultural cosmopolitanism. Interestingly, Swedish masculin-
ity works here not in opposition to nature and wildlife, but through Viagra, as 
realigned with natural virility. It seems almost as if the defeminization of the 
north requires the enforcement of heterosexual masculinity. Viagra virility, also 
as the commodification of men’s sexual health, presents itself as a striking and 
counterintuitive account of white masculinity coupled with a national phantasy of 
uncompromised, and uncompromising, nature.
Concluding remarks
In this investigation of the Viagra imaginary and the techno-social identities it 
enacts, we dealt predominately with identity-forming intersections such as a 
nationalized (Swedish), middle-class sexuality and naturalized, white masculin-
ity. This is a masculinity which nonetheless is conspicuously malleable, vulner-
able and a target for a virility-enhancing drug like Viagra. Importantly, we dealt 
with a visual and spectacular kind of embodied subjectivation to both public and 
medical scrutiny, a subjectivity creating processes otherwise historically pre-
served for the female body (Jordanova 1989; McClintock 1995). In fact, Pfizer 
has positioned the drug as important to ‘every’ man through discourses that pre-
sent masculinity as the opposite of sexual impotence. Masculinity is equated with 
‘successful’ sex, a very specific, narrowly defined act of penetration in (usually 
heterosexual) intercourse. Being able to perform with an erect penis in this spe-
cific way is equated with manhood. By aligning masculinity with physiological 
sexual performance and promising reliable performance with the assistance of a 
pill, this discourse asserts that a man can maintain his masculinity regardless of 
age. Inflected by a strong sense of constant vigilance or disciplining of the male 
body, Viagra discourse demands individual responsibility so to manage the risk of 
losing such a virile masculinity even before one enters ‘old age’ (Marshall 2006, 
355). As the consumption of Viagra promises a youthful sexuality long into ‘old 
age’, it also becomes another building block in the construction of an ideology 
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about ‘successful ageing’ as the responsibility of the individual as s/he is framed 
within a liberal discourse of individualized self-care and biological citizenship 
(cf. Stacey 1997, 2000; Rose and Novas 2005; Åsberg and Johnson 2009).
Our observations about the glocal images of the Swedish Viagra man can be 
read in line with previous research, which has already shown that Pfizer adjusts 
its marketing strategy to appeal to local consumers. For example, whereas in the 
US advertisements for Viagra have used baseball stars to promote Viagra, in New 
Zealand, Pfizer enrolled sports heroes from rugby (Vares and Braun 2006, 325). 
Likewise, a television ad in New Zealand has featured a couple riding a motor-
bike on a sheep farm with the woman driving (Vares and Braun 2006, 318). How 
this advertising has been localized for the Swedish context says much about how 
and to whom Viagra is marketing itself in Sweden, and about what stereotypical 
images of masculinity and gender relations it feels are legitimate to base such a 
campaign on. Perhaps our results are surprising for a nation that prides itself on 
gender equality. These images can also be read as suggestions of what concepts 
of masculinity are so stable and unassailable that they can withstand association 
with a drug that is, in essence, an acknowledgement of ‘failed’ masculinity and 
‘dysfunctional’ sexuality. Or, as Vares and Braun call it, ‘a pill not only to repair, 
but also to enhance or improve, both erectile functioning and masculinity’ (Vares 
and Braun 2006, 325). As such, the online imagery of the Swedish Viagra man 
provides a telling account of naturalized Swedish masculinity as intersected by 
sexual orientation, ethnicity, age and class. And, like the work of Mamo and Fish-
man, our analysis has shown that Viagra is a gendered drug, ‘transmitting cultural 
scripts which serve as enforcers of normatively gendered expressions of sex and 
sexuality’ (Mamo and Fishman 2001, 20). According to the international Viagra 
script, male sexuality is always active and desirous, the on-demand erected penis 
is central in its penetrative function (Potts and Tiefer 2006, 268–9), and accord-
ing to the Swedish site, the Viagra man can easily be transposed into a different 
national context, sustaining its hegemonic, naturalized and nationalized image of 
the common (or, rather common-ized) ‘Svensson’ who in effect is not so anony-
mous or unmarked but visibly heterosexual and white, while haunted by blue 
yearnings of sexual un-fulfilment. He is associated with a wide, middle-class 
socioeconomic group, one which has the capital to access the seaside and take 
holidays in the Swedish archipelago, perhaps using the peaceful nights there to 
dream about tax deductions.
In spite of the mythical figure created online of the ordinary Swedish Viagra 
man, users of Viagra come in many shapes, sizes, ages, classes and genders. In 
addition, internationally, there are less than positive stories about using Viagra 
(Grace et al. 2006), reflected in the fact that at least half of Viagra customers do 
not refill their prescriptions – which is a statistic also found in Swedish studies of 
Viagra users (Ströberg et al. 2006). Further, an interview study by Potts and col-
leagues (2004) suggests that the importance of bodily experience of both erection 
and impotence is far more complex. Interviewees in that study challenged medi-
cal definitions of the meaning of sexual function as well as the straightforward 
link between Viagra and a satisfying sexual life. Instead, reports were given of 
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how erectile difficulties led to more gratifying intimate relations by expanding the 
sexual repertoire. Some even reported how the use of Viagra, contrary to being a 
quick fix for relationships, affected sexual relationships for the worse.
At the same time, alternative uses of Viagra, not least of all by women, have 
come to light, suggesting that as Viagra is integrated into our understandings 
of sexual practice, it becomes a flexible medical technology that means differ-
ent things to different people. Viagra discourse is symptomatic of sociocultural 
imaginaries that are glocally situated, as these involve branding techniques and 
marketing strategies that breach distinctions between public and private (even 
intimate), health and commerce. While widely promoted as a pharmaceutical suc-
cess and a scientific breakthrough, Viagra is also a symbolic materialization of the 
commodification of sexuality and gender, health and old age. It is in this sense that 
the Viagra imaginary is important to study (and by implication then take part in 
and intervene into) as it provides an indicator of embodied subjectivities as they 
take shape.
Notes
 1 An earlier version of this chapter has been published as Åsberg, C. and Johnson, E. 
(2009). Viagra Selfhood: Pharmaceutical Advertising and the Visual Formation of 
Swedish Masculinity. Health Care Analysis, 17 (2), 144–59.
 2 Accessed in October 2007, February and April 2008, November 2009 and October 2015.
 3 See the special issue of Sexualities. Sexualities, 9 (3), 2006.
 4 Intersectionality accounts for how identities are never just sexed and gendered, but 
also conditioned by nationhood, ethnicity and racialization, class and so forth. An ana-
lytical insistence on intersectionality emerged from within the social sciences and anti-
racist feminist theory (Haraway 1989; McClintock 1995; Davis 2008). In that vein, 
we argue that the educational advertising of Viagra in Swedish in fact does more than 
merely provide information. It generates cultural negotiations over gender and sexual-
ity as these are intersected by issues of, for instance, age and ability, nationhood and 
ethnicity.
 5 All translations are the authors’.
 6 Lyrics and melody by Thomas Ledin.
8  Conclusions
Glocal pharma and the Swedish 
Viagra man
Ericka Johnson
In this book we have been looking at how pharmaceuticals are localized in a 
specific context: in Sweden, with its well-developed, Northern/Western medical 
system and the welfare policies that provide this medical system at very little 
point-of-contact cost to the majority of people living there.
Specifically, we have analyzed the presence and influence of Viagra through 
the theoretical lens of pharmaceuticalization, as Williams and colleagues (2011a) 
described. Following their lead, we look at pharmaceuticals even ‘outside the 
medical domain and explore the broader way in which pharmaceutical futures are 
shaping how we think about innovation, policy and the very meaning of health 
and illness, therapy and enhancement’ (Williams et al. 2011b; 730 emphasis in the 
original). We have paid particular attention to three aspects: the way pharmaceu-
ticals change forms of governance and are changed themselves by local policies; 
the redefinition of health problems as issues with a pharmaceutical solution; and 
the creation of new techno-social identities around drugs and the way pharma-
ceuticals become essential actors in relationships between subjects. Doing so, we 
see quite clearly that Viagra and its perceived threat of eventually emptying the 
state coffers by over-demand has been part of a discussion that changed the way 
pharmaceuticals are subsidized and governed (and govern) in Sweden. Viagra 
has redefined impotence in the Swedish context as erectile dysfunction, and been 
presented as the solution available through medical treatment. While this is not 
a process that has only happened in Sweden, the medical discourse around it has 
incorporated aspects of pharmaceutical treatment that are particularly relevant in 
a context which provides subsidized medicine. Finally, as the last two chapters 
showed, Viagra has created a ‘Swedish Viagra man’ drawing on unique – if ste-
reotypical – Swedish masculinities. Viagra has also been placed as an essential 
element in this man’s relationships with sexual partners and doctors.
Our work in this book has focused on discourses, but the carrier or medium 
of those discourses is sometimes text, visual images and the materialities of the 
pills themselves. Our approach to discourse, and the subjects one can read from 
it, is framed by science and technology studies (STS) understandings of relational 
agency and non-human actors. These understandings allow us to articulate the 
role of Viagra as an actor in processes of pharmaceuticalization, but we are also 
keen to show – as the previous chapters have done – that other (human) actors 
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and (policy and commercial) interests and structures are implicated in pharma-
ceuticalization, too. Articulating pharmaceuticals in the local context with these 
theoretical concerns helps us show specific aspects of global pharmaceuticals as 
they are refracted in Sweden. Here, in the final chapter, we would like to present 
the reader with an analysis of glocal pharma through the trope of the Swedish 
Viagra man, to give form to these glocal manifestations of pharmaceuticalization.
The Swedish Viagra man
We have used Viagra as a prism through which to observe the glocal aspects of 
pharmaceuticalization. Cultural and social studies of Viagra in other contexts 
have shown how it influences more than just blood flow in the penis. Viagra has 
introduced the term erectile dysfunction (ED) to the general public, changing how 
impotence is perceived and treated (Chapter 4; Bordo 1998; Marshall 2002; Loe 
2004a; Tiefer 2006). It has reinforced a coital imperative – the idea that all sex and 
intimacy must involve penetrative intercourse – stressing quick, hard (youthful) 
erections and constant male desire (Tiefer 2000, 2006; Fishman and Mamo 2001; 
Mamo and Fishman 2001; Marshall 2002, 2006; Potts 2004; Loe 2004b), and it 
has connected successful ageing with successful sex and successfully taking one’s 
medications (Marshall and Katz 2002; Moynihan and Cassels 2005; Marshall 
2006). Yet much of the critical work about Viagra comes from the North American 
context, where DTC advertising has been widespread and overpowering (Elliot 
2003; Moynihan and Cassels 2005). In our work, we have asked how Viagra has 
influenced ideas about disease, sex and pharmaceutical use in this small, periph-
eral country, Sweden, with its laws against DTC advertising of prescription drugs, 
with state-funded, universal health care and a history of, or at least a reputation 
for, sexual freedom. Taking a look at ‘downstream’ effects of pharmaceutical sci-
ence, we show that the specific structural characteristics of the health care system 
and the cultural landscape influence how Viagra acts and is received in Sweden. 
We use the figurative Swedish Viagra man in our analysis to represent a subject 
position which is facilitated, described and prescribed by the multitude of local 
and global responses to Viagra as it is called into being in the Swedish context and 
discourse. This figure sits at the juncture of the Swedish state, Swedish cultural 
identity (as it is imagined, not necessarily as it is), the internationally acclaimed 
pharmaceutical product and the consumer(s) of it (see Johnson et al. 2011).
State subsidies and ED
Who should pay for the Viagra man’s Viagra? This question has generated heated 
debate, both in the United States (should insurance companies pay for Viagra but 
not birth control pills?) and in Sweden (what if a huge public demand drains the 
state coffers?). Historically, government regulation has often been seen as part 
of the process to bolster medical expertise (Starr 1982; Petryna and Kleinman 
2006). As medical practices were regulated by the state, they were simultaneously 
granted legitimacy and positioned against traditional medicine and unscientific 
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cures. Likewise, the development of regulated medical schools and the licensing 
practices they facilitate creates legitimate experts out of medical doctors. ‘The 
increased standardization of the therapeutic process was believed to promote sci-
entific progress in medicine while protecting the public against inflated claims 
about the effects and uses of substances claimed as remedies to restore health. 
One unintended effect of such regulation has been that it works as a barrier to mar-
ket entry for prescription drugs – thus ensuring profits for those who are allowed 
to enter’ (Petryna and Kleinman 2006, 10).
In the discussion about Viagra’s subsidy debate in Sweden (Chapter 2), 
however, we detailed an example of this happening, but in a nuanced way that 
responded to local concerns and structures. In 2003, the newly formed Swedish 
Pharmaceutical Benefits Board decided that Viagra would not be subsidized. Doc-
tors could prescribe Viagra, but the Swedish Viagra man would have to pay for it 
himself. The decision was controversial because people in Sweden had, until then, 
been accustomed to receiving prescription medication free, past a basic co-pay 
level, and Pfizer promptly appealed the decision. During the course of the next 
few years, the question of Viagra subsidies made its way through a series of court 
cases and appeals until, in 2008, the Supreme Court upheld the initial decision. 
Today, Viagra is still not subsidized in Sweden.
The Pharmaceutical Benefits Board was convinced subsidizing Viagra would 
be a legitimate use of tax money for severe ED but not for mild ED. However, it 
was also convinced that patients would claim to suffer from the severe form of the 
disease to beguile doctors into prescribing subsidized Viagra, which would both 
give subsidies to men who really did not deserve them, and lead to diagnostic 
bracket creep, that is an expansion of the diagnostic categories to match medica-
tion. Thus, rationalized both the Benefits Board and the court, it would be better 
not to subsidize the drug at all. The decision reflected concerns about patient and 
doctor compliance with government policies. The clincher in their argument was 
that two other drugs against severe ED, one injected by syringe into the penis 
and one inserted as a stick into the urethra, were already subsidized in Sweden. 
According to the Benefits Board and the court, these two drugs are so unpleasant 
to administer, compared to taking a pill, that men with mild ED would not reason-
ably be expected to use them, de facto limiting their subsidized use to ‘legitimate’ 
patients with severe ED.
In the discourse the state (represented by the regulatory agency) presented in 
court documents, medical doctors were presented as invalid experts, as easily 
beguiled individuals who could not diagnose a patient correctly. And the result-
ing regulation removed the responsibility to diagnose severe erectile dysfunc-
tion from the medical expert, placing it instead with the pharmaceutical and its 
delivery method, a clear example of what Biehl terms pharmaceutical forms of 
governance (Biehl 2006, 218). As predicted, this regulation had significant effects 
on which pharmaceuticals were sold and subsidized, working as a market entry 
barrier (although probably not a particularly effective one; see Chapters 4 and 
5). The unsubsidized Swedish Viagra man was influenced by the particular local 
structural framework of the Swedish welfare state.
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Chapters 2 and 3 of this book show that the regulatory changes we noted were 
a response to pharmaceuticals, especially Viagra. Analyzing the court documents 
that followed Viagra through the long and arduous series of court cases surround-
ing the decision (finally upheld) to not subsidize it in Sweden, we saw that the 
regulatory body tasked with deciding about pharmaceutical subsidies in Sweden 
was producing very local, nation state–specific responses to the integration of 
international pharma within an allegedly culturally neutral, objective, scientific, 
medical knowledge paradigm. This regulatory board was, of course, working 
within an international (European) regulatory framework, but its decisions were 
influenced by cultural aspects of the Swedish medical system. A new drug – Via-
gra – and a new regulatory body led to new regulatory tools. Because of local 
peculiarities like the uneven distribution of urologists throughout the country and 
the political ideology of the health care system’s framework with the principle of 
equal access to health care guaranteed by law, the drug precipitated a debate and 
decision about subsidy based on structural and ideological aspects of the Swedish 
health care system. The glocal of Viagra provision became inseparable from the 
local context of the regulatory body.
Chapter 3 then discussed how this Swedish government agency, the Pharma-
ceutical Benefits Board, has tried to include or exclude certain other prescrip-
tion drugs from the national pharmaceutical benefits scheme. By looking at cases 
which involve ambiguous knowledge, the chapter showed how regulatory bodies 
appreciate stable objects and stable categories, both of patients and diseases, and 
of pharmaceutical treatments. When technology destabilizes these things, as new 
pharmaceuticals do, and as pharmacogenomics technologies threaten to do even 
more, the regulatory bodies have to find ways of reacting to unstable categories. 
How this is done can vary from nation state to nation state, even within a collec-
tive framework like the EU, which is striving towards regulatory harmonization. 
In Sweden, we have seen a tendency to disregard specific knowledge and inclu-
sion criteria and instead use broadly inclusive or exclusive categories for treatable 
patients and reasonable drugs.
The impotent Swedish man and his dysfunctional penis
In our analysis of impotence and ED in the Swedish medical literature, using the 
weekly trade journal Läkartidningen, we noted a distinct change before and after 
Viagra’s 1998 introduction. Prior to Viagra, impotent men were written about as 
a heterogeneous group: some had partners, others were older, single men; some 
were shy, young men with problems relating to women, others were men ‘with 
a secret’, although what that secret could be was never clearly articulated. The 
treatment options for these various patients differed, but the doctor was always 
supposed to be a trusting confidant who saw the man on several occasions, lis-
tened to his feelings and discussed his concerns. Furthermore, the patient’s partner 
was encouraged to be involved in these discussions because she (the partner was 
always imagined to be a woman in this literature) could play an important role in 
the man’s treatment. After the introduction of Viagra to Sweden, the partner almost 
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disappeared from the medical discourse. So did the term impotence. Instead, erec-
tile dysfunction was discussed, an affliction of the man’s penis, a disease of blood 
flow and tissues rather than an illness related to relationships, feelings, expecta-
tions and disappointments (which has also been seen in other national contexts; 
see Tiefer 2006). Since 1998, Viagra has dominated the Swedish medical dis-
course so completely that its availability determined the concept of the patient 
(reduced to a penis) and the disease (a biomechanical shortcoming) in the medical 
discourse. Not until 2006, when statistics showed more than half of the men pre-
scribed Viagra in Sweden chose not to refill their prescriptions, was this discourse 
undermined. Reporting on interviews with men who stopped taking Viagra, an 
article in Läkartidningen suggested that Viagra failed because of social, cultural 
and relationship issues, unwittingly bringing the discussion back to the relation-
ship and lifestyle causes of impotence that had been prominent in the early 1990s. 
But this article is the exception to the rule. Viagra today still dominates the way 
impotence/ED is defined and treated in the Swedish Läkartidningen: impotence 
has become erectile dysfunction and is a condition to be treated pharmaceutically.
Addressing this aspect of pharmaceuticalization in Chapters 4 and 5, we demon-
strate the way health problems which already had a medical solution, that is were 
already medicalized, became issues with a pharmaceutical solution at a glocal level 
in the Swedish medical discourse. We analyzed how Viagra and alpha-blockers 
for BPH (Viagra is often prescribed together with alpha-blockers because of side 
effects of the alpha-blockers) were discussed in the Swedish medical journal 
Läkartidningen. We also paid close attention to who was allowed to give voice to 
concerns about the use of Viagra and alpha-blockers. Distinct global trends were 
visible in the Swedish material, like in the construction of impotence and erectile 
dysfunction as a condition related solely to blood flow after the introduction of 
Viagra. Discussions shifted from social and relationship causes of impotence to 
mechanical and biomedical explanations in Sweden as in other Western/Northern 
countries. Specifically Swedish aspects of the Viagra (and alpha-blocker) medi-
cal discussion were also prominent, many related to the solidarity principle in 
Swedish health care. These aspects included debates about the (un)availability 
of urologists in different parts of the country, the right a patient has to the best 
care regardless of his geographical location, the extent to which erections were 
an aspect of health that should be provided by state-funded medicine (and who 
was the patient in such cases, the man or the partner), and the connection between 
erectile dysfunction and other serious medical conditions which had already been 
deemed justified to treat from the public purse.
Viagra has (largely) replaced sexual and relationship therapy for the Swed-
ish Viagra man, and it far outsells other, earlier, more mechanical solutions like 
pumps, implants and insertable sticks. The alpha-blockers discussed in Chapter 5, 
on the other hand, have not had this same effect on treatment options. To some 
extent, alpha-blockers have become a pharmaceutical solution to a medical prob-
lem – enlarged prostates – that previously relied on surgery to correct, but not 
nearly as completely as Viagra took over erectile dysfunction. In Sweden today, 
surgeons still perform large numbers of surgeries on benign prostate hyperplasia. 
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So while alpha-blockers are being prescribed to shrink the prostate more than 
they were twenty years ago, they have not completely pharmaceuticalized this 
already medicalized problem in the same way Viagra did. Analyzing the discourse 
in Läkartidningen and comparing it to that of Viagra, one thing that strikes us is 
that the authorship of articles about impotence/erectile dysfunction shifted dra-
matically with the introduction of Viagra, from being dominated by sex therapists 
to being dominated by urologists. But within the discourse on enlarged prostate 
treatments, urologists were always the main authors of articles in Läkartidningen. 
The introduction of alpha-blockers to the enlarged prostate treatment regime did 
not imply a change in which medical specialty claimed the disease. Perhaps this 
can in part explain why the original treatment, surgery, is still performed. Rather 
than shifting care site, the pharmaceuticals merely added another weapon to the 
arsenal at the urology clinic. The relative success of Viagra compared to alpha-
blockers may have more to do with the relative strengths and weaknesses of urol-
ogy surgeons and sexologists as professional groups than the drugs themselves. 
Viagra has wrestled customers away from the sexologists, but alpha-blockers are 
having a more difficult time taking prostate operation patients away from the urol-
ogy surgeons.
Commercial images of the Swedish Viagra man
The discursive contours of the Swedish Viagra man’s subject position become very 
clear in the commercial marketing material for Viagra in Sweden. Pharmaceutical 
marketing has received a good deal of academic attention, in both its pure form 
as advertisements (see Moynihan and Cassels 2005) and its more subtle forms, 
like clinical trials, ghost-written scientific articles, medical activism by supported 
patient groups and disease awareness campaigns (Healy 2006, 62). The marketing 
of pharmaceuticals is international in its scope, and our Swedish material featured 
many characteristics which were similar to, for example, marketing produced for 
the United States. However, there were also distinctions. While these similari-
ties and differences are interesting in detail (and are discussed in Chapters 6 and 
7), what we find more relevant to an analysis of pharmaceuticalization is how 
the marketing discourses created both diseases and subjects which and who are 
then both actively produced and produce action through their relationship to the 
drugs. As Healy succinctly notes, ‘companies now sell diseases rather than just 
drugs’ (Healy 2006, 82). Our material supports this and shows that the concept 
of ‘consumer’ must also be viewed as flexible. Pharmaceuticals enrol and enable 
relationships to sell their diseases and drugs. Such advertisements target not only 
the person injecting, ingesting or applying the product, but also the person’s fam-
ily, doctor, school, job or prison facility suggesting, encouraging, prescribing or 
mandating consumption.
Most DTC advertising of prescription medicine is forbidden in Sweden, so 
instead of using television commercials, pharmaceutical companies provide infor-
mation about drugs and medical conditions in pamphlets distributed by doctors 
and nurses, through supporting patient advocacy groups and on informational 
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websites – a useful way to circumvent DTC rules, according to industry insiders, 
and seen in other contexts, too (Applbaum 2006, 103–4). This sort of advertising 
is a clear example of the selling of sickness which can occur; the construction 
of an illness with a pharmaceutical solution that Moynihan and Mintzes (2010) 
and Williams and colleagues (2009; 2011a) discuss. Pharmaceuticals are often 
presented to the patient together with online quizzes that can be used for self-
diagnosis or for diagnosis in the clinical setting. These quizzes are frequently 
translated and appear on websites in many different languages and for many dif-
ferent diseases (erectile dysfunction, depression, benign prostate hyperplasia, 
female sexual dysfunction, to name a few).
When we analyzed the images of men that populate the Pfizer-funded, Swedish- 
language webpage about ED, we saw examples of both global harmonization and 
local adaptation. Much of the information about ED is similar to that found in 
US commercial material, but the Swedish Viagra man as a collective trope is a 
slightly different man than the one(s) found in the United States. He is, for starters, 
very white – which mirrors a traditional image of the Swedish man even though 
Sweden is, at this point, a country which has a significant non-Caucasian popula-
tion – and the Swedish Viagra man is slightly older than the middle-aged men and 
sports stars found as Viagra representatives in the United States. The Swedish 
Viagra man is also very connected to nature; he is presented in wilderness scenes, 
toughing the winter cold or jumping into pristine water from rugged, stony out-
croppings. The Swedish Viagra man is comfortable in the uncivilized wilderness, 
which by association naturalizes both his condition and its cure, Viagra.
We also notice that the Swedish Viagra man is not alone in his affliction; he is 
accompanied by his partner. Images of smiling women next to their men, couples 
walking along the seaside and two sets of feet sticking out from under a blanket 
pepper the websites and informational literature. While the partner all but disap-
peared from the medical discourse when Viagra appeared in Sweden, she (there 
is little to suggest homosexual relationships in the material, even if the language 
is gender neutral) is actively enrolled and present in the commercial material. We 
suspect this is because Viagra needs sexual stimulation to function properly. For 
some men and in some cases, Viagra will ensure the maintenance of an erection, 
but initial sexual stimulation has to come from somewhere or someone else, and 
the partner is a convenient ally for Pfizer.
The Swedish Viagra man does not act in solitude, and in Chapter 6 we have 
shown how Viagra is used to create three subject positions in the commercial/
informational discourse: a shy and reluctant Swedish Viagra man; his helpful 
doctor who represents science and knowledge and who is concerned about his 
patient’s impotence in part because of what it says about his patient’s heart and 
general health status; and a supportive partner who can facilitate and produce the 
nearness and intimacy that a loving, sexual relationship needs.
Chapter 7 paid closer attention to the representations of masculine traits that are 
given to the Swedish Viagra man within the pages of the Pfizer-sponsored website 
providing health information on erectile dysfunction to potential Swedish Viagra 
customers. We have articulated the images of a potential Swedish Viagra man in 
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relation to sexual health and cultural cues of masculinity. We argue that the mas-
culine traits highlighted in the webpages are indicative of Swedish cultural values 
of male virility that are strong enough to withstand discursive coupling with a 
pharmaceutical used to address ‘failed’ virility.
In both of these chapters, the global and the local are relevant as the websites 
and informational pamphlets we have analyzed are local adaptations of interna-
tional marketing approaches (including the self-help quiz and the database of 
local, Viagra-friendly doctors) and are produced and distributed within a regula-
tory framework that (more or less successfully) forbids DTC advertising of pre-
scription pharmaceuticals. They therefore provide a glocalized cultural imaginary 
of Viagra, the subject positions it engenders and the particular relationships it 
facilitates.
Glocal pharma
Pharmaceuticals and the commercial forces behind them are incredibly flexible 
and determined in their drive to conquer new markets and ensure a global reach 
(Petryna and Kleinman 2006, 7). However, we also see in our material that the 
local can push back. Cultural-specific discourses can be and are incorporated into 
ideas about the consumer subject, and perhaps this is testimony to their obduracy. 
Medical professionals and opinion makers address the integration of pharmaceuti-
cal solutions into clinical practice and treatment, and while many of them may be 
enthusiastic supporters and/or be receiving pharmaceutical industry support, not 
all are. Their participation in this discourse is also testimony to a belief that their 
locally generated opinions are useful, valid and objective. Likewise, the industry 
supports their role as independent opinion makers with valuable expert advice 
to be considered by policymakers and other political and administrative bodies. 
Both industry’s use of local doctors and the doctors’ willingness to participate 
attend to a belief that the local is relevant. And that regulatory bodies in a small 
nation state like Sweden still feel that they have a duty to the citizen (the citizen 
patient and the citizen taxpayer), which should be considered before the industry’s 
demands, and a court system which facilitates this, attests to the relational agency 
that develops as global drugs meet local structures.
As we mentioned in the introduction, in drawing conclusions about the glocal 
of pharmaceuticalization, it is useful to ask how a drug’s presence has altered the 
concept of a disease and its treatment, who suffers from it and how to cure it, in 
the local context and internationally. Drugs can both create new and refract with 
existing stereotypical images of a patient, images which carry markers of class, 
race and sexuality. And they lead to new laws and policies to regulate the practices 
of both doctors and patients.
But of course it is not only the drug that prescribes behaviours or identities, it 
is decision makers, commercial actors and medical experts who attach the drug to 
specific demands, images and expectations to influence the behaviours of groups 
they are trying to govern, cajole or cure. These actors are located in different coun-
tries, have different cultural starting points and work within different institutional 
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frameworks, so how they construct and use a pharmaceutical varies. Thus, the 
series of Swedish court cases and subsidy debates about Viagra reflect the specif-
ics of Swedish law, its national health care programme and its basis in the con-
cept of solidarity. This becomes a framework which creates a specific, local legal 
context within which Viagra must be governed, and which also influences the 
discursive contours of Viagra in Sweden. While Viagra’s influence on the medical 
discourse in Sweden was similar to the international one, it also contained a great 
deal of debate about the connection of ED to other established medical conditions 
like diabetes and MS, reflecting the subsidy controversy and concern that Viagra 
would be unavailable to ‘legitimate’ patients. Likewise, the commercial construc-
tion of Viagra on Pfizer’s Swedish webpage in many ways parallels that on the 
US pages, with a self-help diagnostic quiz, a database of Viagra-friendly doctors 
and information for partners. Yet there are also specific elements manipulated to 
reflect and resonate with Swedish sensibilities, like the imagined race of the user, 
the connection to Swedish forests and coastlines and the Swedish survey of mas-
culine personality traits on the Pfizer-sponsored Swedish potency website. These 
details show a global pharmaceutical being localized.
When an analysis of pharmaceuticalization teases out the actors behind a drug, 
one can see that a drug is much more than the pill that is claimed to cure a disease 
or alleviate a symptom. It can become a discursive conflation of values, actors, 
structures, biomedical understandings, social identities and personal desires. The 
mere existence of a pharmaceutical product can influence the medical discourse, 
reinforce and even construct cultural ideas and identities, change the practices of 
experts and lay people and reimagine ways relationships are performed between 
patients and doctors and between patients and their loved ones (see Whyte et al.  
2006). Pharmaceuticals are global in their reach and regulated by international 
institutions, but our work here articulates drugs as flexible artefacts as they 
encounter local social and institutional frameworks. While there are very Swedish 
aspects of Viagra in Sweden, the drug has carried with it previously established 
ideas about disease, medical treatments for ageing and appropriate intimacy prac-
tices. These are strong, disciplining discourses that influence even as they become 
embedded in the cultures that encounter them. The globalization of the pharma-
ceutical market not only makes medicines available to international consumers, it 
also spreads ideas about the healthy subjectivities those medicines are prescrib-
ing. This, we feel, calls for further consideration, to articulate the prescribed sub-
jectivities that prescription medicines carry when they are sold on a globalized 
pharmaceutical market. We want to consider the images of healthy identities, 
relationships and practices they claim to facilitate. We also call for careful atten-
tion to the local particularities they challenge and are challenged by: the medical 
structures that provide access to them; the ideological basis of local health care 
provision; and the regulatory frameworks that govern them. These are the local 
aspects we have examined which, when combined with a global pharmaceutical, 
relationally construct glocal pharma. A question this awakes is if, and how, these 
local productions of pharmaceutical artefacts and subject positions can be seen to 
inform backwards, from the peripheral local to the industry’s centre.
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